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Breast cancer is the most common cancer in women and unspayed female 
dogs. The Epithelial to Mesenchymal Transition (EMT) is a process involved in 
embryogenesis, carcinogenesis, and metastasis. The Transforming Growth Factor-
Beta (TGF-β) pathway and its associated transcription factors are crucial for EMT 
induction, during which epithelial cells lose their defining characteristics and acquire 
mesenchymal properties. EMT has been implicated as a driver of metastasis as it 
allows cells to migrate and invade different organs. Recent evidence indicates that 
cancer stem cells are required to establish metastatic tumours at distant sites, and that 
EMT may promote development of cancer cells with stem-cell characteristics, thus, 
the EMT pathway may be an important molecular determinant of tumour metastasis. 
 The main objective of this project was to characterise TGF-β-induced EMT 
in breast cancer models. EMT was induced by TGF-β in human, canine and feline 
breast cancer cell lines, and confirmed by morphological changes and molecular 
changes at the protein level by Western blot analysis. Changes at the mRNA level 
were confirmed in human and canine mammary carcinoma cell lines by qRT-PCR; 
migratory properties were assessed by invasion assays in vitro in feline and canine 
mammary carcinoma cells. Importantly, we observed that feline and canine 
mammary carcinoma cells stimulated by TGF-β acquired stem cell characteristics 
including sphere-forming ability, self-renewal, and resistance to apoptosis, and also 
enhanced migration potential. Canine cells showed resistance to chemotherapeutic 
drugs after TGF-β stimulation. These data suggests a link between EMT and cancer 
stem-cells. Moreover, global changes in microRNA expression were mapped during 
TGF-β-induced EMT of canine mammary carcinoma cells. This gave significant 
insight into the regulation of EMT in canine cancer cells and identified several 
potential targets, which require further investigation. During EMT cells acquire 
migratory properties and cancer stem-cell characteristics, suggesting that EMT and 
the stem-cell phenotype are closely related during cell migration and metastasis, 
therefore making the TGF-β pathway a potential target for the development of novel 
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Chapter 1: Introduction 
Chapter 1:  Introduction  
1.1 Cancer aetiology 
Cancer is one of the major health problems in humans and animals. Some 
important characteristics of this fatal disease are the uncontrolled growth and 
proliferation of cells, which will frequently act against their host. Even though it is 
not fully understood how a regular cell is transformed into a neoplastic cell, different 
researchers state that the majority of cancers are originated from a single cell 
(reviewed by Al-Hajj and Clarke, 2004, and Reya et al., 2001). It has been thought 
that the initial changes in neoplastic cells are related to a deregulation of genetic 
mechanisms, which control cell growth, cell division and differentiation as reviewed 
by Dobson, 2014.  
Cancer is caused by mutations which lead to resistance to apoptosis and the 
consequent proliferation of cells. Different genes direct and regulate several steps in 
the cell cycle, ensuring that there is always a balance between cell division and cell 
death during all stages of life, thus, damage to these genes can lead to tumour 
formation. In cancer, some of these genes are also known as oncogenes and tumour 
suppressor genes. An oncogene is a gene that can contribute to convert normal cells 
into cancer cells when mutated or aberrantly expressed, producing a dominant gain 
of function in the cells, leading to carcinogenesis (reviewed by Argyle and Khanna, 
2013). Tumour suppressor genes are genes that naturally protect cells from the path 
of cancer and can also be called anti-oncogenes. Carcinogenesis can be initiated by 
mutations provoking the inhibition or loss of function of tumour suppressor genes 
which will facilitate progress to cancer cells, usually combined with other genetic 
alterations including the activation of oncogenes (reviewed by Yoshida, et al., 2000, 
and Weinberg, 2014).  
Proto-oncogenes are cellular oncogenes that cannot transform normal cells 
into cancer cells on their own. They need to be altered in order to lead cells to form 
tumours. Many of these proto-oncogenes have developmental functions, including 
cell growth and proliferation (reviewed by Balmain and Brown, 1988). They can be 
divided into different groups such as growth factors and their receptors; protein 
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kinases; signal transducers; and nuclear proteins and transcription factors. The 
mechanisms by which these proto-oncogenes can be activated and transformed into 
oncogenes leading to malignancy can be achieved by chromosomal translocation, 
gene amplification, point mutations and viral insertions.  
Some important features that can be considered as hallmarks of cancer are: 
the uncontrolled cell proliferation without the need of new cell formation by the 
organism; resistance to apoptosis; angiogenesis induction; replicative immortality; 
aberrant expression of proto-oncogenes stimulating neoplastic growth and 
overproduction of growth factors; the inactivation of tumour suppressor genes 
resulting in a failure to stop inadequate cell growth; cell reprogramming; and the 
potential to evade the immune system of the host. It is thought that at least six 
mutations in different genes are necessary to develop these features and consequently 
form the vast majority of cancers as reviewed by Hanahan and Weinberg, 2011. As a 
result of oncogenic mutations, regular cells can progress to neoplastic cells by the 
acquisition of these tumorigenic features (reviewed by Dobson, 2014). 
Cancer is a multifactorial disease which can be developed by several causes, 
including different types of viruses, radiation, UV light, chemical products, 
nutritional problems and hereditary mutations among others as reviewed by Dobson 
et al, 2014. Examples of hereditary mutations that can cause different types of 
cancers include mutations of the genes BRCA1 (Nieto et al., 2003) and BRCA2 
(Ochiai et al., 2001), which are important for the development of breast cancer in 
dogs and humans.  
In humans, the tumour suppressor gene most frequently mutated is p53, a 
stress-activated transcription factor which is considered the guardian of the genome 
(reviewed by Lane, 1992). It promotes cell cycle arrest and apoptosis in DNA 
damaged cells, thus, stopping cell division in genetically altered cells which could 
possibly lead to neoplastic formation (Sluss and Jones, 2003). Mutation of this gene 
inhibits cell cycle arrest and apoptosis, leading to aberrant cell growth and fosters the 
consequent formation of different types of tumours like breast carcinoma, leukaemia, 
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glioma, adrenocortical carcinoma, and soft tissue sarcomas (Tabori and Malkin, 
2008). 
1.2 Breast cancer 
Breast cancer is one of the most common types of cancer around the globe 
and the most common cancer among women in the UK accounting for approximately 
30% of new cases every year (Cancer Research UK, 2014). According to Parkin et al 
(2005), there are wide variations in risk factors around the world due to the 
difference in exposure to environmental or lifestyle changes, thus, it becomes quite 
difficult to prevent the disease in different regions (Parkin et al., 2005). In 2011, 
there were 49,936 new cases of breast cancer in women in the UK, showing that 
there are approximately 155 new cases of breast cancer for every 100,000 women in 
the UK (Cancer Research UK, 2014). 
Breast cancer is the most common cancer in unspayed female dogs 
constituting approximately half of all tumours in female dogs (Moe, 2001, reviewed 
by Sorenmo et al., 2003). In unspayed bitches, mammary tumours comprise around 
50% of all types of tumours, and approximately 50% of them are malignant. Overall, 
breast cancer in dogs has approximately 3 times the incidence of breast cancer in 
humans as reviewed by Sorenmo, 2003. Both in humans and dogs mammary tumours 
are rich in epithelial cells and usually metastasise to the lungs or bone (Owen, 1979, 
Sonnenschein et al., 1991,  and reviewed by Sorenmo, 2003). Canine mammary 
tumours share clinical and biological similarities with mammary tumours in humans, 
making dogs good animal models for cancer research in humans. In dogs and 
humans, tumours usually arise spontaneously due to genetic alterations as reviewed 
by Porrello et al., 2006 and Cassali et al., 2011. Moreover, mammary tumours in 
both species are staged according to the tumour, lymph node and metastasis (TNM) 
system established by the World Health Organisation (WHO) (Owen, 1980). 
Interestingly, skin ulcerations and local inflammatory reactions are clinical signs 
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Kumaraguruparan et al, 2006 showed that apart from other similar gene 
mutations, including p53 (Rungsipipat et al., 1999), BRCA1 (Nieto et al., 2003) and 
BRCA2 (Ochiai et al., 2001) already described in both species by different groups, 
canine and human breast cancer also share pro- and anti-apoptotic molecular 
changes. These include increased expression of anti-apoptotic genes including B-cell 
lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), and 70 and 90 
kilodalton heat shock proteins (Hsp 70 and 90) in both species whilst the expression 
of pro-apoptotic molecules like Bcl-2-associated X protein (Bax) and caspase was 
downregulated (Kumaraguruparan et al., 2006). These similarities give rise to the 
elucidation that small animals like dogs and cats could work as better animal models 
than rodents, which usually are immunosuppressed, for the development of novel 
strategies in the diagnosis and therapeutic protocols for human cancer. Moreover, 
they affirm that as laboratory animals do not share the same environmental factors as 
humans, they would not provide the same results as companion animals, which 
usually experience a similar lifestyle and environment as humans (Kumaraguruparan 
et al., 2006). Furthermore, Gama et al, 2008 showed that canine mammary cancer is 
also similar to that in humans based on its molecular classification where it displays 
a heterogeneous panel of receptors including oestrogen receptor (ER) and human 
epidermal growth factor receptor 2 (HER2). They classified 102 canine mammary 
carcinomas into 4 different groups: Luminal A, luminal B, HER2 overexpressing and 
basal tumours. Luminal A tumours were ER+/HER2- and had the lowest 
proliferation rate and a better prognosis compared with the other types. They also 
had the highest incidence reaching 44.8%. Luminal B tumours were ER+/HER2+ 
with just 13.5% of incidence, and the lowest incidence was 8.3% shown by the 
HER2 overexpressing tumours (ER-/HER2+). Finally, the basal tumours (ER-
/HER2-) had 29.2% of incidence and showed the highest proliferation rate with the 
shortest survival rates, similar to basal-type mammary carcinomas in humans. (Gama 
et al., 2008). The determination of a molecular phenotype within mammary 
carcinomas contributes to a better and more accurate prognosis. HER2+ carcinomas 
in humans can be targeted with adjuvant therapy with trastuzumab, a monoclonal 
antibody that inhibits the HER2/neu receptor (Slamon et al., 2011). Furthermore, as 
HER2 overexpression has also been identified in canine mammary carcinomas, their 
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therapeutic approach could be similar to that of HER2+ tumours in humans (Hsu et 
al., 2009, Martin de las Mulas et al., 2003). 
 
1.3 The mammary glands of companion animals 
Dogs and cats usually develop 5 and 4 pairs of mammary glands, 
respectively, divided in three different blocks, being M1 and M2 the cranial thoracic 
and caudal thoracic pairs, respectively (cats only have one pair of thoracic glands), 
M3 and M4 the cranial and caudal abdominal pairs, and M5 the inguinal pair of 
mammary glands (Evans and Christensen, 1979, Silver, 1966 and reviewed by 
Ettinger and Feldman, 2010). The mammary glands are vascularised by branches of 
the thoracic, intercostal, superficial and deep epigastric, abdominal and iliac arteries  
bilaterally (Evans and Christensen, 1979, Slatter, 1998). The lymphatic drainage 
from the thoracic pair of glands (cranial and caudal) and the abdominal cranial 
glands is directly connected to the axillary lymph nodes whereas the inguinal lymph 
nodes receive the drainage from the lymphatic vessels derived from the abdominal 
caudal and inguinal mammary glands.  The lymphatic drainage can also be directed 
from the mammary glands into the abdominal and/or thoracic cavities via lymphatic 
vessels (Evans and Christensen, 1979, Slatter, 1998). This was confirmed by Pereira 
et al by lymphoscintigraphy in 2008. The aim of their study was to standardise a 
lymphoscintigraphy protocol by intramammary administration of 99mTc-dextran to 
provide a rapid lymphatic drainage examination in the mammary glands of 25 female 
medium-weight mongrel dogs. They observed that not only the axillary lymph nodes 
were involved in the lymphatic drainage from the thoracic and cranial abdominal 
pairs of glands, but also the superficial cervical, the cranial sternal and the accessory 
axillary lymph nodes were radioactive after the administration of the radionuclide. 
Furthermore, they showed that both, the caudal abdominal and the inguinal pairs of 
glands were drained by the superficial inguinal and simultaneously by the medial 
iliac lymph nodes (Pereira et al., 2008). Interestingly, important variations were 
found among their groups of study. They observed radioactivity in the sternal lymph 
node after administration of the radionuclide in the caudal thoracic mammary glands 
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in 60% of the bitches in their experimental group. This pair of mammary glands was 
considered to be exclusively drained towards the axillary lymph node by the 
previously mentioned authors. They also identified important variations regarding 
the lymphatic drainage from the caudal abdominal mammary glands. They observed 
radioactivity in cervical, cranial mediastinal, superficial inguinal and medial iliac 
lymph nodes after injection in the caudal abdominal glands. These findings brought 
to their attention the need to perform individualised lymphoscintigraphy protocols 
for each patient when lymphatic drainage is of clinical relevance for therapeutic 
planning and confirmation of regional metastasis (Pereira et al., 2008). 
 
1.4 Canine mammary gland tumours  
In developing countries, where the practice of ovariohysterectomy (OHE) is 
not common in dogs, mammary tumours have a remarkably high incidence, making 
breast cancer the most common type of cancer in bitches (reviewed by Sorenmo, 
2003). Vascellari et al., 2009 showed that 56% of dogs with diagnosed cancer have 
breast cancer, and interestingly, other studies have described that similar to humans, 
the male population in dogs, compared with females, has a very low incidence in 
which the potential risk of developing breast cancer is lower than 1% (reviewed by 
Saba et al., 2007, Todorova, 2006, Vascellari et al., 2009). According to Perez-
Alenza et al., 2000, increased age; irregular oestrous cycles; cystic endometrial 
hyperplasia; and late or a lack of ovariohysterectomy history would be major risk 
factors associated with breast cancer development in small animals (reviewed by 
Perez-Alenza et al., 2000). 
It has been well established that, similar to mammary neoplasia formation in 
humans, sexual hormones oestrogen and progesterone contribute to the development 
of breast cancer in dogs (Munson and Moresco, 2007), thus, according to Schneider’s 
findings more than 40 years ago, canine breast cancer can be prevented by 
performing OHE before the first oestrus cycle of the bitch, as these individuals 
would only have ≤ 0.5% probability to develop a mammary tumour (Schneider, 
1970, Schneider et al., 1969). 
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1.4.1 Clinical aspects and diagnosis of canine mammary 
tumours 
After a physical examination in which a growing mass is located in any of the 
5 pairs of mammary glands, a histological diagnosis is needed to establish the type of 
tumour and if it has a benign or malignant character. Mammary tumours can be 
solitary, but they can also be presented as multiple masses invading one or more 
mammary glands (Image 1.1). Some important clinical parameters to associate 
canine mammary tumours with lower chance of survival and worse prognosis include 
large tumour size, ulceration of skin and adherence to surrounding tissues, lymph 
node invasion, irregular shape and increased age at the time of diagnosis as reviewed 
by Perez-Alenza et al., 2000. Three view thoracic radiography and sampling of 
lymph nodes should be performed to rule out metastasis after a mammary tumour has 
been diagnosed (Image 1.2), as approximately 50% of canine mammary tumours 
metastasise to regional lymph nodes and lungs as reviewed by Nelson, 2000 and 
Ogilvie, 2006. 
 
Image 1.1. Unspayed female dog with a mammary carcinoma presented as multiple masses. 
Image courtesy of Alejandro Cabrera Bedolla,  Clinica Veterinaria de Especialidades de 
Morelos, Mexico, 2013. 
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Image 1.2. Right lateral view of a thoracic radiography of an unspayed female dog with 
mammary carcinoma in which multiple pulmonary nodules are visible, creating a nodular 
interstitial pattern. These radiographic signs are compatible with advanced lung metastasis (no 
cytologic or histopathologic diagnosis was performed for this case). Image courtesy of Alejandro 
Cabrera Bedolla, Clinica Veterinaria de Especialidades de Morelos, Mexico, 2013. 
Furthermore according to Rutterman et al., 2001, mammary tumours in dogs 
and cats can be staged through a TNM (Tumour, lymph node and metastasis) 
modified classification system similar to that of the World Health Organisation  
(WHO) system for mammary tumours in humans (reviewed by Rutteman et al., 
2001). In this modified TNM system, tumours are classified in 5 stages according to 
the size of the tumour and lymph node involvement and distant metastasis. The letter 
T stands for tumour and it has 3 stages, T1 when the tumour is <3 cm in diameter, T2 
for tumours measuring 3-5 cm and T3 for tumours larger than 5 cm. If there is or 
there is not lymph node involvement the tumour would be classified as N1 or N0, 
respectively, and similarly for distant metastasis, the tumour would be classified as 
M0 if there are no signs of metastasis or M1 if distant metastasis is diagnosed. The 5 
different stages in this modified TNM system can be determined by a combination of 
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Stage Tumour size Lymph node involvement Distant metastasis 
Stage I T1 <3 cm N0 (negative) M0 (negative) 
Stage II T2 3-5 cm N0 (negative) M0 (negative) 
Stage III T3 >5 cm N0 (negative) M0 (negative) 
Stage IV T1-T3 N1 lymph node involved M0 (negative) 
Stage V T1-T3 N0-N1 M1 metastasis 
Table 1.1. Modified TNM classification for mammary tumours in dogs according to the World 
Health Organisation to classify different stages of breast cancer in humans. 
Different classification systems based on the recommendations of the WHO 
have been described in the past, where canine mammary tumours can be separated by 
histopathological origin and prognosis (Misdorp, 1999, Hampe and Misdorp, 1974), 
and recently Goldschmidt et al., 2011, proposed a more accurate histological 
classification using the previous papers as a base (Goldschmidt et al., 2011). Tumour 
growth in the canine mammary glands can therefore be divided into different 
categories depending on their histopathological origin and malignancy. Benign 
mammary neoplasms are divided into several types, including adenomas (ductal, 
intraductal papillary), fibroadenoma, myoepithelioma and adenomyoepithelioma 
(complex adenoma) (Goldschmidt et al., 2011). Interestingly, a study carried out by 
Soremno et al. in 2009 shows how, similarly to human mammary neoplasia, benign 
tumours in dogs can progress to a malignant phenotype (Sorenmo et al., 2009).  
The tumour classification proposed by Goldschmidt et al., 2011, is shown in 
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1. Malignant Epithelial neoplasms  
Carcinoma in situ Well demarcated nodules without involvement of 
surrounding tissue. 
Simple carcinoma a) Tubular (cells arranged in tubules) 
b) Tubulopapillary (tubules are arranged in a 
papillary fashion) 
c) Cystic-papillary (papillae extend into cystic 
tubular lamina) 
d) Cribiform (neoplastic cells form a sieve-like 
arrangement) 
Micropapillary invasive carcinoma One or more nodules with intraductal neoplastic cells 
forming small intraluminal aggregates and papillae. 
Solid carcinoma Solid masses of cells without lumina. 
Comedocarcinoma  Necrotic areas in the centre of the neoplastic cell 
aggregates. 
Anaplastic carcinoma Most malignant of mammary carcinomas. Neoplastic 
cells usually invade interlobular connective tissue and 
lymphatic vessels. 
Carcinoma arising in a complex 
adenoma/mixed tumor 
Either a complex adenoma or a mixed tumour, with 
areas of more pleomorphic epithelial cells with 
increased numbers of mitoses. 
Complex carcinoma A malignant epithelial component and a benign 
myoepithelial component. 
Carcinoma and malignant 
myoepithelioma 
Two cell populations in which both, the epithelial and 
myoepithelial components are malignant. 
Mixed carcinoma Uncommon neoplasia with a malignant epithelial 
component and a benign mesenchymal component. 
Ductal carcinoma Neoplastic cells arranged in cords and tubules lined by 
a double layer of epithelial cells. 
Intraductal papillary carcinoma Proliferation of a multilayered population of epithelial 
cells. Papillae are supported by fibrous connective 
tissue and myoepithelial cells. 
2. Malignant epithelial neoplasms 
– special types 
Squamous cell carcinoma                       
Adenosquamous carcinoma                                
Mucinous carcinoma                                                    
Lipid-rich (secretory) carcinoma                             
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3. Malignant mesenchymal 
neoplasms - Sarcomas 
Osteosarcoma                                        Chondrosarcoma                                        
Fibrosarcoma                                      Hemangiosarcoma                                                    
Other sarcomas 
4. Carcinosarcoma – Malignant 
mixed mammary tumour 
Composed partly of epithelial cells and connective 
tissue elements, both malignant. Epithelial cells 
metastasise via lymphatic vessels to regional lymph 
nodes and lungs. Mesenchymal cells migrate through 
blood vessels to the lungs. 
Table 1.2. Classification of canine mammary tumours proposed by Goldshmidt et al., 2011. This 
table emphasises the malignant epithelial neoplasms. 
 
1.4.2 Prognosis  
According to Sorenmo et al., 2011 and 2013, the following 3 prognostic 
factors are the most consistently associated with canine mammary cancer prognosis 
(Sorenmo et al., 2013, Sorenmo et al., 2011): 
1) Tumour volume; MacEwen et al., 1985, showed that the most significant 
prognostic factor in a study with 144 dogs diagnosed with malignant 
mammary tumours, was the volume of the masses, where tumours smaller 
than 41 cc (approximately 3.4 cm) had statistically significant better 
prognosis in terms of survival time than those bigger than 41 cc 
(MacEwen et al., 1985). 
 
2) Lymph node status; different studies have shown that lymph node 
invasion is highly prognostic and important for consideration of 
therapeutic protocols after surgery (reviewed by Kurzman and Gilbertson, 
1986, Szczubial and Lopuszynski, 2011). 
 
3) TNM staging; tumour size and lymph node status are parameters included 
in the TNM staging system, both of which provide important information 
regarding mammary cancer prognosis. In two separate studies, Yamagami 
et al., 1996 and Philibert et al., 2003, observed that when combining the 
TNM staging with the WHO histological grading system in 175 and 99 
bitches, respectively, the results of the evaluations were determinant for 
prognosis. This data could be useful for the prognostic determination in 
canine mammary tumours (Yamagami et al., 1996, reviewed by Philibert 
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1.4.2.1 Molecular markers of mammary carcinoma 
Mammary carcinoma in women and bitches is highly curable if diagnosed at 
early stages; thus, it is of great importance to identify molecular biomarkers as 
potential prognostic factors. 
A number of potential biomarkers for mammary carcinoma have been widely 
studied. Common molecules usually utilised to identify cancer patients with early 
stages of breast cancer include markers of proliferation, hormone receptors and the 
human epidermal factor receptor (EGFR) (Esteva and Hortobagyi, 2004). Cell 
proliferation rate is one of the most important prognostic factors in breast cancer and 
Ki-67 is a nuclear antigen commonly used as a proliferation marker. It is expressed 
during M phase of the cell cycle (proliferation phase), and overexpression of Ki-67 
in patients with breast cancer has been associated with tumour recurrence (Veronese 
et al., 1993). In breast cancer, Ki-67 expression has also been correlated with 
expression of other proliferation markers, including the proliferating cell nuclear 
antigen (PCNA) (Keshgegian and Cnaan, 1995). 
Hormone receptors such as ER and progesterone receptor (PR) are also well-
established prognostic factors for breast cancer in humans. Overexpression of ER has 
been associated with longer disease-free survival (DFS) rate, where patients with 
ER+ breast cancer had a longer DFS compared to ER- patients (Thorpe et al., 1986). 
As PR has a close relation with ER, its overexpression would indicate that the ER 
pathway is intact and the patient’s prognosis would be as if the tumour was ER+ 
(Esteva and Hortobagyi, 2004). 
Human Epidermal Growth Factor Receptor 2 (HER-2), a member of the 
EGFR family, is important during breast cancer pathogenesis, and is overexpressed 
in breast cancer patients (Slamon et al., 1987). HER-2 overexpression is associated 
with shorter disease-free survival and death in node-positive patients (Borg et al., 
1990). 
Matrix Metallopeptidase-9 (MMP-9), a zinc-dependent endopeptidase of a 
large family of matrix metallopeptidases, has also been found to be a valuable 
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prognostic factor in breast cancer in humans. MMP-9 has a broad capacity for tissue 
remodelling by degrading the basement membrane and inducing angiogenesis, which 
in part can trigger tumour invasion and metastasis (Nowac et al., 2008). It has been 
demonstrated that MMP-9 overexpression in stromal cells is a predictive factor for 
poor survival in small breast tumours, but interestingly, the expression of this 
enzyme is associated with survival in breast carcinoma cells (Pellikainen et al., 
2004). In the need for novel therapies against cancer, MMP-9 has been targeted 
previously with disappointing results due to toxicity produced by MMP inhibitors as 
reviewed by Fingleton, 2008. Perhaps because some MMPs act as protective 
enzymes, the indiscriminate inhibition of MMPs can produce musculoskeletal 
toxicity (Sparano et al., 2004 and reviewed by Decock et al., 2011). New approaches 
for MMP-9 inhibition include small molecules that inhibit gelatinases (Kruger et al., 
2005) and subsets of MMP-9 substrate (Bjorklund et al., 2004), as well as 
monoclonal antibodies targeting the catalytic domain of MMP-9 (Sela-Passwell et 
al., 2012). 
In a similar approach, the identification of molecular markers in canine breast 
cancer can prove useful for the determination of prognosis, but also to establish 
therapeutic targets. Among these markers, Ki-67 and PCNA have been studied and 
confirmed to have prognostic value. Pena et al., 1998 observed that their expression 
was directly proportional to malignancy and metastasis in canine mammary tumours. 
Also in benign tumours and dysplasias, these proteins were poorly expressed 
compared to malignant tumours (Pena et al., 1998). Santos et al., 2013 later 
confirmed these observations and moreover, it was found that MMP-9 was also 
associated with malignancy in canine mammary tumours, and consistent with the 
human disease (Pellikainen et al., 2004), suggesting that these molecules could be 
potential targets after surgical treatment (Santos et al., 2013).  
p53 is the most frequently mutated tumour suppressor gene in cancer in 
humans as reviewed by Vogelstein et al., 2010. Veldhoen et al., 1999 and Lee et al., 
2004 showed that p53 mutation and overexpression of its protein were also 
associated with malignancy and poor prognosis in canine mammary tumours, as in 
humans (Veldhoen et al., 1999, Lee et al., 2004). These findings could prompt 
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further research with new experimental models to elucidate protective mechanisms to 
prevent this tumour suppressor gene from being mutated in companion animals. 
 
1.4.3 Treatment 
For canine mammary cancer, treatment can be divided into surgical and 
systemic. The treatment of choice is surgical removal of the mass or multiple masses, 
except for those patients diagnosed with distant metastasis or with inflammatory 
carcinoma as reviewed by Sorenmo et al., 2013. Adjuvant systemic treatment, 
including chemotherapy, radiotherapy and hormonal therapy can be recommended in 
dogs with high-risk tumours with aggressive histology and positive lymph nodes, 
where surgery alone is not enough to treat them (Sorenmo et al., 2013). Even though 
surgery will always be the first option, there is a lack of prospective clinical trials in 
dogs that could elucidate the benefits of different “doses” or extent of surgical 
excision. The owner must be aware of the goals of the surgical procedure and discuss 
the aims of the surgery with the veterinary surgeon as there are several surgical 
techniques, including simple lumpectomy or nodulectomy, mastectomy, regional 
mastectomy, chain mastectomy and bilateral mastectomies (reviewed by Sorenmo et 
al., 2013). Lana et al., 2007 recommend specific surgical approaches depending on 
the extent of the tumour. For tumours smaller than 0.5 cm, they suggest a simple 
lumpectomy, but if the tumour is ≤ 1 cm with ulcerated skin or adhesions, a 
mastectomy is recommended. For larger tumours either a simple mastectomy with 
wide excision, or a regional or a chain mastectomy would be recommended 
depending on the extension of the tumour and if there are multiple masses. Wide 
excisions should have at least 2 cm lateral margins and in some cases with deeper 
tumours, the abdominal muscular fascia and parts of the abdominal wall should be 
included in the excision as reviewed by Lana et al., 2007 and Sorenmo et al., 2013. 
However, different retrospective studies have shown that there is no difference in 
overall survival time and disease-free interval after simple mastectomy or chain 
mastectomy (MacEwen et al., 1985, Chang et al., 2005). 
Systemic treatment is usually recommended for high-risk tumours although 
there is no clinical evidence of its efficacy due to the lack of adequate prospective 
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randomised trials with different therapeutic protocols, reviewed by Sorenmo et al., 
2013. Systemic treatment protocols include hormonal therapy, and most commonly 
chemotherapy, usually combined with nonsteroidal anti-inflammatory drugs 
(NSAIDs) (Marconato et al., 2009, De M. Souza et al., 2009). Karayannopulou et al., 
2001 carried out a prospective non-randomised trial on 16 bitches with high risk 
mammary tumours, where they separated 2 groups of 8 patients. Both groups had had 
surgical treatment, but only one of the groups received adjuvant chemotherapy with a 
combination of 5-fluorouracil and cyclophosphamide, and they observed that the 
chemotherapy treated group had longer disease-free interval and survival time; and 
even though most of the patients had a decrease in leucocyte counts, they remained 
within normal limits except for one bitch that presented temporary leukopenia 
(Karayannopoulou et al., 2001). Nevertheless, as this study utilised a small group of 
patients, it may have a low impact as a clinical trial, but it still suggests that 
chemotherapy as adjuvant treatment might be useful for high-risk tumours. More 
prospective studies are needed to determine proper and specific chemotherapeutic 
protocols for different types of mammary tumours in dogs. 
Two different retrospective studies confirmed that the use of NSAIDs alone 
or in combination with chemotherapy to treat canine mammary inflammatory 
carcinoma was beneficial in terms of survival time (Marconato et al., 2009, De M. 
Souza et al., 2009). These effects were also confirmed in vitro by observing 
cytotoxic effects in a canine mammary carcinoma cell line after treatment with the 
NSAIDs piroxicam and deracoxib, suggesting that cyclooxygenase-2 (COX-2) 
inhibition might be a useful approach for the development of novel therapeutic 
protocols against canine mammary cancer (Ustun Alkan et al., 2012). Moreover, 
Pang et al., 2014 showed that mavacoxib, a long-acting COX-2 inhibitor has a direct 
anti-proliferative effect in canine cancer cells, including osteosarcoma, glioma, 
lymphoma, mast cell tumour and hemangiosarcoma cells in vitro. They also proved 
that this NSAID has an inhibitory effect on cell migration and a pro-apoptotic effect 
on osteosarcoma cell lines; and more importantly, osteosarcoma-derived cancer stem 
cells were sensitive to its cytotoxic effects, making this drug a potential therapeutic 
candidate for canine cancer treatment (Pang et al., 2014). 
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Tamoxifen citrate has been used in humans as a selective inhibitor of 
oestrogen receptors in ER+ breast cancer in women (Jordan, 2006) but there is no 
evidence of its clinical relevance in dogs. It has been associated with adverse effects 
regarding hormonal disparity between oestrogen and progesterone in intact bitches 
that could potentially lead to the development of pyometra (Tavares et al., 2010). 
Thus, it is not a standard care in un-spayed female dogs.  
There is still much to be elucidated regarding the use of systemic therapeutic 
protocols alone or in combination with other treatments, and thus, there is no 
consensus that they are clinically relevant, even in cases with lymph node metastasis 
or distant metastasis. Currently the best way to combat mammary tumours in dogs is 
preventive by performing OHE at early stages of life (Schneider, 1970, Schneider et 
al., 1969). 
1.5 Introduction to EMT  
Epithelial to mesenchymal transition (EMT) is a process through which 
epithelial cells lose their characteristics and acquire mesenchymal properties. This 
process is rapid and reversible (reviewed by Klymkowsky and Savagner, 2009) and 
can facilitate cell migration. The EMT program is essential throughout different 
embryonic stages, including organogenesis and gastrulation. Cells acquiring 
mesenchymal characteristics are able to move towards different places in the embryo 
in order to generate organs and their anatomical structures as reviewed by Shook and 
Keller, 2003, and Thiery, 2003. This process, by increasing cell motility and 
invasiveness, plays roles in wound healing, and metastasis. Based upon the 
fundamental roles that EMT has, this process has been classified as follows: 
Type  I Embryogenesis and organ development  
Type II Fibrosis - wound healing and tissue regeneration   
Type III Metastasis – enabling neoplastic cells to invade different 
tissues and organs during cancer progression 
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Epithelial to mesenchymal transition mediates reorganisation of the 
cytoskeleton by decreasing cell-cell contact and changing cell polarity as reviewed 
by Acloque et al., 2009. Epithelial cells adhere to each other by lateral cell-cell 
junctions. These cells are polarised such that the bottom is defined as basal, and the 
top as apical. The matrix binding areas are located at the basal aspect of the 
epithelium. Due to these properties, epithelial cells generally form groups with tight 
junctions. In contrast, as shown in Figure 1.1, mesenchymal cells have a more 
elongated shape and their polarity is reversed, therefore they do not form large 
groups, and easily migrate (reviewed by Acloque et al., 2009). These changes are 
induced by transcriptional repression of proteins, such as cadherins, occludin, claudin 
and desmoplakin. This repression can be accomplished by a range of transcription 
factors including ZEB1, Snail, Slug and Twist. Furthermore, epithelial cells undergo 
cytoskeletal changes, acquiring increased motility and invasiveness (reviewed by 
Savagner et al., 1994, and Thiery and Chopin, 1999). 
If a cell is to achieve colonisation of a distant site, then EMT has to be 
reversed. This reversion is called Mesenchymal to Epithelial Transition (MET), and 
without it, cells would not be able to form any tissue or organ, including any kind of 
metastatic colonisation as reviewed by Lee et al., 2006. After MET, cells gain back 
their lost polarity and adhere to each other by tight junctions. This is due to an 
upregulation of proteins that help create adherens junctions such as E-cadherin and 
β-catenin, and the downregulation of those which can enable cells to break their 
adhesions and change their shape and polarity, such as fibronectin and vimentin 
(Zeisberg et al., 2005). All three sub-types of EMT (Types I-III) require the reverse 
Mesenchymal-Epithelial Transition (MET) program to enable cells to attach to their 
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Figure 1.1. Polarity changes in cells undergoing EMT and the reverse program MET. Epithelial 
cells acquire front-back polarity and lose cell-cell contact, becoming mesenchymal and 
migrating through surrounding tissues and blood and lymphatic vessels. Once they reached the 
new microenvironment (niche), they regain their epithelial characteristics by MET. 
This process is relevant in cancer progression, as in some cancers with 
epithelial origin like skin, stomach or breast cancer, cells would have to go through 
an EMT process in order to migrate and invade a different organ as reviewed by 
Kalluri and Weinberg, 2009. This process is part of metastatic progression where a 
primary tumour evolves and produces a secondary or metastatic tumour, which in 
most cases can be lethal. During EMT, cells acquire migratory properties and cancer 
stem-cell characteristics (reviewed by Polyak and Weinberg, 2009, Morel et al., 
2008, Mani et al., 2008), suggesting that EMT and the stem-cell phenotype are 
closely related during cell migration and invasion. The EMT process has been 
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1.6 Metastatic progression 
The molecular mechanisms and pathogenesis underlying metastasis are not 
fully understood yet. Undoubtedly, a better understanding of these mechanisms 
would help create novel therapeutic protocols against cancer and its progression 
(Smit et al., 2009).  
Tumour metastatic progression has been considered the final stage of cancer, 
which causes approximately 90% of cancer deaths (reviewed by Im et al., 2012, and 
Wu and Zhou, 2008). It is a complex, multistep process in which malignant tumour 
cells migrate through surrounding tissues and invade distant sites where they can 
spread and attach to different organs creating a secondary tumour as reviewed by 
Kusewitt and Rush, 2007. Four distinct steps have been named to describe this 
process: invasion, intravasation, extravasation, and metastatic colonisation (reviewed 
by Chambers et al., 2002, Pantel and Brakenhoff, 2004).  
It has been suggested that the presence of the primary tumour modulates the 
microenvironment, also called niche, of the site where metastatic cells will attach, 
prior to the arrival of most of them. Once cells arrive at their new niche, they must 
survive and proliferate to start modulating it to their convenience, a process that 
would be necessary for a metastatic tumour to grow and progress within its 
surrounding stroma (reviewed by Kaplan et al., 2006). The tumour itself can modify 
this stroma, and interestingly, Transforming growth factor-Beta (TGF-β) may play a 
crucial role during the metastatic niche modulation by stimulating angiogenesis and 
recruiting different types of host cells, including myofibroblasts, in order to prepare 
the “scaffolding” for the metastatic tumour (De Wever and Mareel, 2003). 
Interestingly, Twist and Snail (transcription factors with important roles in the TGF-
β pathway) have been associated with tumour progression, by suppressing/increasing 
resistance to anoikis, thus, contributing to metastasis (Smit et al., 2009). Therefore, a 
tumour can be considered as a complex system which supports the malignant 
characteristics that lead to metastasis. This complex system is composed by cancer 
cells and cancer stem cells in the first place, followed by endothelial cells, pericytes, 
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immune cells and tumour-associated fibroblasts as reviewed by Argyle and Khanna, 
2013.  
Stephen Paget first suggested in 1889 that tumour cells grew preferentially in 
specific organs due to their microenvironment interacting with colonising cells. He 
called this “the seed and soil hypothesis”, where the tumour cells would be the seed 
and the microenvironment of these specific organs would be the soil (Paget, 1889). 
This hypothesis has been supported by different research groups, for instance, in 
1960; Kinsey demonstrated that lung melanoma cells in syngeneic mice, migrated to 
normal and ectopically placed lung tissues, but not to other places around the 
organism (Kinsey, 1960). Furthermore, in 1988, Schackert and Fidler showed that 
mouse melanoma and fibrosarcoma cells metastasised to specific organ regions 
within the central nervous system (Schackert and Fidler, 1988). However, other 
studies reported that metastasis was not due to the seed and soil hypothesis, but to a 
specific anatomical site of the primary tumour and the vascular and lymphatic 
drainage leading to the first organ encountered (Ewing, J., 1928). Regarding these 
hypotheses, Langley and Fidler, 2011 concluded that neither of them is necessarily 
exclusive of each other (Langley and Fidler, 2011). 
 
1.7 Mammary carcinoma metastasis 
Metastatic potential is very high among mammary carcinomas from which 
metastatic cells migrate and invade different organs, where they will colonise, and be 
more aggressive than the primary tumour. In humans, the primary site for breast 
cancer metastasis is bone, followed by lungs (Chen et al., 2010, Coleman, 2006). In 
canine and feline breast cancer, the primary metastatic site is the lungs (reviewed by 
Nelson, 2000, Ogilvie, 2006). Canine mammary carcinoma is the most common 
cancer among female dogs and is often fatal due to the development of distant 
metastases, reviewed by Von Euler, 2014. Moreover, in bitches, 50% of mammary 
tumours are malignant, and half of them usually progress and metastasise to distant 
organs (reviewed by Argyle et al., 2008). 
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Lymph node metastasis is considered the first step in the metastatic cascade 
of mammary carcinoma (Olmeda et al., 2007b), and is one of the most well founded 
factors for predicting a poor prognosis (Fisher et al., 1978) due to the fact that distant 
metastases are not common findings at presentation (Wingo et al., 1995). Most 
mammary carcinomas in dogs metastasise through lymphatic vessels. The most 
cranial pairs of glands (M1 and M2) are typically drained through lymphatic vessels 
to the axillary lymph nodes. The third pair (M3) can be drained by the axillary and 
inguinal lymph nodes, whilst the two most caudal pairs (M4 and M5) typically drain 
towards the inguinal lymph nodes. Regional lymph nodes metastasis usually leads to 
a worse prognosis as reviewed by Von Euler, 2014. As described above, the lungs are 
the most affected organs after lymphatic invasion in dogs, thus, it is always 
recommended to perform three view thoracic radiography to rule out lung metastasis 
prior to any therapeutic protocol, although in 2003, Djupsjobacka and Eksell 
observed that in dogs younger than 8 years of age with a metastatic pulmonary 
tumour measuring 1 cm or less, the possibility to detect thoracic metastases was only 
3% (Djupsjobacka and Eksell, 2003). Distant metastasis can also involve other 
organs, including liver, kidneys, spleen, bones, central nervous system and pleura as 
reviewed by Von Euler, 2014. 
 
1.8 EMT in cancer and during metastasis 
Recent data show that EMT is commonly observed in primary tumours at 
their cancer invasion front (reviewed by De Weber, 2008). It is also associated with 
resistance to anticancer agents such as EGFR inhibitors (Voulgari and Pintzas, 2009). 
During EMT III cancer cells follow similar pathways as normal cells during 
embryonic development and wound healing. The existence of a reversible program 
(MET) which would enable cells to form a new epithelial sheet has been proposed by 
Thiery, 2002 (Thiery, 2002) and Hugo et al., 2007 (Hugo et al., 2007). Some cancer 
cells may also pass through just a partial EMT, expressing both, mesenchymal and 
epithelial markers during the process as reviewed by Yang and Weinberg, 2008. 
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There are three important pathways in EMT: wingless-related integration 
site/β-catenin (Wnt/β-catenin); fibroblast growth factor (FGF); and transforming 
growth factor-beta 1/Bone morphogenetic protein (TGFβ1/BMP). These pathways 
are vital for embryogenesis, and also play important roles in tumour formation and 
progression. The transforming growth factor β1 (TGFβ1) pathway is crucial in EMT 
induction due to its multiple downstream effectors capable of repressing E-cadherin 
and subsequently enabling upregulation of mesenchymal promoters, such as 
fibronectin and vimentin as reviewed by  Thiery and Sleeman, 2006 and Oft et al., 
2002. 
 
1.9 Molecular features of EMT during tumour 
progression  
There are four important stages in cancer development and cell migration 
which are 1) Invasion, 2) Intravasation, 3) Extravasation, and 4) Metastatic 
colonisation (Weinberg, 2008). In order for an epithelial tumour to complete each 
step during this process, molecular changes are required to enable EMT.  
One of the principal characteristics of EMT is the loss of E-cadherin. This 
protein participates in cell-cell adhesion and interacts with other molecules to form 
epithelial junctions. It is a calcium-dependent cell adhesion molecule that connects 
epithelial cells by calcium-dependent homotypic interactions as reviewed by 
Schmalhofer et al., 2009, playing an important role in the maintenance of epithelial 
layers (Matos et al., 2006). The expression of E-cadherin is inversely proportional to 
tumour grade and stage, and patient prognosis as reviewed by Schmalhofer et al., 
2009. β-catenin is also essential for keeping cells attached to each other, it acts by 
binding E-cadherin and α-catenin to the actin cytoskeleton as depicted in Figure 1.2 
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Figure 1.2. The extracellular domains of E-cadherin homodimers are connected by calcium-
dependent homotypic interactions with those of dimers on adjacent cells. The intracellular 
domain of E-cadherin attaches to β-catenin and α-catenin to interact with the actin cytoskeleton 
and form the adherens junctions. 
Once epithelial cells detach from other cells and their epithelial sheet, they 
can acquire motility by changing their shape and polarity in order to migrate through 
different tissues, and lymphatic and blood vessels as reviewed by Thiery, 2003. 
Vimentin is an intermediate filament protein with structural features, which enables 
it to play a main role in switching the cell’s shape and making its cytoskeleton 
stronger so it can be more flexible and prevent damage to the cell membrane 
(reviewed by Goldman et al., 1996). It binds with microtubules and actin 
microfilaments to make up the cytoskeleton, without this protein migrating cells 
would be very fragile. Not only is a robust cytoskeleton necessary for migrating 
cells; it is also necessary to guide these cells during migration as reviewed by 
Goldman et al., 1996. Fibronectin is a high molecular weight extracellular matrix 
glycoprotein that plays important roles in cell adhesion, growth, migration and 
differentiation (Williams et al., 2008), by guiding cells and binding to collagen and 
fibrin. Genetic alterations in fibronectin have been associated with pathologies, 
including fibrosis and metastasis (Darribere and Schwarzbauer, 2000, Hao et al., 
2004, Williams et al., 2008).  
These molecular alterations are due to different transcription factors, which 
act as EMT inducers by stimulating and/or suppressing functions of different proteins 
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involved in this complex process. Snail, Slug (Snail 2), Twist and ZEB1 are 
important transcription factors involved in EMT (Mathias et al., 2009). They bind to 
the proximal E-boxes of the promoters of E-cadherin in order to contribute to its 
transcriptional repression, considered to be the hallmark of EMT (Bolos et al., 2003). 
The Snail family is made up of Snail and Slug (Snail 2) and they are involved in 
different stages of development such as gastrulation, mesoderm formation, cell 
differentiation, cell motility and apoptosis (Boulay et al., 1987, Seki et al., 2003 and 
reviewed by Hemavathy et al., 2000 and Arias, 2001). They are implicated in EMT 
by downregulation of expression of E-cadherin (Sugimachi et al., 2003, Hajra et al., 
2002, Bolos et al., 2003). Olmeda et al., 2007b showed that when Snail and Slug 
were inhibited in mammary tumour cell lines, tumour growth was impaired and their 
metastatic potential was lowered in mice (Olmeda et al., 2007b). Twist is part of the 
basic helix-loop-helix protein family and one of its most important features is the 
ability to inhibit apoptosis (Maestro et al., 1999). It is also known to trigger EMT by 
downregulating E-cadherin expression (Yang et al., 2004). Two members of the zinc 
finger E-box binding proteins family are ZEB1 and ZEB2, both of which can 
regulate E-cadherin and thus, are capable of stimulating EMT as depicted in Figure 
1.3 (reviewed by Peinado et al., 2007, Eger et al., 2005, Comijn et al., 2001). Burk et 
al., 2008 showed that ZEB1 was overexpressed in colorectal, pancreatic and breast 
cancer cell lines undergoing EMT induced by TGFβ1 and TNFα (Burk et al., 2008). 
Moreover, when ZEB1 was knocked down by siRNA, EMT was partially prevented. 
Each of these different epithelial/mesenchymal biomarkers and transcription factors 







Chapter 1: Introduction 
 
Figure 1.3. EMT induces cells to acquire stem cell-like characteristics. After undergoing EMT, 
epithelial cancer cells acquire not only mesenchymal characteristics like spindle shape and 
front-back polarity, but also stem cell-like features such as tumour seeding abilities and 
resistance to apoptosis. However, once they reach their new microenvironment, they undergo 
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Upregulation 
(Peinado et al., 
2007, Eger et al., 
2005, Burk et al., 
2008) 
Table 1.3. EMT biomarkers (epithelial and mesenchymal) and transcription factors 
characteristics as well as their expression during EMT. Every component of this complex 
network has different characteristics; some of which would enable cells to acquire mesenchymal 
features whilst losing epithelial properties. Their expression can be downregulated or 
upregulated, depending on their role in EMT. 
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1.10 Signalling pathways and EMT inducers 
In cancer, EMT can be induced by extrinsic and intrinsic stimuli. The 
microenvironment of a tumour plays a very important role as an extrinsic stimulus 
during cancer progression and metastasis. Some EMT inducing factors can be 
promoted by the interaction between the microenvironment and tumour cells, for 
example, members of the Snail family (E-cadherin repressors) can be activated by 
extracellular factors. Extrinsic stimuli include activators of Wnt, Hedgehog, Notch, 
Nuclear Factor-κB (NF-κB) and TGF-β signalling pathways. Subsequently, TGF-β is 
a potent EMT inducer during tumour progression (Voulgari and Pintzas, 2009, 
reviewed by Huber et al., 2005 and Moustakas and Heldin, 2007). Crosstalk between 
these signalling pathways has been implicated in E-cadherin repression and EMT 
induction. For example, Wnt and Hedgehog signalling cascades induce Snail 
upregulation, which subsequently represses E-cadherin. Hedgehog signals interact 
with Notch and TGF-β signalling pathways to induce EMT (Katoh and Katoh, 2008). 
Wnt signalling pathway is disrupted during different cancer stages leading to EMT 
induction.   
TGF-β is a member of a very complex multifunctional family of cytokines 
which act as mediators of development stages and tissue homeostasis. However, they 
have paradoxical functions depending on cell type. TGF-β can act as a physiological 
and pathophysiological regulator through different stages of life (reviewed by Singh 
and Settleman, 2010 and Derynck et al., 2001). For example; it can promote 
apoptosis and/or cell cycle arrest in normal epithelial, endothelial and haematopoietic 
cells, but when there is a deregulation or a mutation in the TGF-β pathway, apoptosis 
can be inhibited while cells acquire tumorigenic characteristics and also become 
motile and invasive to the surrounding tissues as reviewed by Blobe et al., 2000. 
Mutations in the TGF-β type II receptor were demonstrated by Markowitz et al., 
1995 (Markowitz et al., 1995) and Myeroff et al., 1995 (Myeroff et al., 1995) in 
different kinds of cancer showing loss of expression of this receptor. This resistance 
to its anti-proliferative characteristics can contribute to the formation of different 
kinds of cancer.  The PI3K signalling pathway (induced by TGF-β), via its 
downstream effector Akt, can block apoptosis in mammary epithelial cells 
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chronically treated with TGF-β by sequestering Smad3 into the cytoplasm after 
insulin treatment (Gal et al., 2008, Remy et al., 2004). Moreover, TGF-β acts as a 
tumour suppressor during early stages of tumorigenesis by its growth inhibitory 
effects and stimulation of apoptosis. Interestingly, during late stages of tumour 
progression, it can also act as a tumour promoter with pro-metastatic effects. This 
was confirmed by Shipitsin et al., 2007 (Shipitsin et al., 2007), who observed a high 
level of expression of TGF-β in CD44+/CD24- metastatic breast cancer stem cells.  
In addition, following TGF-β inhibition, these cells demonstrated a more epithelial 
behaviour. TGF-β can stimulate two of the most important features of cancer 
progression, which are invasion and metastasis (reviewed by Wendt et al., 2009). 
Furthermore, when TGF-β binds to its receptors (TGF-βRI and TGF-βRII), a 
signalling cascade is initiated by their phosphorylation, which can activate different 
proteins, in which the Smad family of transcription factors is one of the most notable. 
Specifically, when Smad2 and Smad3 bind with co-smad (Smad4) after their 
activation via TGF-βRI, this complex associates with different transcription factors 
like ZEB proteins to repress E-cadherin during EMT (reviewed by Derynck et al., 
2001, Levy and Hill, 2005, Verschueren et al., 1999).  
TGF-β also activates a range of downstream effectors, which can induce 
EMT. One of the most important downstream effector is NF-κB. As yet, the exact 
way NF-κB works is not fully understood, but one of its major roles is to suppress 
apoptosis. It remains unclear how NF-κB regulates EMT and metastasis, however, 
Huber et al, 2004 demonstrated that in Ras-transformed mammary epithelial cells, 
EMT is induced by gain of NF-κB (Huber et al., 2004). They also demonstrated that 
inactivation of NF-κB causes Mesenchymal to Epithelial Transition (MET), 
suggesting that this signalling pathway not only induces EMT, but also helps to 
maintain it. Inhibitory proteins of NF-κB, known as Inhibitor κB (IκB) proteins, 
which are involved in NF-κB activity regulation (Huber et al., 2004), have been 
utilised to further elucidate NF-κB function in different model systems. For example, 
Huang et al., 2001 used a mutant form of IκBα to downregulate NF-κB activity in 
metastatic human prostate cancer and, as a result, they observed inhibition of tumour 
growth, invasion and metastasis in vitro and in vivo (Huang et al., 2001, Huber et al., 
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2004). Furthermore, they also confirmed this in human melanoma cells (Huber et al., 
2004, Huang et al., 2000). NF-κB regulates Snail expression, leading to its increased 
transcription. Subsequently, Snail represses Raf kinase inhibitor, an inhibitor of NF-
κB activity. Therefore, Snail overexpression suppresses E-cadherin activity, inducing 
EMT while repressing RKI (Wu and Zhou, 2010). 
Genetic alterations such as mutations/perturbations can act as intrinsic stimuli 
of EMT during cancer progression by potentiating EMT inducers or inhibiting EMT 
repressors. TGF-β can act as a tumour suppressor after acquiring a specific gene 
mutation, but its un-mutated form can function as an EMT inducer to promote 
invasion and metastasis (Levy and Hill, 2005). Lehmann et al., 2000 showed that 
during cancer progression, the TGF-β growth inhibitory effect can have a negative 
feedback and cancer cells can proliferate due to an upregulation of Ras proteins and 
consequential activation of the MAP kinase pathway (Lehmann et al., 2000). TGF-β 
also lost its pro-apoptotic but not its pro-invasive activities through this pathway. 
TGF-β activates a range of different signalling pathways leading to EMT during 
tumour progression (Figure 1.4), such as Rho Family of GTPases (Figure 1.4 A), 
PI3K/AKT (Figure 1.4 B), Integrin-linked Kinase (ILK) (Figure 1.4 C), NF-κB 
(Figure 1.4 D) and MAP Kinases (Figure 1.4 E) (reviewed by Wendt et al., 2009). 
Each of these signalling pathways involves different features that are inter-related, 
for example, E-cadherin can be downregulated by a range of transcription factors, 
including Snail; Slug; Twist; and ZEB1 as reviewed by Wendt et al., 2009. 
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Figure 1.4. TGFβ1 stimulated signalling pathways. Among the signalling pathways stimulated 
by TGFβ1, there are at least these 5 that can promote EMT through different molecular 
changes. (A) Rho family of small GTPases. Comprised by RhoA, Rac1 and Cdc42. If RhoA is 
activated via TGF-β, epithelial cells can acquire mesenchymal characteristics by losing their 
cell-cell adhesion and gaining motility in order to migrate. This can be achieved by RhoA and its 
downstream effector ROCK. (B) PI3K/AKT. This signalling pathway is crucial to achieve EMT 
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because it enhances cancer cell survival. As we understand, when cells migrate through different 
tissues and vessels, they can be seriously damaged and killed. (C) Integrin-linked Kinase (ILK). 
Its elevated expression can be associated with downregulation of E-cadherin (cell-cell adhesions) 
and with formation of stress fibres and invasion which can be due to upregulation of fibronectin 
and vimentin. ILK can also be coupled with the AKT pathway. (D) NF-κB. This pathway can 
stimulate cell survival by regulating apoptosis, tumour cell growth and immune response. TGF-
β suppresses its activity in normal cells, but it can stimulate it in cancer cells, leading to EMT by 
downregulation of E-cadherin and upregulation of vimentin. NF-κB can be repressed by IκB to 
block EMT and prevent migration. (E) MAP Kinases. This is a big family of protein kinases 
including ERK1/2, JNK’s and p38 MAPKs. Activation of these family members by TGF-β 
promotes EMT by downregulating E-cadherin and increasing the formation of stress fibres with 
the upregulation of fibronectin. Invasion can also be achieved by the activation of prometastatic 
genes via p38 MAPKs. 
 
1.11 Cancer Stem Cell Theory 
The cancer stem cell theory proposes that a tumour contains heterogeneous 
cell populations. A small percentage of cancer cells have stem cell characteristics, 
such as self-renewal and pluripotency, enabling them to drive tumour recurrence and 
metastasis. These specific cells are able to produce all cell types within a tumour 
(reviewed by Nowell, 1976) and have been named cancer stem cells (CSCs) or 
tumour-initiating cells as reviewed by Reya et al., 2001. The concept that tumours 
can arise from small populations of tumorigenic cells was proposed in the late 19th 
century, but was tested almost one hundred years later by different research groups 
with human haematopoietic stem cells and leukaemia stem cells (Bonnet and Dick, 
1997, Hope et al., 2004, reviewed by Dalerba et al., 2007, Eyler and Rich, 2008, and 
Winquist et al., 2009). These seminal studies helped to define this CSC theory by 
showing that a single cell was capable of generating a population of heterogeneous 
cells in mouse models. They confirmed that human acute myeloid leukaemia is 
arranged hierarchically, by looking for expression of haematopoietic cell-surface 
markers. They identified leukaemia-initiating cells as CD34+ CD38-, and capable of 
forming tumours in transplanted severe combined immune deficient (SCID) mice. In 
a similar study, Lapidot et al., 1994 observed that CD34+ CD38- and CD34- cells 
did not have the same colony-forming properties (Lapidot et al., 1994).  
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Furthermore, research in different types of cancer is providing strong 
evidence of the existence of CSCs (reviewed by Reya et al., 2001). As previously 
explained, these tumour-initiating cells were first discovered in the haematopoietic 
system, but have been recently identified in several kinds of solid tumours including 
colon, breast and brain cancer (Al-Hajj et al., 2003, O'Brien et al., 2007, Ricci-
Vitiani et al., 2007, Singh et al., 2004). 
   
1.12 Linking EMT and Cancer Stem Cells 
Recent evidence indicates that CSCs are required to establish metastatic 
tumours at distant sites in vitro, and that EMT may promote development of cancer 
cells with stem-cell characteristics and aid metastasis (reviewed by Reya et al., 2001, 
Mani et al., 2008).  
In addition to morphological changes during EMT, epithelial cells may also 
develop altered functional properties, such as increased tumour-seeding ability, 
tumoursphere formation and expression of transcription factors Twist and Snail.  In 
addition, they also play an important role in invasiveness and migration in different 
types of cancer as reviewed by Gupta et al., 2009. Independent groups have 
demonstrated in vitro that cells that have undergone EMT, by expressing different 
transcription factors or induced by TGF-β, showed stem cell characteristics, such as 
the ability to form spheres and expressed stem cell associated cell surface markers 
(Mani et al., 2008, Morel et al., 2008, and reviewed by Polyak and Weinberg, 2009). 
Mani et al., 2008 showed that by over expression of Twist or Snail in immortalised 
human mammary epithelial cells (HMECs), these cells became more mesenchymal, 
and their expression pattern demonstrated downregulation of epithelial markers, such 
as E-cadherin, and upregulation of mesenchymal markers such as vimentin and 
fibronectin (Mani et al., 2008). After confirming that EMT took place in these cells, 
they used flow cytometry analysis to see if these cells had stem cell characteristics. 
This group also confirmed that these cells expressed CD44+CD24-, which are cell 
surface markers for mammary epithelial stem cells and human breast CSCs, and were 
capable of forming at least 30-fold more mammospheres than the untreated cells. 
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Cell sorting was performed in HMECs, mouse mammary stem cells and normal and 
neoplastic human breast stem cells and confirmed the overexpression of mRNAs 
encoding mesenchymal markers and downregulation of epithelial markers in 
CD44+CD24- (human) and CD49high CD24med (mouse). Immortalised HMECs, 
transformed by the HER2/neu oncogene, were then transfected with a vector 
expressing the tamoxifen-activatable form of Snail or Twist transcription factors in 
order to confirm the possibility of EMT generating cells with stem-like properties.  
These treated cells were assayed for tumoursphere forming efficiency where it was 
found that cells expressing Snail and/or Twist underwent EMT, and formed 10-fold 
tumourspheres than the untreated group (Mani et al., 2008). In a different study, 
EMT-derived cells were capable of differentiating into other cell lineages (Battula et 
al., 2010). Morel et al., 2008 confirmed that CSCs can originate from a more 
differentiated cell line by utilising FACS analysis to demonstrate that cells 
expressing CD44+CD24-/low can be derived from cells expressing CD44lowCD24+ 
through the activation of the Ras/MAPK signalling pathway, and most interestingly, 
that this process can be stimulated and accelerated by EMT (Morel et al., 2008). The 
abilities of HMEC’s and an oncogenic line (HMLER) to form mammospheres was 
compared and confirmed that only HMLER cells were able to form mammospheres. 
Subsequently the cell phenotypes of these different cell lines were analysed by FACS 
confirming that HMECs were CD44lowCD24+ and HMLER were CD44+CD24-
/low. Furthermore, they performed cell sorting and single-cell cloning assays after H-
RasV12 retroviral expression in HMECs and seeded CD24+ cells into 96-well plates 
with limiting cloning conditions and saw that after three weeks, 19% of the 
population of cells were CD44+CD24-. This population of cells was able to grow 
tumours when injected into mammary pads of nude mice, compared with 
CD44lowCD24+, which were not able to establish tumour growth. CD44+CD24- 
cells in HMEC and MCF10 (immortal human mammary epithelial cell line) cell lines 
showed a spindle shape and expressed lower levels of E-cadherin and β-catenin 
(epithelial markers) and higher levels of fibronectin and vimentin (mesenchymal 
markers), suggesting that these stem cell properties were related to EMT. Finally it 
was confirmed that EMT enabled cells to acquire stemness when the CD44-CD24+ 
cell lines were treated with TGFβ1, which is one of the most potent EMT inducers, 
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for eight days and showed upregulation of vimentin and downregulation of E-
cadherin, as well as presence of CD44+CD24- cells (Morel et al., 2008). 
Collectively, these results strongly suggest that EMT is potentially a precursor to 
generate CSCs from more differentiated cell lines. Further work is required to 
consolidate these theories.   
 
1.13 Clinical and therapeutic implications of an 
EMT/CSC Axis 
EMT may play a fundamental role in cancer progression and metastasis, thus, 
the development of novel therapeutic and diagnostic protocols targeting this 
transition process would be relevant in the search for cancer treatment. EMT has 
been associated with resistance to antineoplastic agents (Voulgari and Pintzas, 2009), 
and if this feature is confirmed, further research could lead to new treatment against 
cancer progression and metastasis. 
Recent data demonstrates that epithelial cells induced by EMT may play an 
important role in invasiveness and migration in different types of cancer as shown in 
Figure 1.3 (reviewed by Gupta et al., 2009). The percentage of CSCs in a tumour 
may vary between different tumours and patients (Figure 1.5 A), as reviewed by 
Pardal et al., 2003. The subpopulation of CSCs identified in human breast cancer 
exhibit CD44+ and CD24- cell surface-markers, and were found to be more resistant 
to conventional therapies than the more differentiated cancer cells, (Li et al., 2008) 
suggesting that tumour relapse can be accomplished by these CSCs after treatment 
(Figure 1.5 B). Therefore, these cells must be eliminated to affect a cure on cancer 
(Figure 1.5 C). 
 
35 
Chapter 1: Introduction 
 
Figure 1.5. Cancer stem cells are resistant to conventional therapy. A) Self renewal and 
differentiation from single cancer stem cells (red) to differentiated cancer cells or progeny 
(blue). B) Tumour relapse after conventional chemotherapy against differentiated cancer cells. 
C) If cancer stem cells are eliminated, then their progeny would pass through a period of 
multiple apoptosis, and the result would be a slowly decrease in tumour cells until the tumour 
disappears completely. 
As CSCs are proposed to be more resistant to conventional therapies, it 
becomes necessary to find new ways to target them in order to treat cancer and 
prevent its recurrence. The central role that EMT has in tumour progression makes it 
an obvious target for therapeutic intervention.  Olmeda et al., 2007a have shown that 
by silencing Snail with shRNA, they can block EMT by enabling E-cadherin 
expression and leading to a MET process (Krutzfeldt et al., 2005, Olmeda et al., 
2007a). EMT plays a main role in generating CSCs, screening with different drugs to 
block EMT and its precursors (transcription factors) may inhibit cancer progression.  
If this crosslink between EMT and CSCs is confirmed, treatment of cancer at 
early stages should include EMT blocking agents that could inhibit TGF-β 
downstream effectors like ZEB1. By these means, resistance to apoptosis and self-
renewal characteristics might be nullified, preventing not only migration of cancer 
cells, but also the development of the primary tumour by stopping CSCs 
multiplication (Figure 1.6). However, the inhibition of EMT may also have serious 
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Figure 1.6. Therapeutic intervention for EMT. This diagram shows two different possible 
therapeutic levels regarding the blockage of EMT precursors and miR-21 as an oncomir. After 
inhibiting Zeb1 and/or miR-21 cancer stem cells would lose their acquired stem cell 
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1.14 Cellular Reprogramming, EMT and E-Cadherin 
Cell reprogramming can be defined as the ability of specific transcription 
factors to change the identity of specialised differentiated cells into different cell 
lineages (Graf and Enver, 2009, and reviewed by Sanges and Cosma, 2010). As 
described by Yamanaka et al., 2006, it is an important step in the acquisition and 
maintenance of pluripotency of epithelial cells in vitro (Figure 1.7) achieved by 
defined pluripotency transcription factors: OCT4, SOX2, KLF4 and c-MYC 
(OSKM), also known as the Yamanaka cocktail (reviewed by Lowry, 2011, 
Takahashi and Yamanaka, 2006). This group showed that pluripotency can be 
induced in vitro in mouse embryonic fibroblasts (MEFs), and these can be 
reprogrammed by the above mentioned factors to become induced pluripotent stem 
cells (iPSCs) (Takahashi and Yamanaka, 2006). 
 
Figure 1.7. Cell reprogramming and cancer stem cells. A somatic cell can be induced by 
oncogenic mutations to acquire pluripotency and become a tumour initiating cell (TIC), which 
will generate cancer stem cells (CSC) and differentiated cancer cells (DCC), and might lead to 
metastasis after an EMT process. 
In a review paper published by Sanges and Cosma, 2010 it has been 
described that a MET is necessary for the reprogramming process (Sanges and 
Cosma, 2010), which was then confirmed by Redmer et al., 2011, showing that E-
cadherin might play an important role in maintaining pluripotency in mouse 
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embryonic stem cells (mESCs), and it can also replace OCT4 during reprogramming 
with a MET (Redmer et al., 2011). How E-cadherin maintains pluripotency was not 
further explored in that study.   However, its role was confirmed by replacing OCT4 
in the OSKM combination with an E-cadherin-expressing retrovirus which 
demonstrated that this new combination of factors reprogrammed MEFs into iPSCs. 
These iPSCs were able to form teratomas in non-obese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice, while clones lacking OCT4 and E-cadherin 
expression just formed small lumps (Redmer et al., 2011). 
The metastatic progression of different types of cancer is carried out by a complex 
network of pathways in which E-cadherin plays different roles in EMT, MET and as 
mentioned above, cell reprogramming (Figure 1.8). The role of E-cadherin in cell 
reprogramming as a pluripotency inducer could be one of the essential features of 
metastasis due to its ability to change cellular identity once the cancer cells have 
reached their new niche after EMT and subsequent MET (in which E-cadherin is 
highly upregulated). 
 
Figure 1.8. Cell reprogramming. After epithelial cells acquire mesenchymal characteristics by 
downregulation of E-cadherin during EMT and migrate through blood and lymphatic vessels, 
they colonise their new target organ (niche) when E-cadherin is upregulated and cells return to 
their epithelial phenotype through a MET. While these cells colonise their new niche, E-
cadherin and defined pluripotency factors (OCT4, SOX2, KLF4 and c-MYC) reprogram cells to 
become pluripotent stem cells. 
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Furthermore, Liao et al., 2011 showed that cell reprogramming through a 
MET could also be carried out by microRNA (miRNA) expression in mesenchymal 
cells. They demonstrated that overexpression of miR-302 complex in addition to 
miR-367 in fibroblasts was enough to downregulate TGF-β receptor 2, thus, 
facilitating MET by upregulation of E-cadherin and cell reprogramming into iPSCs 
(Liao et al., 2011). These findings support a link between the epithelial phenotype 
and pluripotency, suggesting potential targets for prevention or treatment of 
metastases. 
 
1.15 microRNA expression in cancer 
MicroRNAs (miRNAs) are small RNA molecules with 19-25 nucleotides, 
which can work in a post-transcriptional fashion (reviewed by Ambros, 2004 and 
Hwang and Mendell, 2006) and contribute to fundamental physiological cell 
processes, such as tissue differentiation, and in the progression of several diseases 
like cancer (Foubert et al., 2010). MiRNAs guide the RNA-induced silencing 
complex (RISC), targeting complementary mRNAs, but they can also be targeted by 
other mRNAs as reviewed by Bartel, 2004. Targeted mRNAs are usually 
translationally silenced or cleaved by RISC, depending on its degree of 
complementarity with the targeting miRNA. When there is an imperfect 
complementarity between an miRNA and an mRNA, the target is translationally 
silenced, a mechanism which is activated by most mammalian miRNAs. However if 
there exists a perfect complementarity between miRNA and target mRNA, cleavage 
by RISC follows (reviewed by Hwang and Mendell, 2006). Bioinformatic assays 
have suggested that miRNAs are able to regulate approximately 30% of all genes of 
a mammalian genome (Lewis et al., 2005). Interestingly, recent data shows that more 
than 50% of predicted human miRNAs are located within fragile genomic sites 
susceptible to mutations during oncogenesis and tumour progression (Calin et al., 
2004 and reviewed by Croce, 2009).  
The knowledge that some cancer-related genes can be repressed or promoted 
by miRNAs is useful in the rational development of diagnostics and therapeutics. 
 
40 
Chapter 1: Introduction 
Some miRNAs repress tumour promoter genes while others are able to repress 
tumour suppressor genes by inhibiting target genes encoding oncogenic or tumour 
suppressor proteins as reviewed by Croce, 2009. MicroRNAs promoting cancer and 
its progression have been described as oncomirs (Taylor and Schiemann, 2014). Yan 
et al., 2011 inhibited human breast cancer proliferation in vitro and in vivo by 
blocking microRNA-21 (miR-21) in MCF7 cells. After confirming that these cells 
overexpress miR-21, they utilised sequence-specific functional inhibition of miR-21 
by transfection with a locked nucleic acid-antimiR-21, observing inhibition of cell 
growth, proliferation and migration in vitro. Moreover, in order to confirm these 
effects in vivo, MCF7 cells treated with peptide nucleic acid-antimiR-21 before 
injection were injected subcutaneously into female nude mice in which the detectable 
tumour masses were fewer and smaller than those induced by control cells (Yan et 
al., 2011). The inhibition of oncomirs might be a useful resource to block EMT-
induced cancer progression. There is still much to be elucidated on how these gene 
regulators are involved in cancer and its progression. There are different families of 
identified miRNAs which can regulate different functions in the organism and the 
cell cycle, including differentiation and apoptosis, but it is thought that cancer and its 
progression might also be a consequence of an impaired miRNA expression, either 
inhibiting tumour suppressor genes or enhancing tumour promoter genes as reviewed 
by Esquela-Kerscher and Slack, 2006. Further investigation is needed to confirm the 
role of miRNAs in cancer. The identification of diverse miRNAs expression in 
different kinds of tumours might be a useful tool for diagnostic and therapeutic 
approaches in cancer and its progression. 
MicroRNAs have also been involved in several studies of EMT and CSC 
theory. Gregory et al., 2008 observed that after suppression of endogenous miR-200 
family members, EMT was induced in normal and cancer cell lines through ZEB1 
and ZEB2 targeting (Gregory et al., 2008). Moreover, another study showed that 
after chemotherapy exposure, resistant breast cancer cells did not express members 
of the miR-200 family, suggesting that these stem-like, chemotherapy-resistant 
cancer cells lack expression of the miR-200 family, in contrast with the 
chemotherapy-sensitive cancer cells from the same patients (Yu et al., 2007). 
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There is still much to be understood and further investigation is needed to 
fully elucidate the role of miRNAs in cancer and its progression. 
1.16 EMT in companion animals 
EMT in companion animals (dogs and cats) has not been widely studied. 
Chandler et al., 2007 showed the importance of Slug as a transcription factor during 
cell migration in wound healing. They induced corneal wounds in 12 dogs and 
measured Slug expression in wounded and unwounded corneas in order to assess the 
rate of wound healing with and without Slug expression. Their results showed an 
upregulation of Slug expression in wounded corneas compared to the unwounded 
ones. Interestingly, downregulation of E-cadherin and β-catenin (epithelial markers) 
was observed in healing tissues, meaning that cells were losing their adherens 
junctions, consistent with enhanced ability to move through the cornea (Chandler et 
al., 2007). 
Furthermore, in two different studies, Aresu et al., 2008 and 2007, the role of 
EMT in canine renal fibrosis was studied, in which EMT was found to be essential to 
generate this disease. During renal inflammation-fibrosis, leading to diseases such as 
glomerulonephritis, epithelial markers E-cadherin and β-catenin (Aresu et al., 2008), 
and cytokeratin (Aresu et al., 2007) are downregulated whilst the mesenchymal 
marker vimentin is upregulated at sites of inflammation. Similarly, a study conducted 
in 2009 by Mathias et al. highlighted the involvement of several proteins during 
EMT in Madin-Darby canine kidney (MDCK) cells. They compared the secretome 
from MDCK and oncogenic Ras-transformed MDCK cells using a combination of 
fluorescence difference gel electrophoresis labelling and mRNA transcript analysis in 
order to identify proteins that are differentially expressed during EMT in these cells. 
They first showed that Ras induces EMT in MDCK cells where Ras-transformed 
cells morphologically appeared more fibroblast-like with an elongated shape, while 
untransformed MDCK cells appear round and tightly adjoined with surrounding 
cells. They also observed a lower expression of the epithelial marker E-cadherin and 
a higher expression of the mesenchymal marker vimentin in Ras-transformed cells. 
To assess whether the Ras-transformed cells acquired migratory features, a wound 
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healing assay was conducted in which untransformed MDCK cells exhibited a 
limited migratory capacity. In contrast, Ras-transformed MDCK cells showed a more 
dynamic migration as individual cells moved faster into the wounded area. They 
demonstrated that cells undergoing EMT increased secretion of proteases that 
facilitate migration, such as MMP-1, and also decrease expression of proteins 
important in cell-cell and cell-matrix adhesion such as clusterin and desmocollin 
(Mathias et al., 2009). Interestingly, some of these proteins had not been previously 
described as important components of the mechanisms underlying EMT. 
Several research groups have published important results regarding type II 
EMT (wound healing and fibrosis), but these studies have yet to be applied to type 
III EMT (cancer progression and metastasis). 
Several authors from different research groups have published interesting 
results regarding expression of cell adhesion molecules and their correlation with 
tumour growth and cell proliferation. Han et al., 2010 observed an increased 
expression of β-catenin accumulation in the cytoplasm and nucleus in canine 
cutaneous melanotic tumours (Han et al., 2010). Normally, β-catenin is degraded in 
the cytoplasm; however, deregulation of the Wnt/β-catenin signalling pathway leads 
to accumulation of this protein, causing uncontrolled cell proliferation (reviewed by 
Larue and Delmas, 2006). These findings have been also documented in canine 
colorectal tumours (McEntee and Brenneman, 1999) and canine osteosarcoma (Stein 
et al., 2011). Moreover, Nowak et al., 2007 and 2008 compared the relationships 
between extracellular matrix metalloproteinase-9 (MMP-9), E-cadherin, the 
proliferation associated antigen Ki-67 and β-catenin in canine mammary 
adenocarcinoma, and found that the decreased expression of E-cadherin is inversely 
proportional to the expression of MMP-9, Ki-67 and nuclear-located β-catenin, 
whereas a direct correlation was observed between MMP-9 and Ki-67; and β-catenin 
and Ki-67 expression. They also observed increased cell growth and proliferation 
associated with higher expression of nuclear accumulation of β-catenin (Nowak et 
al., 2007, Nowak et al., 2008). 
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In canine colorectal adenocarcinoma, Aresu et al., 2010 observed lower 
expressions of E-cadherin and β-catenin on the cell membrane of the majority of 
analysed tumours. A correlation between low expression of E-cadherin with higher 
grade tumours and higher mean age of patients was observed in this study. Reduced 
expression of β-catenin was also related to tumours with higher grade, and with 
increased tumour size (Aresu et al., 2010). Furthermore, Ide et al., 2011 found that 
increased expression of cell adhesion molecules N-cadherin, doublecortin and 
nuclear β-catenin was closely associated with progression of canine meningioma (Ide 
et al., 2011).  
Furthermore, to assess the correlation between adhesion molecules and 
transcription factors in cancer progression, Im et al., 2012 examined the role of Snail 
in canine mammary tumours. Even though they did not observe any association 
between the expression of Snail and E-cadherin in mammary tumours (11 adenomas 
and 43 carcinomas), they identified a significant correlation of Snail expression with 
tumour grade, histological type and lymphatic invasion, where they observed higher 
expression of this transcription factor in carcinoma samples when compared with 
adenomas and normal tissues (Im et al., 2012).  
A significant paper was published in 2014 by Salgado et al., where they 
assessed the expression of EMT-associated proteins by immunohistochemistry in 
canine mammary carcinoma. They observed loss of epithelial marker E-cadherin and 
overexpression of mesenchymal proteins (N-cadherin, Snail, S100A4 and MMP-2) in 
carcinomas, but not in benign tumours or non-neoplastic lesions. High expression of 
Snail was related to loss of E-cadherin. They suggested that these findings might 
have great importance to evaluate canine mammary carcinoma patients, as they could 
serve as an important tool to distinguish between adenomas and carcinomas (Salgado 
et al., 2014). On a similar approach, Fonseca-Alves et al., 2015, carried out a study 
on type III EMT in prostatic carcinoma in dogs. One of the most important findings 
they showed was loss of E-cadherin and a higher expression of vimentin at the 
protein expression level in the tumour group compared with normal tissue samples. 
They also carried out immunohistochemical analyses where they found loss of 
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epithelial markers and overexpression of mesenchymal markers in metastatic prostate 
carcinoma cells (Fonseca-Alves et al., 2015). 
1.17 Aims of our research 
The principal aim of this research was to determine if induction of EMT can 
generate cells with a CSC phenotype. To study this we induced EMT in a panel of 
mammary carcinoma cell lines by treating them with TGF-β, and subsequently 
analysed expression of EMT markers and sphere forming ability. Our hypothesis was 
that canine and feline mammary cancer cells undergo phenotypic changes after TGF-
β-induced EMT, acquiring stem cell characteristics and invasive properties. 
Here, we have studied EMT as a feature of human, canine and feline 
mammary carcinoma in an attempt to elucidate the role of EMT in cancer 
invasiveness and in the acquisition of stem cell-like characteristics. We have 
demonstrated that dog and cat cells undergoing EMT by TGF-β stimulation show a 
mesenchymal morphology; increased expression of mesenchymal markers 
(fibronectin and vimentin); decreased expression of epithelial markers (E-cadherin 
and β-catenin) and increased cell invasion capacity in vitro. Interestingly, cells that 
underwent EMT were more capable of forming spheres, which are representative of 
CSCs. We also carried out miRNA expression analysis in TGF-β-stimulated canine 
mammary carcinoma cells and untreated cells. We found significant differences in 
specific canine miRNAs suggesting their importance in the study of mammary 
tumours in dogs. Although further investigation is needed, such as the correlation of 
our in vitro findings in clinical samples, these results suggest EMT is a worthwhile 
potential therapeutic target in companion animal oncology.  
In conclusion, EMT is an emerging field of cancer research. This transition 
process might be very relevant to cancer induction and progression. Moreover, if we 
can confirm that the EMT/MET process enables cancer cells to acquire stem-cell 
characteristics, then we would be able to generate new targeted therapies against 
cancer and its progression and metastasis, potentially combatting tumour relapse and 
metastasis in thousands of patients around the world.
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Chapter 2: Material and Methods 
 
2.1 Tissue culture reagents and equipment 
Tissue culture plastics were obtained from Becton Dickinson-Biosciences, 
UK (Falcon tubes) and Sigma-Aldrich, UK (Corning® low adhesion tissue culture 
plates and pipette tips). 
The microscope used for all fluorescence and phase contrast images was a 
Zeiss Axiovert40 CFL microscope fitted with digital Axiocam monochrome or 
colour cameras (Carl Zeiss Ltd., UK). Carl Zeiss Imaging systems AxioVisionTM 
Software (Release 4.27.2) was used for image capture and image processing. 
 
2.2 Cell Culture 
2.2.1 Cell lines 
The MCF7 cell line is a fully characterised human breast carcinoma cell line 
and was a kind gift from Dr. Maura Wallace at the Royal (Dick) School of 
Veterinary Studies and The Roslin Institute, University of Edinburgh. 
The REM cell line is a canine mammary carcinoma cell line derived from a 
spontaneous primary canine mammary carcinoma. The CAT M cell line (CMC) is a 
feline mammary carcinoma cell line derived from a feline mammary 
adenocarcinoma. These cell lines were received from Professor Rod W. Else, Royal 
(Dick) School of Veterinary Studies, University of Edinburgh (Else et al., 1982, 
Norval et al., 1985).  
All cell culture reagents were obtained from Gibco® Invitrogen, UK unless 
otherwise specified. The MCF7, REM and CMC cell lines were grown in Dulbecco´s 
Modified Eagle´s Medium (DMEM) 41965 supplemented with 10% FBS, 1% 
Penicillin-Streptomycin at 37°C and 5% CO2.  
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2.2.2 Cell Recovery 
To recover cells from a frozen stock at – 70 °C, cells were quickly thawed at 
37 °C and resuspended in 5 ml phosphate buffered saline (PBS) and centrifuged at 
125 x g for 5 minutes. The supernatant was discarded and the cell pellets were 
resuspended in 8 ml of their respective media, transferred to T25 flasks, and 
incubated at 37 °C and 5% CO2 overnight. 
2.2.3 Passaging cells 
To detach adherent cells, 0.25 % trypsin-EDTA (Life Technologies, USA) 
was used. At first passage, cell lines were transferred to T75 flasks. Cells were 
routinely passaged at 80-95 % confluency every 3-4 days. To passage cells, media 
was removed by pipetting, and the cells were washed twice in 10 ml of PBS before 
incubation at 37 °C in 3 ml of 0.25 % trypsin-EDTA until detached. Trypsinisation 
was terminated by adding at least twice the trypsin volume of FBS containing media 





into new T-75 (75 cm
2
) culture vessels with fresh medium. 
2.2.4 Determining cell density and viability  
Cell counts were performed with a haemocytometer (Neubauer ruling: Square 
volume 1x10-4 ml; grid volume 9x10-4 ml) (Sigma-Aldrich). Ten microliters of cell 
suspension mixed with 10 µl of 0.4 % trypan blue (Sigma-Aldrich) was pipetted into 
each side of the counting chamber. Cells excluding trypan blue were counted within 
at least 4 squares. The result was divided per each square counted in order to get the 
average count for each side of the chamber. The result was then multiplied by 2, due 
to the dilution factor after adding trypan blue, so the cell count was calculated as: 
Number of cells = (Average count x 2) x 104 cells per ml. 
2.2.5 Harvesting adherent cells 
To harvest cells, medium was discarded and cells were washed with ice-cold 
PBS, then scraped in 1 ml ice-cold PBS and transferred to 1.5 ml eppendorf tubes 
(Becton Dickinson-Biosciences). The cell suspension was centrifuged at 200 x g for 
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4 minutes at 4 °C. Supernatant was discarded and cell pellets were snap frozen on 
dry ice and stored at -70 °C.  
2.2.6 Cryopreservation 
Cells were frozen in freezing media containing 10 % Dimethyl Sulphoxide in 
FBS (Sigma-Aldrich). After washing and trypsinisation, cell suspensions were 
centrifuged at 125 x g for 5 minutes and resuspended in 1 ml of freezing medium, 
aliquoted into cryo-vials (Thermo-Scientific, USA), transferred to freezing container 
containing 100 % isopropyl alcohol (Mr Frosty, Thermo.Scientific) and placed in a -
80 °C freezer for a minimum of 3 hours. Using a freezing vehicle allowed for a 
steady freezing rate of 1 °C per minute which enhances successful cryopreservation 
of cells and decreases overall cell death (Simione, 1992) . Cells were later transferred 
to liquid nitrogen for long term storage.   
 
2.3 TGF-β 
TGF-B was purchased from PeproTech EC Ltd., UK and reconstituted as 
indicated by the manufacturer. Briefly, the vial was centrifuged prior to opening and 
reconstituted in 10 mM Citric Acid (Sigma-Aldrich), pH 3.0 to a concentration of 0.5 
mg/ml. it was further diluted in 0.1 % BSA (Sigma-Aldrich) and stored in working 
aliquots of 60 µl at -20 ºC.  
2.3.1 TGF-β treatment 
Cells were treated at the indicated concentration (2.5 – 10 ng/ml) at different 
time points. After observing morphological changes after TGF-β stimulation, control, 
mock-treated and TGF-β-stimulated cells were harvested according to Chapter 2.2.5 
and stored at -70 ºC. Each sample was harvested in two eppendorf tubes that then 
were used for either protein or RNA extraction. For protein expression, the samples 
were harvested after 6 days of TGF-β stimulation. For mRNA expression analysis by 
qRT-PCR, samples were harvested at different time points for 24 days with different 
concentrations of TGF-β (2.5, 5 and 10 ng/ml). 
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2.3.2 Time course 
TGF-β stimulation was optimised by treating cells with different 
concentrations of TGF-β. The concentrations utilised for TGF-β treatment were 2.5, 
5 and 10 ng/ml of medium (previously enriched with FBS and antibiotics) in the 
three different cell lines. Medium was changed and TGF-β was added to cells every 
day. Cells were passaged as outlined in chapter 2.2.3, when approaching confluency, 
and seeded with medium enriched with TGF-β. In order to assess which 
concentration of TGF-β induced the greatest morphological change and to define 
how long epithelial breast cancer cells needed such TGF-β stimulation to induce 
morphological changes, we treated cells at different time points with the three 
different concentrations previously mentioned.  
 
2.4 Sphere assay protocol 
2.4.1 Setting up spheres from adherent cells 
For sphere assays the cells were grown in N2 media with methylcellulose 
prepared in house. All the constituents for the N2 media were obtained from Sigma-
Aldrich, except the recombinant human epidermal growth factor (EGF) and the 
recombinant human basic fibroblast growth factor (bFGF) which were obtained from 
PeproTech EC Ltd. The N2 media was prepared in a laminar hood using basic 
protective clothing. To 15.6 g of double standard strength DMEM/F12 base medium, 
was added 474 ml of distilled water, 12.5 mg transferrin, 5 µg EGF and 5 µg bFGF. 
The resultant solution was made up to 20 nM progesterone, 100 µM putrescine, 30 
nM sodium selenite and 3.48 µM insulin, making a final volume of 500 ml. An equal 
volume of 1.6% methylcellulose dissolved in distilled water which had been 
autoclaved was added to a final volume of 1000 ml. The pH of the DMEM/F12 
medium was adjusted to 7.2 utilising sodium hydroxide (NaOH) or hydrochloric acid 
(HCl) as needed before the solution was filtered sterilised through a 0.22 µm filter 
bottle (Corning® 500mL Vacuum Filter/Storage Bottle System. USA). The resulting 
N2 medium was aliquoted into 100 ml sterile bottles and stored at -20°C until use. 
Thawed media stored at 4°C were used for up to 4 weeks. 
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REM and CMC cells were trypsinated as described in Chapter 2.2.3, and 1 ml 
of cell suspension was removed and centrifuged at 100 x g for 5 minutes and 
resuspended in 1 ml PBS. Cells were then counted and seeded in six-well low 
adherence plates (Sigma-Aldrich). Per well, 60,000 cells were seeded in 2 ml of N2 
media. Cells were incubated at 37 °C/5 % CO2 and N2 media was supplemented 
with 500 µg per ml of EGF and bFGF each every 48 hours. 
2.4.2 Passaging spheres 
To passage spheres, cells were transferred to Falcon tubes and the wells were 
washed in PBS to maximise collection. The pooled cells and washings were then 
centrifuged at 125 x g for 5 minutes and the N2 media was discarded. Five ml of 
0.25% trypsin-EDTA was added to the cells and incubated at room temperature for 
10 minutes. Three ml of media containing FBS was added to terminate 
trypsinisation. Cells were collected by centrifugation at 125 x g for 5 minutes. The 
cell pellet was resuspended in 1 ml of PBS and counted using a haemocytometer as 
outlined in chapter 2.2.4. A six-well low adherence plate was seeded with 60,000 
cells per well in 2 ml of N2 media.  
 
2.5 Recovery and detection of protein  
2.5.1 Reagents and antibodies 
All samples were probed with primary antibodies against EMT markers. The 
primary antibodies used were mouse monoclonal anti-E-Cadherin, clone 36/E-
cadherin (BD Biosciences, UK) at a 1:5,000 dilution, mouse monoclonal anti-β-
Catenin, clone 14/Beta-catenin (BD Biosciences) at 1:2,000 dilution, mouse 
monoclonal anti-fibronectin, clone 10/Fibronetin (BD Biosciences, ) at 1:10,000 
dilution, mouse monoclonal anti-vimentin, clone RV202 (Abcam, UK) at 1:1,000 
dilution, rabbit polyclonal anti-Twist (L-21) (Santa Cruz Biotechnology, USA) at 
1:100 dilution, rabbit polyclonal anti-ZEB1 (H-102) (Santa Cruz Biotechnology) and 
mouse monoclonal anti-β-actin (Abcam) at 1:4,000 dilution. The secondary 
antibodies used were polyclonal swine anti-rabbit (SAR) HRP conjugated 
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immunoglobulins (P0217) and polyclonal rabbit anti-mouse (RAM) HRP conjugated 
immunoglobulins (P0260), both purchased from Dako Cytomation, Denmark. 
2.5.2 Cell lysis 
All manipulations were performed on ice. Cells were harvested as described 
in chapter 2.1.5. Twice the pellet volume of chilled urea lysis buffer (7M urea 
(Sigma-Aldrich), 0.1M DTT (Sigma-Aldrich), 0.05% Triton X-100 (Sigma-Aldrich), 
20mM HEPES-KOH (Life Technologies), pH7.6, 25mM NaCl (Sigma-Aldrich)) was 
added to the frozen cell pellet, and allowed to thaw on ice. The pellet was then mixed 
by pipetting until no cell clumps were visible and incubated for 30 minutes on ice. 
The cell lysates were centrifuged at 4°C at 1000 x g for 10 minutes, snap frozen on 
dry ice, and stored at minus 70°C.  
2.5.3 Bradford assay 
One µl of cell lysate or known BSA protein standard dilutions was mixed 
with 200 µl of Quick Start™ Bradford Dye Reagent (BioRad, USA) and added to a 
clear 96 well plate (Sigma-Aldrich). The absorbance at 595 nm was measured with a 
Perkin Elmer 1420 Multilabel Counter Victor3™ plate reader (Perkin Elmer, USA) 
and the protein concentrations of the different cell line lysates were determined from 
a standard curve generated from the known BSA concentrations using Excel, 
Microsoft Office, version 97-2003.  This information was used to standardise the 
amount of lysate protein to be used for gel loading for Western Blot analysis.  
2.5.4 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
Protein samples were resolved on denaturing SDS-polyacrylamide gels by 
electrophoresis. Different percentage SDS-polyacrylamide gels were poured 
according to size of protein of interest with low percentage gels used to separate high 
molecular weight proteins (e.g. fibronectin: 240 kDa) and higher percentage gels for 
lower molecular weight proteins (e.g. Twist: 24-41 kDa). 
The SDS-polyacrylamide gels were prepared and assembled using the 
Protean II minigel system (Bio-Rad). The resolving gel (8-10 % acrylamide) was 
made according to manufacturer´s instructions and was poured and overlaid with 
 
51 
Chapter 2: Material and Methods 
isopropanol to remove air bubbles. The gel was allowed to set at room temperature 
for 20 minutes, and the isopropanol was removed. The stacking gel (5 % acrylamide) 
was made according to manufacturer´s instructions and was poured, ten well loading 
combs were inserted, and the gel was allowed to set at room temperature for 20 
minutes.  
Protein samples were prepared into 45 µl aliquots in 4 x Laemmli Sample 
buffer (120 mM Tris-HCl (Sigma-Aldrich) pH 6.8, 4 % (w/v) sodium dodecyl 
sulphate (SDS) (Sigma-Aldrich), 20 % (v/v) glycerol (Sigma-Aldrich), 200 mM DTT 
(Sigma-Aldrich), 0.04 % (w/v) bromophenol blue (Sigma-Aldrich)) and boiled in a 
heat block for 5 minutes at 95 °C to denature the proteins. The gel was immersed in 
running buffer (25 mM Tris (Sigma-Aldrich), 190 mM glycine (Sigma-Aldrich), 0.1 
% (v/w) SDS (Sigma-Aldrich)). Each well was loaded with 10-30 µg of protein 
lysate diluted in Laemmli Sample (10 µl total volume) and the gels were run at 180 
V for approximately one hour using the Mini-protean electrophoresis system (Bio-
Rad), until the dye had run off the resolving gel. Five µl of pre stained Full Range 
Rainbow Marker (Amersham Pharmacia Biotech, Sweden) was run in parallel with 
the protein samples to allow size determination of protein bands.    
2.5.5 Immunoblotting 
The resolved proteins were electrophoretically transferred using the Mini-
protean electrophoresis system (Bio-Rad), onto nitrocellulose membranes 
(Hybond™-C, Amersham Biosciences, UK) in transfer buffer (25 mM Tris (Sigma-
Aldrich), 190 mM glycine (Sigma-Aldrich), 20 % (v/v) methanol (Sigma-Aldrich)) 
at 300 mA for 60 minutes or 30 mA overnight. Nitrocellulose membranes were ink 
stained (0.4 % ink (Pelikan, UK) in PBS) for 15 minutes to visualise protein bands 
and ensure equal loading. The membranes were blocked for 1 hour at room 
temperature in PBST/5 % Milk (5 % Skimmed milk (Sigma-Aldrich) in 2% PBS-
tween 20 (Sigma-Aldrich)) before being incubated with primary antibodies for 4 
hours at room temperature or overnight at 4 °C in blocking solution.  
After three 5 minutes washes in 2% PBST the membranes were incubated for 
1 hour at room temperature with HRP-conjugated secondary antibodies diluted 
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1:1,000 in blocking solution. After a further three 15 minutes washes with 2% PBST 
the blots were developed using ECL Western Blotting Detection Reagents 
(Amersham Biosciences) and sites of peroxidase activity were visualised by 
exposure to X-ray film (Hybond™-ECL™ Film, Amersham Biosciences).  
 
2.6 Isolation and quantification of nucleic acids 
2.6.1 RNA extraction 
Total RNA was isolated from the cells utilising two methods: The RNeasy 
Mini Kit with QIAshredder (Qiagen Ltd., UK) according to the manufacturer’s 
Animal Cells Spin protocol including a DNase on-column digestion step utilising the 
RNase-free DNase Set (Qiagen); and the RNA Bee protocol (AMS Biotechnology, 
UK), according to the manufacturer’s protocol, adding chloroform, isopropanol and 
ethanol. All samples were analysed with NanoDrop™ ND1000 (Thermo Fischer 
Scientific, USA) to quantify RNA. 
2.6.1.1 RNeasy Mini Kit with QIAshredder: 
 This commercial kit extracts RNA from cells utilising the spin column-based 
nucleic acid extraction principle. Cells were counted and lysed by adding 350-600 µl 
of RLT lysis buffer (a highly denaturing buffer). Samples were then mixed 
thoroughly by pipetting or vortexing with the Vortex Mixer (Altec Lab Products, 
India). The cell lysate was then passed through a QIAshredder homogeniser by 
centrifugation at full speed for 2 minutes to shear high molecular weight genomic 
DNA and other cellular components which can reduce RNA binding to the silica-gel 
membrane. To promote adsorption of RNA to the silica-gel membrane, 70 % ethanol 
was then added. The lysate was transferred to the spin column. The spin column was 
centrifuged at 8000 x g for 15 seconds and the flow through containing denatured 
protein and cellular debris was discarded. A further wash with buffer RW1 removed 
further contaminants. To ensure no DNA contamination of RNA sample an on-
column DNase digestion was performed with the RNase-Free DNase Set, according 
to the manufacturer´s instructions. After 15 minutes of incubation at room 
temperature a further wash step with 350 µl RW1 buffer was performed. A further 
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two wash steps with 500 µl RPE buffer containing 80% ethanol with centrifugation 
followed. A one minute centrifugation step at full speed was performed to ensure the 
membrane was dried completely. RNA was eluted in 30-50 µl of RNase-free water 
by centrifugation at 8000 x g for 1 minute. 
2.6.1.2 RNA Bee protocol: 
The protocol describes isolation of RNA with 1 ml of RNA-Bee using the 
following steps:  
Cells were counted and lysed by adding at least 0.2 ml of RNA-Bee per 106 
cells. Then 0.2 ml chloroform (Sigma-Aldrich) was added per 1 ml of RNA-Bee and 
shaken vigorously for 15 - 30 seconds. The samples were incubated on ice (or 
refrigerated at 4 ºC) for 5 minutes and the homogenates were centrifuged at 12,000 x 
g for 15 minutes at 4 ºC. Following centrifugation, the samples form the lower blue 
phenol-chloroform phase, interphase, and the upper colourless aqueous phase. RNA 
remains exclusively in the aqueous phase. For RNA precipitation, the aqueous phase 
was transferred to a clean tube, 0.5 ml of isopropanol was added, and the samples 
were incubated for 10 minutes at room temperature and then centrifuged at 12,000 x 
g for 5 minutes at 4 – 25 ºC.  
Finally, the supernatant was discarded and the RNA pellet washed once with 
75 % ethanol (Sigma-Aldrich), vortexing to dislodge the pellet from the side of the 
tube and centrifuged for 5 minutes at 7,500 x g at 4 – 25 ºC. At least 1 ml of ethanol 
solution was used per 1 ml of RNA-Bee used for the initial homogenisation. An 
additional wash with 75 % ethanol was included to improve the 260/280 ratio, which 
would be indicative of a greater nucleic acid purity. 
At the end of the procedure, the RNA pellets were briefly air-dried for 10 
minutes and the RNA was dissolved in 50 µl of RNase-free water.  
2.6.2 Quantification and quality assessment of nucleic acids 
RNA samples were quantified using the NanoDrop™ ND1000 (Thermo 
Fischer Scientific) by measuring absorbance at 260 and 280 nm (A260, and A280, 
respectively). Purity of RNA was determined using the A260/A280 ratio, and all 
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samples utilised in our experiments had a A260/A280 ratio between 1.8 and 2.1, 
which is the minimum to assess RNA purity as reviewed by Udvardi et al., 2008. 
 
2.7 Real-Time Polymerase Chain Reaction (Real-Time 
PCR) 
All Real-Time PCR reactions were performed on the Stratagene Mx3000p 
QPCR System (Qiagen, Germany) following manufacturer’s recommendations and 
analysed with the Stratagene MxPro QPCR Software, version 4.10. All samples were 
run in triplicate. Triplicate no-template controls (replacing cDNA template with PCR 
grade water to reveal possible contamination problems) were included in each assay. 
2.7.1 Reverse Transcription Polymerase Chain Reactions 
(RT-PCR)  
The RT-PCR reactions were performed using commercially available kits and 
the optimum conditions were established in optimisation reactions. One available 
first strand cDNA synthesis kit (Quanti Tect Reverse Transcription Kit, Qiagen) was 
used during the study according to the manufacturers’ protocol to generate cDNA for 
use in RT-PCR from RNA. An aliquot of 0.5 µg of total cellular RNA in RNase free 
water was heat denatured at 65°C for 5 minutes and then quenched on ice. A master 
mix was prepared on ice consisting of 2 µl of 10x Buffer RT, 2 μl of dNTP mix (5 
mM each dNTP), 0.2 μl of oligo-dT primer (10 µM), 2 µl of DTT (100 mM), 1 µl of 
Omniscript Reverse Transcriptase and RNase free water (all Qiagen) enough to make 
up a 19.75 µl volume per reaction, to which 0.25 µl of rRNasin ® RNase inhibitor 
(Promega, USA) (40 U/µl) was added and then aliquoted into PCR tubes (Bio-Rad) 
containing the denatured RNA. The solution was then incubated at 37°C for 1 hour 
using the Bio-Rad iCycler thermal cycler. PCR reactions were set up using one 
commercially available PCR kit (GoTaq® PCR Core Systems, Promega). The 
thermal profile utilised with this kit is displayed in Table 2.1. To ensure consistency 
all experiments were performed on the same thermal cycler (iCycler, Bio-Rad) using 
the optimised conditions for the respective primers. 
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Table 2.1. Summary of RT-PCR reaction cycling conditions used to generate cDNA. 
The cDNA produced was used immediately for PCR or stored at -20°C.  
2.7.2 Real-Time PCR primers and probes 
All DNA oligonucleotides were purchased from Eurofins MWG Operon 
(eurofinsdna.com). As primers for the genes of interest could not be found in the 
existing literature, primer sets were designed to span the genes of interest. 
The human and canine primers utilised for mRNA expression analysis, 
excluding reference genes RPL32 and HPRT, were all EMT markers. 
2.7.3 Primer design 
The canine and human housekeeping genes HPRT and RPL32 were designed 
from published sequences (NCBI Reference Sequence: NM_000194.2 and 
NM_001003357.1 for HPRT of human and canine origin, respectively, and 
NM_000994.3 and NM_001252169.1 for RPL32 of human and canine origin, 
respectively). All other primers were designed using the online PCR primer design 
tool on eurofinsdna.com. All primers are presented in Table 2.2.  
 
Step Temperature Time Number of cycles 
1) Initial denaturation 95ºC 2 min 1 
2) Denaturation 95ºC 40 sec  
2) Annealing 55ºC 40 sec 30 
2) Extension 72ºC 1 min  
3) Final extension 72ºC 5 min 1 
4) Synthesis 4ºC ∞ - 
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Primer set Sequence (5’-3’) Amplicon size 
Human Forward ATGGACAGGACTGAACGTCTT 113 
HPRT Reverse TCCAGCAGGTCAGCAAAGAA  
Canine Forward TTATGGACAGGACTGAGCGG 82 
HPRT Reverse TTGAGCACACAGAGGGCTAC  
Human Forward AGCCATCTCCTTCTCGGCAT 105 
RPL32 Reverse ATATCGGTCTGACTGGTGCC  
Canine Forward CATCGATCGCTGGGCATCAT 90 
RPL32 Reverse CTGGTGCCGGATGAACTTCT  
Human Forward GGTGCTCTTCCAGGAACCTC 86 
E-cadherin Reverse TAAGCGATGGCGGCATTGTA  
Canine Forward TGACAGCTACACGTTCACCG 80 
E-cadherin Reverse TGCATCCTTCAAAACTCACCCT  
Human Forward CAGCAGCAATTTGTGGAGGG 93 
β-catenin Reverse TCGGTTGTGAACATCCCGAG  
Canine Forward GGAATGGCTACCCAAGCTGA 91 
β-catenin Reverse AAGACTGTTGCTGCCAGTGA  
Human Forward ATACCATCATCCCAGAGGTGC 101 
Fibronectin Reverse GGTGGAAGAGTTTAGCGGGG  
Canine Forward GACCTAGAGGTCATCGCTGC 115 
Fibronectin Reverse CAGGGCTGTTTCCTCCTGTT  
Human Forward GGCTCGTCACCTTCGTGAAT 113 
Vimentin Reverse ATGCCACAGGACTCCATAC  
Canine Forward GGACCAGCTCACCAACGACA 99 
Vimentin Reverse AGCATCTCCTCTTGCAACTTCTC  
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2.7.4 Real-Time PCR reactions 
The Real-Time PCR reactions were performed using Platinum® SYBR 
Green qPCR SuperMix-UDG (Invitrogen) master mixes with a reaction volume of 25 
µl in a 96 well plate format. Real-Time PCR reactions contained 12.5 µl of SYBR 
Green mix, 1.25 μl of each primer (forward and reverse), 0.5 μl of a one in ten 
dilution of reference dye (ROX) and 9.5 µl of a one in twenty dilution of cDNA 













2.7.5 Data Analysis of Real-Time results 
All analyses of relative gene expression levels were performed using the 
comparative delta-delta CT method (Pfaffl, 2001). All data analyses and graphs were 
generated using Microsoft Office Excel 2003. 
Step Temperature Time Number of cycles 
1) UDG Incubation 50ºC 2 min 1 
2) Taq activation 95ºC 2 min 1 
3) Denaturation 95ºC 15 sec 30 
3) Annealing and extension 55-60ºC 30 sec  
4) Dissociation curve 95ºC 1 min 1 
 60ºC 30 sec  
 95ºC 15 sec  
 25ºC 30 sec  
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2.7.6 Primer efficiency 
To determine primer efficiency cDNA from untreated and TGF-β-stimulated 
MCF7 and REM cell lines were used as template. Serial dilutions of cDNA reaction 
mixtures from 1:30 to 1:960 were made and Real-Time PCR reactions were 
performed in three technical replicates with each primer set individually.  
The cycling threshold (Ct) or Crossing point (Cp) values of each of the 
dilutions were plotted against the cDNA concentrations and the slopes were 
calculated from the graphs. High primer efficiency produces graphs with a high 
correlation coefficient (Pearson’s correlation coefficient r>0.99) and with high 
linearity in the investigative range. One hundred per cent efficiency corresponds to a 
perfect doubling of template at every cycle, but the acceptable range is 90-110% for 
assay validation as reviewed by Taylor et al., 2011. This efficiency range 
corresponds to standard curve slopes of -3.6 to -3.9.  
2.7.7 Relative Expression Analysis 
Following primer efficiency estimations, Real-Time PCR reactions were 
performed in triplicate for each sample. To determine the fold change in treated 
samples compared to control samples, the Ct values (also known as delta Ct) of the 
target genes and reference genes were obtained by subtracting the treated sample 
values from the control sample values. This was so that increases will have a positive 
result and decreases a negative result for the delta Ct value (∆Ct). The efficiency (E) 
of each primer was also taken into account to calculate the fold increase in each 
assay by submitting the efficiency percentage to the n ͭ ͪ  power as shown in Figure 
2.1. After calculating the fold increase with both target genes and reference genes, 
we divided the fold change in the target genes by the fold change in the reference 
genes in order to normalise and correct the data for each assay as expressed in a 
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Fold change in target or reference gene: 
Fold change = (E)
n
 
Fold change = (primer efficiency)
 control sample value – treated sample value
     
Figure 2.1. Fold change formula for target or reference genes. E= efficiency; n= ∆Ct (treated 
sample values – control sample values). 
 
It is expected that the reference genes have very close Ct values and the ratio 
in the treated and control samples would be close to 1. This would suggest that they 
are good reference genes for the experiment. 
    
 
Figure 2.2. Normalisation of fold change for each assay. Etarget= primer efficiency of the target 
gene; Eref= primer efficiency of the reference gene; ∆Ct target= ∆Ct of the target gene; ∆Ct ref= 
∆Ct of the reference gene. 
 
2.8 In vitro scratch assay 
TGF-β-stimulated and unstimulated cells were passaged and counted as 
previously described in Chapter 2.2, after TGF-β stimulation. REM and CMC cells 
were stimulated with 10 ng/ml of TGF-β every 24 hours for 6 days, changing media 
and passaging when necessary. After 6 days of stimulation, cells were seeded at high 
density (0.8-1.0 X 106 cells) into 6 well plates and allowed to reach confluency 
(usually after 24 hours). A scratch was then created with a 200 μl pipette tip in the 
monolayer of each well. Following the creation of the scratch, the media was 
removed and the wells were washed with 2 ml PBS per well until all floating cells 
were removed and a clean, sharp edge of cells could be visualised in all wells by 
phase contrast light microscopy. The cells were photographed using the 10x 
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objective at different time points. The area photographed was marked by permanent 
marker on the lid and the bottom outer part of each well so that the same areas could 
be photographed at every time point.  
The gap width was then measured at ten different places within each scratch´s 
length. The mean gap width was then determined for each time point and compared 
to the starting mean gap width so that the closing percentage could be determined. 
The mean gap width was then expressed as relative migration distance 
covered by cells closing the wound (scratch). Then, the percentage closing was 
compared between TGF-β-stimulated cells and the untreated group. In order to 
calculate these measurements, the following formula was used. 
Formula: Relative migration distance (%) = 100 (A-B) / A. 
A= width of cell wound before incubation, and B= width of cell wound after 
incubation. 
 
2.9 Magnetic cell sorting (MACS sorting) 
The separation columns, magnetic separator and the CD133 MicroBead Kit 
were all purchased from Miltenyi Biotec Inc., Germany. Cells were harvested and 
counted as described in Chapter 2.2. A maximum of 1x108 cells per sample were 
pelleted by centrifugation at 100 x g for 5 minutes and resuspended in 300 µl of 
chilled separation buffer. One hundred µl of FcR blocking reagent and 100 µl of 
CD133 MicroBeads were added and the solution was incubated for 30 minutes at 
4°C with rotation.  
The cells were washed by adding 5 ml of cold separation buffer and 
centrifuged at 300 x g for 10 minutes at 4°C before resuspension in 1 ml of 
separation buffer and transfer to a pre-wet separation column mounted on the 
magnetic separator. The column was washed three times with 3 ml of separation 
buffer and the flow through containing the negative fraction was collected. The 
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column was then removed from the magnetic separator and the labelled fraction was 
flushed out in 5 ml of separation buffer using the plunger. The labelled and 
unlabelled fractions were counted and seeded at required density for 
chemosensitivity assays.   
 
2.10 Chemosensitivity assay 
The CellTiter-Glo® Luminescent Cell Viability assay (Promega, USA) 
determines the relative number of metabolically active cells present in culture based 
on quantification of the ATP present. The luminescence signal generated is 
proportional to the amount ATP present which again is directly proportional to the 
number of metabolically active cells present in culture. 
CD133+ and CD133- cells (with and without TGF-β stimulation) were 
counted and resuspended in DMEM media at 1 x 104 cells / ml and 50 μl of cell 
suspension was seeded into each well of an opaque-walled 96-well plate  (Sigma-
Aldrich), therefore a total number of 500 cells / well. The assay was run in triplicate 
for each group of cells and for each chemotherapeutic´s concentration (10 
concentrations for each drug). Controls included no cell and no drug treatments. The 
plates were incubated overnight at 37ºC, 5% CO2. 
The drugs used were doxorubicin (Pharmacia/Pfizer, UK) and mitoxantrone 
hydrochloride (Baxter Healthcare Ltd, UK) and were prepared at a stock 
concentration of 200 μM in DMEM. A serial dilution of each drug in DMEM was 
prepared in triplicate for each cell line and controls, and 50 μl of each drug dilution 
was added per well and incubated for 72 hours at 37ºC, 5% CO2. 
To generate the ATP standard curve, 50 μl of a 10mM ATP solution (Life 
Technologies) were added to 4.95 ml of culture medium in order to produce a 100 
μM concentration. For each plate, 4 Eppendorf tubes were prepared in which 
medium was used to further serially dilute 1:10 the 100 μM ATP solution in order to 
make 10 µM, 1 µM, 100 nM and 10 nM dilutions,  of which 50 µl were added to 
wells of each plate just before analysis.  
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The CellTiter-Glo substrate was mixed with the CellTiter-Glo buffer to 
produce CellTiter-Glo reagent. Reagents and culture plates were equilibrated to room 
temperature before assaying. One hundred μl was added to each well of an opaque-
walled 96-well plate (Sigma-Aldrich). Plates were incubated on an orbital shaker for 
2 minutes and then immediately incubated at room temperature for 10 minutes to 
stabilise the luminescent signal. Luminescence was recorded using the Perkin Elmer 
1420 Multilabel Counter Victor3™ plate reader (Perkin Elmer).  
 Triplicate vehicle-only (no chemotherapeutic drug) controls were used in 
each plate. Luminescence reading from these wells were used for normalisation of 
the chemotherapy-exposed cell luminescence data to represent 100% cell viability. 
All other readings from chemotherapy-exposed cells were compared to the 
normalised controls in order to give accurate percentage of cell viability. 
 
2.11 microRNA expression analysis 
RNA was extracted from REM as described in 2.6.1.2, then sent to Edinburgh 
Genomics-Roslin Institute (Centre for Comparative and Functional Genomics, The 
Roslin Institute, The University of Edinburgh, UK) for microRNA sequencing. The 
RNA extracts were chosen from a TGF-β time course experiment during which 
harvested protein samples from cell homogenates showed changes in protein 
expression suggesting that they underwent EMT. The analysed samples were: 
REM cells without stimulation (control group) 
REM cells treated with vehicle carrier after days 1, 10, 17 and 23 (REM mock) 
REM cells treated with 10 ng/ml TGF-β after days 1, 10, 17 and 23 (REM TGF-β) 
REM cells at day 23 with TGF-β withdrawal after 19 days (REM wd-19)  
The miRNA library preparation was performed according to the preparation 
guide provided by Illumina® Truseq™ Small RNA (Illumina, Inc., USA), using total 
RNA as starting material. Both 5’ and 3’ RNA adapters were added to 1 µg total 
RNA. These adapters were specially designed so that they would preferentially ligate 
small RNAs. Reverse transcription PCR was then performed to amplify the adapter-
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ligated small RNAs. The products were selected according to their size utilising 
polyacrylamide gel electrophoresis (PAGE), thereafter molecules of 145-160 bp 
were excised from polyacrylamide gel and subsequently purified and concentrated 
through ethanol precipitation. Validation of the miRNA libraries was performed with 
a Bioanalyzer 2100 (Agilent Technologies, Inc., USA). A pool containing all 
libraries was sequenced at Edinburgh-Genomics. 
The reads from the microRNA sequencing experiment were mapped to 
known canine microRNAs using Novoalign™ version 3.0 (Novocraft Technologies 
Sdn Bhd, Malaysia). The unmapped reads were then mapped to human microRNAs. 
A spreadsheet of matched reads was constructed showing rows as microRNAs and 
columns as experiments. These were all normalised to reads per million (RPM) 
mapped sequences. 
For the differential expression analysis, empirical analysis of digital gene 
expression data in R (EdgeR version 3.10.2, Bioconductor, USA) was utilised to 
compare the mock-treated and TGF-β-stimulated samples at each time point. We also 
compared REM TGF-β withdrawal samples with REM mock-treated and REM TGF-
β-stimulated samples after day 23. No biological replicates were used in this 
experiment. 
Normalised counts were calculated as number of reads / total number of reads 
mapped (millions). 
Counts were analysed for: 
- Normalised counts for each microRNA 
- logFC: log(2) fold change. Positive values would be upregulated 
and negative values downregulated. 
- logCPM: the average log(2) CPM (counts per million). High 
values would show that microRNA is highly expressed and low 
values would show lowly expressed microRNA. 
- P-value: unadjusted p-values for each comparison. 
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- FDR (False discovery rate): adjusted p-value using the Benjamini 
and Hochberg correction (Benjamini and Hochberg, 1995). 
Lowly expressed microRNAs were filtered out. Due to the experimental 
design, there were not many microRNAs that passed the FDR≤ 0.05 filter. This 
would be expected when there are no biological replicates. 
 
2.12 MicroRNA validation 
qRT-PCR was performed using the same RNA that was utilised for miRNA 
expression analysis. qRT-PCR was performed as in Chapter 2.7 and was followed 
with specific microRNA expression assays targeting mature miRNA sequences from 
TaqMan®, Life Technologies™. These assays use a target-specific stem-loop 
reverse transcription primer for each microRNA targeted as displayed in Table 2.4. 
This method was utilised as miRNAs are constructed of only 17-24 nucleotides but 
regular qRT-PCR methods typically use templates of at least double the length of 
each primer. This means that the minimum length of each target would typically be a 
minimum of 40 nucleotides. As miRNAs are too short for such methodologies, the 
method used herein utilises a specific reverse transcription primer containing a stem-
loop structure which transcribes a longer miRNA/stem-loop cDNA target, which is 
then sequenced using primers designed for the miRNA/stem-loop cDNA target 
(Kramer, 2011). 
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2.13 Statistical analysis 
Statistical analyses of data were performed using Minitab© 15 Statistical 
Software (Minitab Ltd., UK). P-values <0.05 were considered statistically 
significant. Non-parametric testing was performed. Mann Whitney U-tests were used 
to compare differences between two samples. Adjusted p-values for miRNA 
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Chapter 3: Induction of EMT confers a 
mesenchymal-like phenotype and migratory 
properties to breast cancer cells 
 
3.1 Abstract 
Breast cancer is a very common disease in humans and dogs. It is the most 
common cancer in both women and un-spayed female dogs. The metastatic potential 
of mammary carcinoma is very high, in affected patients. Metastatic cells can 
migrate, invade and colonise different organs. These secondary tumours are often 
more aggressive than the primary tumour, and may be lethal to the patient. Epithelial 
to Mesenchymal Transition (EMT) has been implicated as a driver of metastasis. 
During EMT, epithelial cells acquire a mesenchymal-like phenotype, which enables 
them to move easier through surrounding tissues and vessels to migrate and invade 
different organs. 
The aims of this study were first to establish the level of expression of 
epithelial and mesenchymal markers in breast cancer cells of dogs, cats and humans 
after confirming morphological changes related to a mesenchymal-like phenotype 
(spindle shape, separation from groups of cells and front to back polarity). Mammary 
carcinoma cells from all three species were stimulated with TGF-β to induce EMT 
and each cell line tested showed characteristic mesenchymal changes. After TGF-β 
stimulation cells acquired migratory characteristics, observed by in vitro migration 
and invasion assays. These changes confirm the acquisition of a mesenchymal-like 
phenotype with migratory and invasive characteristics in breast cancer cells through 
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3.2 Introduction 
Epithelial to Mesenchymal Transition (EMT) is a process involved in 
embryogenesis, carcinogenesis, and metastasis as described in Chapter 1.5. The 
Transforming Growth Factor-Beta (TGF-β) pathway and its associated transcription 
factors are crucial for EMT induction, during which epithelial cells lose their 
defining characteristics and acquire mesenchymal properties (Voulgari and Pintzas, 
2009, reviewed by Huber et al., 2005 and Moustakas and Heldin, 2007) as previously 
described in Chapter 1.10. Furthermore, during EMT epithelial cells undergo 
cytoskeletal changes, acquiring increased motility and invasiveness (reviewed by 
Savagner et al., 1994, and Thiery and Chopin, 1999). Interestingly, in some cases 
cells progress through a partial EMT, expressing both, mesenchymal and epithelial 
markers during the process (reviewed by Yang and Weinberg, 2008), indicating that 
phenotypical changes may not be entirely specific for a mesenchymal or an epithelial 
cell even though they have the ability to migrate and invade. 
EMT can facilitate cell migration towards different tissues in the organism, 
enabling metastatic cells to invade other organs due to a type III EMT as reviewed by 
Kalluri and Weinberg, 2009. Once these cells reach a new organ or niche, they can 
produce a secondary, or metastatic tumour and become more harmful (reviewed by 
Kalluri and Weinberg, 2009).  
EMT has been studied at different levels in different species, especially 
humans and mice, as previously described in Chapters 1.5 and 1.12, but to date there 
are few significant studies regarding type III EMT in companion animals including 
dogs and cats, including studies carried out by Salgado et al. in 2014 and Fonseca-
Alves et al. in 2015, mentioned in Chapter 1.16 (Salgado et al., 2014 and Fonseca-
Alves et al., 2015).  
An important difference between humans and companion animals regarding 
metastasis is the predilection for distant metastatic sites during breast cancer 
progression. In humans, bone and lungs are the first invaded organs in that respective 
order (Chen et al., 2010, Coleman, 2006), whereas in dogs and cats, the lungs tend to 
be the first organs affected by distant breast cancer metastasis, as reviewed by Nelson 
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and Couto, 2000, Ogilvie, 2006, Lana and Withrow, 2007, and Sorenmo et al., 2013; 
and the pathophysiology of cancer, diagnostic and therapeutic approaches vary 
between these species (reviewed by Sorenmo, 2003, , Sorenmo et al., 2011, and 
Sorenmo et al., 2013). The diagnostic approach in humans differs from that in 
companion animals as humans often present at an earlier stage following routine or 
self-examination, and some diagnostic tools are not affordable or available in 
animals, especially in developing countries. However, if we consider the fact that 
dogs and cats are more similar to humans than are conventional laboratory animals 
(reviewed by MacEwen, 1990, Vail and MacEwen, 2000, Printz, 2011, Liu et al., 
2014), the current studies were designed to specifically investigate TGF-β-induced 
EMT in human, canine, and feline mammary carcinoma cell lines, thus investigating 
whether dogs and cats are useful animal models for the study of EMT in cancer 
progression. 
Induction of EMT is directly proportional to the repression of E-cadherin as 
described in Chapter 1.5, in which different downstream effectors in the TGF-β 
pathway play important roles. E-cadherin expression is inversely proportional to the 
tumour grade and stage, and patient prognosis as reviewed by Hirohashi, 1998, 
Thiery, 2002, Peinado et al., 2004, and Schmalhofer et al., 2009. 
A subunit of the cadherin protein complex, β-catenin, acts by binding E-
cadherin and α-catenin to the actin cytoskeleton and is essential for keeping cells 
attached to each other (reviewed by Schmalhofer et al., 2009, Acloque et al., 2008, 
Brabletz et al., 2005) as shown in Figure 1.2. The upregulation of mesenchymal 
promoters like vimentin and fibronectin is enabled by repression of cadherins 
including E-cadherin and β-catenin. Vimentin enables cells to change their shapes 
giving strength and flexibility to their cytoskeletons in order to prevent damage 
during migration through surrounding tissues as reviewed by Goldman et al., 1996. 
This protein is an intermediate filament polypeptide present in the cytoskeleton of 
mesenchyme-derived cells but not in epithelia-derived cells which has been shown to 
play a role in type I and type II EMT (reviewed by Zeisberg and Neilson, 2009, 
Dellagi et al., 1983, Franke et al., 1978). Furthermore, fibronectin is an extracellular 
matrix glycoprotein which is essential for vertebrate development and it plays an 
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important role in cell adhesion, migration, cytoskeletal organisation, apoptosis and 
tissue remodelling (Williams et al., 2008). It is continuously produced by adherent 
cells (Darribere and Schwarzbauer, 2000). This glycoprotein plays an important role 
in guiding cells so that they can reach their new niche where it binds to collagen and 
fibrin to enable cells to colonise the new microenvironment (Williams et al., 2008, 
Darribere and Schwarzbauer, 2000, Hao et al., 2004).  
Upregulation and downregulation of transcription factors such as Twist and 
ZEB1 can potentially lead to a series of molecular changes in the epithelial and 
mesenchymal proteins mentioned above,  as demonstrated by Comijn et al., 2001, 
Yang et al., 2004, and Eger et al., 2005, and reviewed by Peinado et al., 2007. Twist 
and ZEB1 are known to trigger EMT by downregulating E-cadherin expression (Bae, 
2013). Thus the downregulation of E-cadherin is considered the hallmark of EMT 
(Bolos et al., 2003).  
In this study we intended to stimulate canine and feline mammary carcinoma 
cell lines with TGF-β and to observe if they underwent an EMT, as has been shown 
in human mammary cancer cell models (Bakin et al., 2000, Dalal et al., 1993, Xie et 
al., 2004). A human mammary carcinoma cell line, MCF7, was utilised as a control, 
and in order to assess the similarities and differences between human, feline and 
canine mammary carcinoma cells undergoing TGF-β-induced EMT. The aims of this 
study were to clarify the role of EMT as a relevant transition process in cancer 
research in animals to promote a better understanding of the disease and pursue 
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3.3 Results 
3.3.1 TGF-β-induced EMT confers cells a mesenchymal morphology 
Cells with epithelial characteristics have a round shape and typically are 
found in groups due to their tight junctions. They have a top to bottom polarity 
facilitating their attachment to their basement membrane and each other and their 
functional roles. These cells are polarised such that the bottom is defined as basal, 
and the top as apical. In contrast, mesenchymal cells have a more elongated shape 
and their polarity is switched to a front to back polarity. Moreover, their intercellular 
junctions are inadequate to stay attached to their basement membrane and each other, 
therefore they do not form large groups, and easily migrate (reviewed by Acloque et 
al., 2009).  Canine mammary carcinoma (REM), feline mammary carcinoma (CMC) 
and human mammary carcinoma (MCF7) cell lines were stimulated with 10 ng/ml of 
TGF-β every 24 hours for 6 days. TGF-β-stimulated cells showed morphological 
changes consistent with a more mesenchymal phenotype after 6 days of treatment 
compared to vehicle-treated cells. Cells of all species became more elongated and 
separated away from each other indicating that they were losing their tight junctions 
and changing their polarity from a top to bottom to a front to back polarity. We 
observed that CMC cell line showed individual cells with a more elongated or 
spindle shape separating from other cells at day 6 of TGF-β stimulation, indicating 
loss of tight junctions and remodelling of cytoskeleton. Interestingly, vehicle-treated 
cells also showed spindle shapes by day 6 but in contrast to TGF-β-stimulated cells, 
they remained closely attached to each other as shown in Figure 3.1. REM cells also 
showed a more mesenchymal morphology after stimulation with TGF-β. A spindle 
shape and a greater separation of cell groups was evident at day 6 of treatment in 
REM cells compared with the vehicle-treated group as shown in Figure 3.2. 
Furthermore, the human breast cancer cell line, MCF7 also showed morphological 
changes consistent with a more mesenchymal phenotype after TGF-β exposure. We 
observed that MCF7 cells did not show a very pronounced spindle shape, but they 
did display cytoplasmic widening and detachment from each other at day 6 of 
treatment as shown in Figure 3.3. 
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Figure 3.4 is a composite of photomicrographs showing the differences 
between the canine, feline and human mammary carcinoma cells studied before and 
after undergoing TGF-β-induced EMT, with evident mesenchymal traits at day 6 of 
treatment with 10 ng/ml TGF-β. All cell lines showed individual cells separating 
from the main group of cells. 
 
 
Figure 3.4. Comparison between the three different cell lines, showing that canine (REM), feline 
(CMC) and human (MCF7) mammary carcinoma cell lines display evident mesenchymal 
features at day 6 of TGF-β stimulation compared to vehicle-treated cells. 0 ng/ml TGF-β = 
vehicle-treated cells. 10 ng/ml TGF-β = cells treated with 10 ng/ml of TGF-β. Scale bar 
represents 50 µm. 
 
3.3.2 TGF-β leads to EMT by downregulation of epithelial and 
upregulation of mesenchymal proteins in breast cancer 
cells 
In order to further assess whether epithelial breast cancer cells in dogs, cats 
and humans acquired mesenchymal traits after TGF-β stimulation, we analysed the 
expression of proteins that are often changed during EMT in the three cell lines 
studied (REM, CMC and MCF7). Cells were treated with 10 ng/ml of TGF-β every 
24 hours, and harvested after 6 days. The protein expression of epithelial markers E-
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cadherin and β-catenin, and mesenchymal markers vimentin and fibronectin, were 
analysed by western blot. We found that epithelial markers E-cadherin and β-catenin 
are downregulated and mesenchymal markers vimentin and fibronectin are 
upregulated after TGF-β treatment as shown in Figure 3.5. These results were 
consistent across the species. The transcriptional repression of proteins, such as 
cadherins (E-cadherin and β-catenin), characteristic of EMT, can be accomplished by 
a range of transcription factors including ZEB1 and Twist as reviewed by Savagner 
et al., 1994, and Thiery and Chopin, 1999.We found that Twist was upregulated in 
REM cells, and ZEB1 was upregulated in CMC cells compared to untreated cells. 
These findings confirm that TGF-β is a promoter of EMT by repressing E-cadherin 
activity and enhancing upregulation of mesenchymal gene expression. This is 
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 A)            B)                  C)       
        
Figure 3.5. EMT-associated changes at the protein expression level after treatment with 10 
ng/ml of TGF-β compared with untreated cells. A) Canine mammary carcinoma cells (REM) 
show down-regulation of epithelial markers (E-cadherin and β-catenin) and up-regulation of 
mesenchymal markers (vimentin and fibronectin) and transcription factor Twist. B) Feline 
mammary carcinoma cells (CMC) show down-regulation of epithelial markers and up-
regulation of mesenchymal markers and transcription factor ZEB1. C) Human mammary 
carcinoma cells (MCF7) show down-regulation of epithelial markers and upregulation of 
mesenchymal markers. Β-actin was used as a loading control for all cell samples. All proteins 
were expressed at the expected molecular weights. E-cadherin = 120 kDa, β-catenin = 92 kDa, 
vimentin = 57 kDa, fibronectin = 240 kDa, Twist = 28 kDa, ZEB1 = 124 kDa and β-actin = 45 
kDa. Thirty µg of protein was loaded for each immunoblot.          
 
3.3.3 EMT changes expressed at the transcriptional level in 
canine and human cell lines 
The mRNA expression levels of EMT markers were determined by qRT-PCR 
after cells were treated with 2.5, 5 and 10 ng/ml of TGF-β for 4 and 8 days, and 
compared with untreated cells for 8 days. Morphological changes were seen by day 6 
of treatment with TGF-β, as previously described in Chapter 3.3.1. We decided to 
assess the expression of epithelial and mesenchymal markers at the transcriptional 
level at day 4 and day 8 to investigate whether the morphological changes were 
supported by a mRNA expression changes supportive of EMT. We observed that 
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cells did not show downregulation of epithelial characteristics’ mRNA by day 4 of 
treatment (data not shown). Whereas, by day 8 cells show significant changes in their 
mRNA expression of epithelial and mesenchymal markers, confirming that they 
maintain a mesenchymal phenotype at the transcriptional level at least 48 hours after 
the acquisition of morphological changes.  
We observed that TGF-β-stimulated MCF7 and REM cells showed 
anticipated transcriptional changes given the EMT associated morphological and 
protein changes. Epithelial marker RNA expression was downregulated and 
mesenchymal marker RNA expression was upregulated at different time points with 
different concentrations of TGF-β after 8 days. All calculations for the relative 
expression analysis were made according to the Pfaffl method described in Chapter 
2.7.7. The reference genes utilised were canine and human RPL32 for REM and 
MCF7 cell lines, respectively. All these experiments were repeated three times. 
The RNA expression of the epithelial markers E-cadherin and β-catenin was 
downregulated in TGF-β-stimulated MCF7 cells in comparison to the untreated cells 
at day 8 with different concentrations of TGF-β. This difference was proved 
significant, as depicted in Figures 3.6 and 3.7, respectively. Moreover, RNA 
expression of the mesenchymal marker vimentin was upregulated at day 8 as 
depicted in Figure 3.8. 
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Figure 3.6. E-cadherin is downregulated in MCF7 cells after 8 days of TGF-β stimulation at 2.5, 
5 and 10 ng/ml. Control = untreated cells, Mock = vehicle-treated cells for 8 days with the 
equivalent of 10 ng/ml of TGF-β, 2.5 ng/ml = cells stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = 
cells stimulated with 5 ng/ml of TGF-β, 10 ng/ml = cells stimulated with 10 ng/ml of TGF-β. Day 
8 = cells harvested at day 8 of treatment. We found statistically significant differences in E-
cadherin expression between cells harvested after 8 days of treatment with TGF-β and control 
and vehicle-treated control cells. P values comparing TGF-β- stimulated samples with control 
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Figure 3.7 β-catenin is downregulated in MCF7 cells after 8 days of TGF-β stimulation at 2.5, 5 
and 10 ng/ml. Control = untreated cells, Mock = vehicle-treated cells for 8 days with the 
equivalent of 10 ng/ml of TGF-β, 2.5 ng/ml = cells stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = 
cells stimulated with 5 ng/ml of TGF-β, 10 ng/ml = cells stimulated with 10 ng/ml of TGF-β. Day 
8 = cells harvested at day 8 of treatment. We found statistically significant differences in β-
catenin expression between cells harvested after 8 days of treatment with TGF-β and control 
and vehicle-treated control cells. P values comparing TGF-β-stimulated samples with control 
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Figure 3.8. Upregulation of vimentin following exposure to TGF-β (2.5, 5 and 10 ng/ml) at day 8 
of stimulation. Control = untreated cells, Mock = vehicle-treated cells for 8 days with the 
equivalent to 10 ng/ml of TGF-β, 2.5 ng/ml = cells stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = 
cells stimulated with 5 ng/ml of TGF-β, 10 ng/ml = cells stimulated with 10 ng/ml of TGF-β. Day 
8 = cells harvested at day 8 of treatment. We found statistically significant differences in 
vimentin expression between cells harvested after 8 days of treatment with TGF-β and control 
and vehicle-treated control cells. P values comparing TGF-β-stimulated samples with control 
cells:* = p value ≤ 0.05.  
 
REM cells did not exhibit an anticipated significant change of epithelial 
marker mRNA expression after TGF-β stimulation, shown in Figure 3.9 and Figure 
3.10. We would expect epithelial markers to be downregulated after TGF-β 
treatment; however, they were highly upregulated. Nevertheless, these samples 
showed an upregulation of the mesenchymal marker fibronectin after 8 days of 
treatment at all concentrations of TGF-β compared with the untreated cells at day 8, 
as shown in Figure 3.11. These results show that at the mRNA level REM cells do 
not lose their epithelial characteristics but do acquire mesenchymal properties as 
discussed below. 
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Figure 3.9. REM cells do not show downregulation of E-cadherin after TGF-β stimulation at 
day 8. Control = untreated cells, Mock = vehicle-treated cells for 8 days with the equivalent of 
10 ng/ml of TGF-β, 2.5 ng/ml = cells stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = cells 
stimulated with 5 ng/ml of TGF-β, 10 ng/ml = cells stimulated with 10 ng/ml of TGF-β. Day 8 = 
cells harvested at day 8 of treatment. P values comparing TGF-β-stimulated samples with 
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Figure 3.10. REM cells do not show downregulation of β-catenin after TGF-β stimulation at day 
8. Control = untreated cells, Mock = vehicle-treated cells for 8 days with the equivalent of 10 
ng/ml of TGF-β, 2.5 ng/ml = cells stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = cells stimulated 
with 5 ng/ml of TGF-β, 10 ng/ml = cells stimulated with 10 ng/ml of TGF-β. Day 8 = cells 
harvested at day 8 of treatment. P values comparing TGF-β-stimulated samples with control 
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Figure 3.11. The mesenchymal marker fibronectin is highly upregulated in REM cells after 
TGF-β stimulation at day 8 compared to the control groups. Control = untreated cells, Mock = 
vehicle-treated cells for 8 days with the equivalent of 10 ng/ml of TGF-β, 2.5 ng/ml = cells 
stimulated with 2.5 ng/ml of TGF-β, 5 ng/ml = cells stimulated with 5 ng/ml of TGF-β, 10 ng/ml 
= cells stimulated with 10 ng/ml of TGF-β. Day 8 = cells harvested at day 8 of treatment. We 
found statistically significant differences in fibronectin expression between cells harvested after 
8 days of treatment with TGF-β and control and vehicle-treated control cells. P values 
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3.3.4 EMT confers migratory properties to feline and canine 
mammary carcinoma cell lines 
The migration capacity of TGF-β-stimulated REM and CMC cells was 
assayed using a wound healing assay. REM and CMC were treated with 10 ng/ml of 
TGF-β for 6 days, prior to a scratch being made on the cell monolayer. To determine 
how quickly cells healed the gap, measurements were taken every 4 hours and the 
relative migration distance was calculated. TGF-β-stimulated REM and CMC cells 
showed a faster migration rate than untreated control cells.  
TGF-β-stimulated REM cells migrated to close the scratch made (wound) 
after 32 hours of incubation, whereas non-stimulated cells took at least 48 hours to 
close the wound as shown in Figure 3.12. 
The CMC cell line also showed a faster migration rate in TGF-β-stimulated 
cells compared to the untreated cells. In this case, stimulated cells closed the wound 
completely after 56 hours of incubation in contrast to untreated cells which closed 
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3.4 Discussion 
In companion animals type III EMT has not been widely studied. Different 
research groups have found important results regarding type II EMT (wound healing 
and fibrosis) (Aresu et al., 2007, Chandler et al., 2007, Aresu et al., 2008, Mathias et 
al., 2009). Other studies have correlated tumour progression with the expression of 
adhesion molecules and EMT-associated transcription factors (Mcentee and 
Brennerman, 1999, Nowac et al., 2007, Nowac et al., 2008, Aresu et al., 2010, Han et 
al., 2010, Stein et al., 2011, Ide et al., 2011, Im et al., 2012) but, interestingly, none 
of them have correlated their findings with type III EMT. Only few studies, including 
papers published by Salgado et al. and Fonseca-Alves et al., report findings regarding 
EMT in companion animals, related to cancer progression. These papers show an 
important correlation between EMT markers and mammary and prostatic carcinoma 
progression in dogs, as described in Chapter 1.16 (Salgado et al., 2014 and Fonseca-
Alves et al., 2015). 
Here, we observed that canine, feline and human mammary carcinoma cells 
undergo an EMT after stimulation with TGF-β and show a more mesenchymal 
phenotype. These mesenchymal-like characteristics were demonstrated by 
morphological and molecular changes. E-cadherin protein expression was repressed 
whilst there was increased protein expression of mesenchymal markers.  Previous 
studies have shown that upregulation of mesenchymal markers is a consequence of 
repression of E-cadherin (reviewed by Thiery and Sleeman, 2006). Here we included 
the human carcinoma cell line MCF7 as a comparative control. 
We have demonstrated that dog and cat mammary carcinoma cells undergo 
EMT following TGF-β stimulation and consequently show morphology associated 
with mesenchymal cells including spindle shapes; loss of cell-cell contact; and 
separation from the group of cells. It took at least 6 days of TGF-β stimulation at a 
concentration of 10 ng/ml every 24 hours for maximal morphological changes to be 
observed. These results were consistent in all three cell lines studied. TGF-β is a 
complex molecule with multifaceted and context-dependent effects on cell function. 
For example, as described in Chapter 1.10, in early stages of cancer, TGF-β can act 
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as a tumour suppressor gene, whereas at late stages it can act as a tumour promoter 
(Shipitsin et al., 2007), enhancing cancer progression and metastasis through an 
EMT (Levy and Hill, 2005).  
The REM and CMC cells, after TGF-β treatment, showed a more spindle 
shape, especially near the edges of the cell group. MCF7 cells also showed similar 
changes in morphology, in which the cells became not only longer but also wider, 
although these changes were quite limited to the edges of the groups of cells. These 
morphological changes would be indicative that these cells are going through an 
EMT process as reviewed by Thiery, 2003. Further to this, protein expression of 
molecular markers of EMT was analysed. Epithelial and mesenchymal markers 
showed a decrease and increase in protein expression, respectively. These changes 
were present at a similar time following TGF-β stimulation to the morphological 
changes associated with an EMT process. These findings were also observed in all 
three cell lines. Several studies have shown the inverse correlation that transcription 
factors ZEB1 and Twist have with E-cadherin expression during EMT-induced 
metastasis. Eger et al, 2005 showed that human breast cancer cells expressing high 
RNA and protein levels of ZEB1 also expressed low levels of E-cadherin and were 
not able to form complete epithelial sheets. They also knocked down ZEB1 and 
observed upregulation of E-cadherin, confirming that ZEB1 is an important repressor 
of E-cadherin and thus, might play an important role in invasion and metastasis of 
epithelial cancer cells (Eger et al., 2005). In a similar way, Yang et al, 2004 
demonstrated the relevance of Twist during EMT in epithelial cancer cells including 
breast cancer in humans. They utilised siRNAs to knockdown Twist and observed 
how breast cancer cells had an inverse correlation between Twist and E-cadherin 
expressions, as the knocked-down cells increased their expression of E-cadherin and 
reduced their migratory abilities. Furthermore, they confirmed that Twist is an E-
cadherin suppressor and also induces mesenchymal markers, such as fibronectin and 
vimentin (Yang et al., 2004).  
In the current study, we showed that CMC, a feline mammary carcinoma cell 
line also showed increased expression of transcription factor ZEB1, which could play 
an important role in type III EMT in feline mammary cancer. Similarly, the REM 
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canine cell line showed overexpression of the transcription factor Twist after TGF-β 
stimulation. These findings could lead to new understanding regarding potential 
effectors of type III EMT in companion animals, although there is still much to be 
understood about the diverse transcription factors and their roles in EMT, tumour 
progression and metastasis. Similar experiments would have to be carried out using 
in vivo models such as the chorioallantoic membrane (CAM) assay to further explore 
these findings and assess the effects of targeting these transcription factors on 
progression and metastasis. Moreover, in order to demonstrate if the effects of ZEB1 
and Twist are crucial for E-cadherin expression during EMT in companion animals, 
it would be of great importance to analyse whether silencing these transcription 
factors enhance E-cadherin expression or not. 
At the transcription level, EMT associated changes were observed by qRT-
PCR where MCF7 cells showed a downregulation of epithelial markers E-cadherin 
and β-catenin after 8 days of TGF-β treatment while the mesenchymal marker 
vimentin was upregulated in a dose dependent manner with TGF-β after stimulation 
for 4 and 8 days. Interestingly, after only 4 days of TGF-β treatment, these cells 
demonstrated increased expression of the above mentioned epithelial markers (data 
not shown). This could be consistent with the variable and context-specific effects 
that TGF-β induces, as mentioned in Chapter 1.10 and described by (Lehmann et al., 
2000, Levy and Hill, 2005 and Shipitsin et al., 2007). If we compare these results 
with our MCF7 morphological data, we can assume that these cells need between 6 
and 8 days of treatment with TGF-β in order to acquire both morphological and 
molecular changes associated with EMT. This gives evidence that MCF7 cells go 
through a TGF-β-induced EMT losing their epithelial characteristics and acquiring 
mesenchymal traits after TGF-β stimulation. In contrast to the MCF7 cell line, the 
REM cell line did not show an evident downregulation of epithelial markers after 
TGF-β stimulation, although, the mesenchymal marker fibronectin was highly 
upregulated in TGF-β-stimulated cells after 8 days with all concentrations of TGF-β. 
While these REM cells acquired mesenchymal properties, they did not show loss of 
epithelial characteristics at the transcription level. This finding is discordant with the 
morphological changes associated with loss of epithelial characteristics that we 
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observed after 6 days of TGF-β stimulation in these same cells. Nevertheless, as 
mentioned in Chapter 3.2, in some cases, cells may pass through a partial EMT 
without showing an evident downregulation of epithelial markers or upregulation of 
mesenchymal markers, making invading cells phenotypically similar to either an 
epithelial or a mesenchymal cell (Thompson et al., 2005, reviewed by Tarin et al., 
2005, and Yang and Weinberg, 2008). This could be an explanation as to why canine 
mammary carcinoma cells did not show an evident downregulation of epithelial 
markers while fibronectin was clearly upregulated after TGF-β stimulation. 
Furthermore, there is disparity between epithelial markers at the mRNA and protein 
levels in REM and MCF7 samples after TGF-β stimulation. This could be happening 
because even though the mRNA expression levels may act as a predictive outcome 
for translational activity, in some cases mRNA expression levels only partially 
predict corresponding protein levels (reviewed by Vogel and Marcotte, 2013). A 
different explanation of these discrepancies is that regulation by different 
mechanisms, including microRNAs, at the post-transcriptional or translational level 
fine-tunes protein expression (Baek, et al., 2008). This can be related to feedback 
loops that can regulate and integrate transcription, translation and degradation levels 
as reviewed by Dahan et al., 2011. Along with this, Laurent et al, (2010) showed that 
protein levels can be more conserved than their corresponding mRNA levels in 
different cells, including bacteria, yeast, human and plants (Laurent, et al., 2010). In 
line with these observations, in this study we focussed our attention more on the 
post-transcriptional levels of protein expression than in transcriptional levels of 
mRNA, as it closely correlates to the observed morphological changes and migratory 
capability of EMT-induced mammary carcinoma cells. 
 As previously mentioned in Chapter 1.5, prior to undergoing an EMT, 
epithelial cells usually remain attached to their basement membrane with a top to 
bottom polarity which prevents them from moving through surrounding tissues as 
reviewed by Acloque et al., 2009. Once they undergo an EMT, they acquire 
migratory features as their polarity is changing to a front to back polarity with 
decreased adherence junctions, enabling them to move more easily and rapidly 
(reviewed by Savagner et al., 1994, Thiery and Chopin, 1999 and Acloque et al., 
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2009). This migratory characteristic can be assessed by different means. Motility is 
one of the most important characteristics of epithelial cells undergoing a type II EMT 
in which they would need to migrate in order to colonise the wound which induced 
type II EMT and heal the tissue, or perhaps promote fibrosis. In this study, we 
assessed how fast mammary carcinoma cells from dogs and cats migrated to colonise 
an artificial wound in vitro with and without exposure to TGF-β. Cells treated with 
TGF-β migrated faster than untreated cells, colonising the wound at least 16 hours 
prior to their untreated counterpart. These observations confirm that EMT gives 
migratory characteristics to feline and canine mammary carcinoma cells and that 
TGF-β is a promoter of this process in vitro. Other research groups have shown 
similar results in vivo, utilising gastric carcinoma cells pre-treated with TGF-β and 
injected into the abdominal cavities of nude mice, where they observed that treated 
cells exhibited higher liver metastatic rates than untreated cells (Fu et al., 2009). 
Although these characteristics have not been studied in dogs and cats in vivo, they 
suggest avenues for future research in this field.  
In conclusion, there is still much to be understood in cancer research; and 
tumour progression and metastasis are some of the most important parts of this field. 
Our results could be further explored with different approaches to continue research 
in this field. For instance, confirmation of some crucial points associated with our 
findings by inhibiting different TGF-β-associated transcription factors with specific 
siRNAs in order to better understand their roles in EMT. Targeted therapies against 
specific molecular receptors or signalling pathways associated with EMT are 
regarded as important tools to prevent cancer progression, as reviewed by Davis et 
al., 2014; and if the inhibition of these molecules proves useful in vitro, this could 
direct the rational development of targeted drugs against the salient molecules within 
the TGF-β pathway, leading ultimately to clinical trials. Small animals (dogs and 
cats) can be utilised as good comparative models for the study of cancer in humans 
(Vail and Macewen, 2000, reviewed by Porrello et al., 2006, Boggs et al., 2008, 
Gama et al., 2008, Cassali et al., 2011). Most of the studies we have been carrying 
out have been already demonstrated in human cell lines with similar outcomes, thus, 
these similarities can be used for the development of novel techniques and 
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experimental protocols. Perhaps the similarities in various types of cancer and its 
progression in humans and companion animals are due to the fact that cancers in 
dogs, cats and humans occur spontaneously compared to artificially-induced rodent 
models (Hansen and Khanna, 2004, Allred and Medina, 2008 and reviewed by Burrai 
et al., 2010, and Printz, 2011). Some specific examples of the similarities between 
human and canine cancers include mammary, prostate, lung and bladder carcinomas 
among other types of sarcomas and lymphomas as reviewed by Porrello et al., 2006. 
Interestingly, Bonnomet et al., 2012, developed and characterised genetically 
engineered mouse models in which they transplanted human breast tumours and 
assessed EMT-associated changes similar to those in human cancer. These changes 
included upregulation of mesenchymal markers such as vimentin, snail and slug, and 
downregulation of E-cadherin among other epithelial markers. However, these 
laboratory animal recipients need to be genetically modified in order to be able to 
receive a xenotransplant and develop the specific tumour characteristics, unlike 
companion animals which can spontaneously develop cancer, as reviewed by Printz, 
2011. It has been suggested that despite the wide variety of mouse models to study 
human prostate cancer (Wang, 2011) it would be impossible to reproduce all 
characteristics of such disease in mice as reviewed by Hensley and Kyprianou, 2012. 
The anatomy and physiology of the prostatic gland in humans and dogs share many 
similarities (Leroy and Northrup, 2009) that could explain the observations of Keller 
et al, that dogs are the only known large mammals  to spontaneously exhibit all 
stages of prostatic disease progression from benign hyperplasia to an invasive, 
metastatic carcinoma as in humans (Keller et al., 2013). Suami et al demonstrated the 
similarities between the lymphatic systems of dogs and humans (Suami et al., 2013), 
an important feature to trace cancer progression and the metastatic potential of 
specific tumours. In line with these observations, it would be of great relevance to 
our future research to assess the similarities in expression of EMT-associated 
markers in lymphatic metastases in humans and dogs with mammary carcinoma. A 
study carried out in 2014 showed that loss of E-cadherin in mammary carcinoma 
primary tumours in humans was related to the acquisition of a mesenchymal 
phenotype in 45% of circulating tumour cells from the same patients, compared with 
only 23% of circulating tumour cells showing a mesenchymal phenotype in patients 
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with tumours that did not show a decrease in E-cadherin expression by 
immunohistochemistry. When comparing primary tumours with metastatic lymph 
nodes, they found upregulation of EMT-associated transcription factors, but re-
expression of E-cadherin with lower cell division rates (Markiewicz et al., 2014). 
Correlation of our findings in primary tumour cell lines with metastatic cell lines 
could reveal the salient EMT factors involved in successful metastasis. 
Other molecular similarities between dogs and humans with regard to cancer 
progression include tyrosine kinase receptors (TKRs).  Tyrosine kinase receptors are 
involved in tumour proliferation and angiogenesis as reviewed by Ranieri et al., 
2014. The epidermal growth factor receptor (EGFR), vascular endothelial growth 
factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem 
cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are TKRs, 
which have been identified in the tumours of both species (reviewed by 
Shchemelinin et al., 2006, Buchdunger et al., 2000, Nakopoulou et al., 2002) . It has 
been proposed that cell proliferation in cancer can be due to alterations in the 
phosphorylation of protein kinases after aberrant activity or deregulation of these 
receptors (reviewed by Cohen, 2002, London et al., 2003). These findings enlighten 
the possibility of creating novel selective and personalised therapeutics against 
cancer and its progression in humans and pets by using this type of TKRs as rational 
targets for the development of  tyrosine kinase inhibitors (TKIs) for both species 
(Krause and Van Etten, 2005, London et al., 2009). It has been proposed that among 
these TKRs, EGFR is able to regulate cell migration and invasion in malignant 
epithelial cells through an EMT (reviewed by Al Moustafa et al., 2012). Thus, TKIs 
which could potentially block EGFR pathways might be able to inhibit cell migration 
and invasion, which would make them important components for combating cancer 
metastasis 
Elucidating the potential roles of several EMT-associated transcription 
factors in different molecular pathways can lead to a more detailed understanding of 
type III EMT  and can help guide the rational development of new diagnostic and 
therapeutic tools for cancer and its progression. 
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generates cancer cells with stem cell 
characteristics 
 
4.1 Abstract  
Induction of EMT can produce cells with stem cell-like characteristics, 
including self-renewal and resistance to chemotherapeutic drugs and apoptosis. This 
gives rise to many questions in the process of metastasis and tumour progression. 
Cells acquiring migratory and invasive properties can also become resistant and can 
become able to colonise a new niche and self-renew in order to produce progeny and 
create micrometastases which can develop into macroscopic secondary masses. Here, 
we have demonstrated the ability of breast cancer cells in dogs and cats to acquire 
stem cell-like characteristics by TGF-β-induced EMT. After TGF-β-induced EMT  
cells showed a better ability to generate spheres, which are representative of CSCs, 
while they showed a more mesenchymal phenotype analysed by epithelial and 
mesenchymal markers at the protein expression level. TGF-β-stimulated cells also 
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4.2 Introduction  
Recent studies have shown that tumours are made up of a heterogeneous mix 
of cells that consists of a small CSC population and a bulk population of more 
differentiated cells as reviewed by Reya et al., 2001. The cells with stem cell 
characteristics usually comprise a very low percentage of the tumour mass and some 
of their properties include constant self-renewal and acquisition of resistance to both 
apoptosis and therapeutic modalities including chemotherapy and radiotherapy 
(reviewed by Dean et al., 2005, Diehn and Clarke, 2006, Phillips et al., 2006, Pang et 
al., 2013). One important aspect of these CSCs is that they are more capable of 
colonising a new microenvironment after cell migration and developing a metastatic 
tumour than regular cancer cells. This observation was confirmed by Nomura et al., 
2015, after they showed in an athymic mouse model that the tumourigenicity of 
injected cultured human pancreatic carcinoma cells was enhanced by ectopic 
overexpression of CD133 (a stem cell marker) compared to the control, empty 
plasmid (Nomura et al., 2015). After arriving at a different organ, these CSCs can 
colonise it and differentiate so they can produce a new tumour in their new niche 
(reviewed by Dave et al., 2012 and reviewed by Dean et al., 2005).  
Tumour-seeding ability and resistance to apoptosis and antineoplastic 
properties is usually exhibited by stem cells and can be acquired by epithelial cancer 
cells after a TGF-β-induced EMT as shown by Mani et al (Mani et al., 2008). They 
demonstrated that TGF-β was able to induce EMT in human mammary epithelial 
cells (HMECs), which was confirmed by EMT-associated changes, whereby 
epithelial markers were downregulated and mesenchymal markers were upregulated. 
These EMT-induced cells were expressing the stem cell markers CD44+CD24-. The 
expression of these cell surface markers is characteristic in epithelial stem cells and 
human breast cancer cells with stem cell-like characteristics (Al-Hajj et al., 2003, 
Mani et al., 2008). 
A number of studies have confirmed the tumorigenic ability of epithelial 
breast cancer cells acquired after an EMT process. Morel et al (Morel et al., 2008) 
observed that a human mammary oncogenic cell line (HMLER), which expressed 
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CD44+CD24- by FACS, was able to form mammospheres, which are considered to 
be tumorigenic. These characteristics are associated with stem cells. They also found 
that the CD44+CD24- fraction in HMEC and MCF10 (immortal human mammary 
epithelial cell line) cell lines showed EMT associated changes at the protein 
expression level, suggesting that there could be a link between EMT and the 
acquisition of stem cell characteristics. They also induced EMT in CD44-CD24+ 
MCF10 and HMEC cell lines by treating them with TGF-β for 8 days and observed 
that mesenchymal markers were upregulated whilst epithelial markers were 
downregulated. Moreover, after EMT induction, small subpopulations of these cell 
lines expressed CD44+CD24- cell surface markers, compatible with cells with stem 
cell-like characteristics (Morel et al., 2008).  
Furthermore, other studies have confirmed the expression of the stem cell 
surface marker CD133 in breast cancer cells. Xiao et al observed that CD133+ 
human inflammatory breast cancer (IBC) cells have the ability to from spheroidal 
cells under limiting survival conditions with serum-free growth medium, suggesting 
that CD133+ cells have stem cell-like characteristics including self-renewal and 
resistance to limiting survival conditions (Xiao et al., 2008). In line with these 
observations, another research group have found that after an induced EMT human 
epithelial breast cancer cells acquire stem cell-like characteristics and express 
CD133. They observed that at least 50% of patients with breast cancer expressing 
CD133 had tumour relapse after chemotherapy, consistent with CD133+ breast 
cancer cells being not only resistant to limiting survival conditions , but also resistant 
to the effects of chemotherapeutic agents (Nadal et al., 2013). In line with these 
observations, the expression of stem cell surface markers are of vital importance for 
the identification and isolation of putative CSCs. Moreover, these cell surface 
markers can be utilised to further validate that epithelial cancer cells can become 
CSCs after induction of EMT. 
In one study by Li et al in 2008, the subpopulation of tumour-initiating cells 
identified in human breast cancer was found to be more resistant to conventional 
therapies than the more differentiated cancer cells (Li et al., 2008). The implication is 
that tumour relapse can be accomplished by these perseverant tumour-initiating cells 
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after conventional treatment. Therefore, CSCs must be eliminated to affect a cure on 
cancer.  
Chemotherapy is more effective against tumours with high growth fraction 
(GF) and low mass doubling time (MDT) as most chemotherapeutic agents act upon 
the process of cell division. Most tumours have a shorter MDT and higher GF during 
early stages of tumour growth, thus, chemotherapeutic agents usually work better at 
early stages. Chemotherapy is not very efficient in large tumours, as they would 
already be in late stages where the GF is lower and the MDT is longer, but metastatic 
lesions are potentially more susceptible as they have shorter MDT and higher GF 
than the primary tumour as reviewed by Argyle, 2008. Even though there are no 
clinical studies confirming their efficacy, two of the most utilised chemotherapeutic 
agents in small animal breast cancer are doxorubicin and mitoxantrone (Novosad, 
2003, Gimenez et al., 2010, Clemente et al., 2009, Clemente et al., 2010). 
Doxorubicin is an antineoplastic antibiotic which can be used alone or in 
combination with other agents. It inhibits DNA, RNA and protein synthesis, 
throughout the whole cell cycle, although the exact mechanism of action is unknown 
(Plumb, 2005). Mitoxantrone is an antineoplastic drug which binds to DNA and 
inhibits DNA and RNA synthesis. It does not act in a specific phase of the cell cycle, 
but it appears to be more active during the S phase (Plumb, 2005). Cancer cells with 
stem cell-like characteristics have been proven to be more resistant to apoptosis and 
to conventional therapies, thus, finding new ways to target them is needed in order to 
treat cancer and prevent its progression and tumour relapse (reviewed Dave et al., 
2012, Phillips et al., 2006 and reviewed by Dean et al., 2005). Targeting EMT 
inducers may offer a novel way to treat cancer patients as it has been demonstrated 
by different research groups that EMT-induced cancer cells exhibit stem cell-like 
characteristics (Mani et al., 2008, Morel et al., 2008, reviewed by Polyak and 
Weinberg, 2009 and Blacking et al., 2007). The development of new therapies 
blocking EMT and its transcription factors might be of great importance to provide 
an effective tool against cancer and its progression. In other words, if we confirm 
that there is indeed a crosstalk between EMT and the acquisition of stem cell-like 
characteristics in breast cancer, treatment of cancer at earlier stages with EMT-
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blocking agents could inhibit EMT effectors including ZEB1 and Snail, as shown by 
Olmeda et al, 2007a (Olmeda et al., 2007a). If EMT were blocked, not only might 
migration of cancer cells be prevented, but also the acquisition of other stem cell-like 
characteristics. Such inhibition of self-renewal and resistance to apoptosis and 
chemotherapeutic agents, could retard or arrest development of primary and 
metastatic tumours by decreasing cancer cells multiplication and augmenting the 
efficacy of currently used therapies. 
In this study, we have demonstrated that mammary carcinoma cells from 
dogs and cats acquired tumorigenic characteristics after TGF-β-induced EMT. Our 
data is consistent with other research groups working on mammary epithelial and 
mammary carcinoma cells in humans (Mani et al., 2008, Morel et al., 2008, and 
reviewed by Polyak and Weinberg, 2009). In these studies, TGF-β-stimulated 
epithelial mammary cells were able to form spheres and expressed stem cell 
associated markers, suggesting a link between EMT and the acquisition of stem cell 
characteristics in breast cancer cells. By confirming the acquisition of tumorigenic 
traits in canine and feline TGF-β-stimulated breast cancer cells, herein we could 
establish a link between EMT and the acquisition of stem cell-like characteristics in 
companion animals. These findings are significant in cancer research in veterinary 
medicine as studies establishing a link between EMT and CSCs have not been 
previously reported. Our findings also further support dogs and cats as important 
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4.3 Results  
4.3.1 TGF-β-stimulated mammary carcinoma cells have 
increased sphere forming ability 
Canine and feline mammary carcinoma cells showed an increased ability to 
form spheres after TGF-β stimulation. Cells were treated with 10 ng/ml of TGF-β for 
6 days before seeding them in N2 media (without serum and low levels of glucose) in 
low-adherent plates as described in Chapter 2.4. We observed that TGF-β-stimulated 
feline and canine mammary carcinoma cells were able to form more spheres than 
vehicle-treated cells. Feline mammary carcinoma spheres were bigger in size than 
the few spheres formed by unstimulated cells as shown in Figure 4.1. On average, 
TGF-β-stimulated feline mammary carcinoma cells formed approximately 44 spheres 
per microscopic field (objective 10x), whereas untreated cells formed approximately 
16, shown in Figure 4.2. Moreover, to assess if spheres had a mesenchymal 
phenotype, we assessed the expression of epithelial and mesenchymal protein 
markers by western blotting. The concentrations of mesenchymal markers were 
upregulated in non-TGF-β-stimulated spheres compared to adherent cells, consistent 
with there being a correlation between the acquisition of stem cell-like characteristics 
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Figure 4.1. Spheres derived from feline mammary carcinoma cell line (CMC) treated with 10 
ng/ml of TGF-β for 6 days are larger than spheres derived from untreated cells. A) Untreated 
CMC cells. B) TGF-β-stimulated CMC cells. Scale bar represents 100 µm. 
 
Figure 4.2. TGF-β-stimulated feline mammary carcinoma cell line (CMC) demonstrate greater 
sphere forming ability compared with untreated cells. Cells were stimulated with 10 ng/ml of 
TGF-β for 6 days and formed an overall average of 44 spheres per 10 x objective field, 
compared to the untreated cells, which formed an average of 16 viable spheres. Each bar 
represents the mean of the average measurements of 6 counts, whiskers represent the SD (p < 
0.005, Mann-Whitney test). 
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Figure 4.3. CMC spheres display a mesenchymal phenotype at the protein expression level. 
When compared to adherent cells, non-TGF-β-stimulated spheres express higher levels of 
mesenchymal markers vimentin and fibronectin, and lower levels of epithelial markers E-
cadherin and β-catenin, associated with a mesenchymal phenotype. Image courtesy of Dr. Lisa 
Pang. β-actin was used as a loading control for all cell samples. All proteins were expressed at 
the expected molecular weights, where E-cadherin = 120 kDa, β-catenin = 92 kDa, vimentin = 57 
kDa, fibronectin = 240 kDa and β-actin = 45 kDa. Thirty µg of protein was loaded for each 
immunoblot. 
 
The canine mammary carcinoma cell line (REM) also showed increased 
sphere forming ability after TGF-β stimulation. TGF-β-stimulated cells formed more 
and up to 10 times larger spheres than the untreated group as shown in Figure 4.4 and 
Figure 4.5. Treated cells produced an overall average count of 37 spheres per 10 x 
microscopic field, compared to the untreated cells, which formed an average count of 
10 spheres per 10 x field. Furthermore, similar to our observations in feline 
mammary carcinoma spheres, we confirmed that canine mammary carcinoma non-
TGF-β-stimulated spheres acquired a mesenchymal phenotype with higher 
expression of mesenchymal markers while epithelial markers were downregulated 
compared to adherent REM cells as depicted in Figure 4.6. 
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Figure 4.4. REM cells acquire enhanced sphere forming abilities after TGF-β stimulation. 
Canine  mammary carcinoma cells were treated with 10 ng/ml of TGF-β for 6 days and formed 
an increased number and larger spheres than untreated cells A) Untreated REM cells. B) TGF-
β-stimulated REM cells. Scale bar represents 100 µm. Image courtesy of Dr. Lisa Pang. 
 
 
Figure 4.5. REM cells show better sphere forming ability in TGF-β-stimulated cells, compared 
with untreated cells.  Cells stimulated with 10 ng/ml of TGF-β for 6 days formed an overall 
average count of 37 spheres per 10 x field, compared to the untreated cells, which formed an 
average count of 10 spheres per 10 x field. Each bar represents the mean of the average 
measurements of 6 counts, whiskers represent SD (p = 0.005, Mann–Whitney test).  
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Figure 4.6. REM spheres display a mesenchymal phenotype at the protein expression level. 
When compared to adherent cells, non-TGF-β-stimulated spheres express higher levels of 
mesenchymal markers vimentin and fibronectin and lower levels of epithelial markers E-
cadherin and β-catenin, associated with a mesenchymal phenotype. Β-actin was used as a 
loading control for all cell samples. All proteins were expressed at the expected molecular 
weights, where E-cadherin = 120 kDa, β-catenin = 92 kDa, vimentin = 57 kDa, fibronectin = 240 
kDa and β-actin = 45 kDa. Thirty µg of protein was loaded for each immunoblot. Image 
courtesy of Dr. Lisa Pang. 
 
Here we have shown that induction of EMT by TGF-β in both canine and 
feline mammary carcinoma cells leads to an increased ability to form spheres in low 
adherence conditions, which is a CSC characteristic. Spheres also have high 
expression of mesenchymal markers and low expression of epithelial markers. 
Together these data supports a link between TGF-β induction of EMT and the 
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4.3.2 TGF-β-stimulated canine and feline mammary 
carcinoma cell lines are enriched for cells expressing 
the stem cell marker CD133  
To assess if TGF-β treatment elevated the number of cells expressing the 
CSC marker CD133, we treated REM and CMC cells with 10 ng/ml of TGF-β for 6 
days as described in Chapter 2.3.1, then sorted by magnetic activated cell sorting 
(MACS), described in Chapter 2.10. Here we found that TGF-β treatment increased 
the percentage of CD133+ cells from 1.08% to 3% in REM cells and from 0.69% to 
1.3% in CMC cells compared to vehicle-treated cells.  These findings suggest that 
the number of REM cells with stem cell characteristics is approximately three times 
higher after TGF-β stimulation than in untreated cells as shown in Table 4.1. 
Similarly, we observed that in the CMC cell line, cells treated with TGF-β express 




Table 4.1. TGF-β-stimulated REM cells express a higher percentage of CD133+ cells than 
untreated cells.  Treatment with 10 ng/ml of TGF-β for 6 days increases the percentage of 
CD133+ cells from 1.08% to 3%. REM T = REM cells treated with 10 ng/ml of TGF-β. REM = 
REM cells without treatment. 
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Table 4.2. TGF-β-stimulated CMC cells express CD133 in a higher percentage than the 
untreated fraction.  Treatment with 10 ng/ml of TGF-β for 6 days increases the percentage of 
CD133+ cells from 0.69% to 1.3%. CMC T = CMC cells treated with 10 ng/ml of TGF-β. CMC 
= CMC cells without treatment. 
 
4.3.3 Breast cancer cells acquire resistance to chemotherapy 
after TGF-β stimulation 
Canine and feline mammary carcinoma cells showed an enhanced sphere 
forming ability after TGF-β stimulation as shown in Chapter 4.3.1. To assess if these 
cells also acquired resistance to therapeutic modalities like chemotherapy, TGF-β-
stimulated cells were treated with two different chemotherapeutic agents. The 
chemotherapeutic agents used were doxorubicin and mitoxantrone; both of which are 
commonly used to treat breast cancer in small animals. We observed that CMC cells 
did not show any significant difference in chemosensitivity between a TGF-β-
stimulated cells and vehicle-treated cells. Both TGF-β-stimulated and unstimulated 
cells demonstrated a dose-response relationship with decreased viability with 
increasing concentrations of chemotherapy agent as shown in Figure 4.7 and Figure 
4.8. 
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Figure 4.7. CMC cell survival showed a dose dependency with increasing concentrations of 
doxorubicin. TGF-β-stimulated cells did not show any difference in chemosensitivity compared 
to untreated cells over a range of concentrations of doxorubicin. A Mann-Whitney test was 
carried out, where the overall p-value = 0.7787. CMC = Vehicle-treated, control feline 
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Figure 4.8. CMC cell survival showed dose dependency with increasing concentrations of 
mitoxantrone. TGF-β-stimulated cells did not show any significant difference in 
chemosensitivity compared to untreated cells over a range of concentrations of mitoxantrone. A 
Mann-Whitney test was carried out, where the overall p-value = 0.2085. CMC = Vehicle-treated, 
control feline mammary carcinoma cell line; CMCT = TGF-β-stimulated CMC 
 
Unlike feline mammary carcinoma cells, TGF-β-stimulated REM cells 
showed enhanced resistance to doxorubicin in a chemosensitivity assay compared to 
vehicle-treated cells as shown in Figure 4.9.  There was no significant difference in 
chemosensitivity between TGF-β-stimulated and vehicle-treated REM cells when 
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Figure 4.9REM cells treated with TGF-β are less sensitive to doxorubicin than are vehicle-
treated control cells.  REM cells stimulated with 10 ng/ml of TGF-β for 6 days prior to 
doxorubicin exposure showed enhanced chemoresistance, compared to vehicle-treated, control 
REM cells. REM = Vehicle-treated, control canine mammary carcinoma cell line; REMT = 
TGF-β-stimulated REM. A Mann-Whitney test was carried out where the overall p-value was 
0.000002 for the whole experiment. An ANOVA test was carried out for the comparison 
between the untreated and treated groups at individual concentrations where p-values were 
0.1067 for 0.001 µM of TGF-β, 0.00000007 for 1µM, 0.0000003 for 5µM, 0.0052 for 10µM, and 
0.9081 for 50µM.  
 
Furthermore, we utilised MACS to separate the CD133+ and CD133- 
fractions in REM cells. Untreated REM cells expressing CD133 showed greater 
resistance to doxorubicin compared to the CD133- fraction as depicted in Figure 
4.10. As stated in Chapter 4.2, CD133 is a stem cell surface marker in some models, 
and cells expressing such validated stem cell markers would be expected to show 
greater chemoresistance than those lacking expression. 
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Figure 4.10. REM cells expressing CD133 are less sensitive to doxorubicin than are CD133- 
cells. REM CD133+ cells showed enhanced chemoresistance compared to CD133- cells. REM 
CD133+ = CD133+ REM cells; REM CD133- = CD133- REM cells.  A Mann-Whitney test was 
carried out where the overall p-value was 0.00012 for the whole experiment. An ANOVA test 
was carried out for the comparison between the CD133+ and CD133- fractions at individual 
concentrations where p-values were 0.999 for 0.001 µM of TGF-β, 0.9551 for 1µM, 0.000884 for 
5µM, 0.0335 for 10µM, and 0.0110 for 50µM. 
Moreover, whether TGF-β-stimulated or unstimulated, sorted CD133+ REM 
cells exhibited resistance to increasing concentrations of doxorubicin. CD133+ cells 
sorted from TGF-β-stimulated REM cells showed no greater resistance to 
doxorubicin compared to CD133+ cells sorted from untreated REM cells, as shown 
in Figure 4.11. This finding suggests that cells expressing this stem cell surface 
marker exhibit the chemoresistance characteristic of stem cell-like cells. 
Interestingly, REM cells survived at increasing concentrations of the same 
chemotherapeutic agent after being treated with TGF-β, even when they did not 
express CD133 as shown in Figure 4.12. A possible explanation for these results 
could be that there might be a subpopulation of cells that do not express CD133 but 
still have stem cell-like characteristics including resistance to apoptosis and 
chemotherapeutic agents.  
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These data suggest that canine mammary carcinoma cells expressing CD133 
are resistant to the cytotoxic effects produced by the chemotherapeutic drug 
doxorubicin regardless of TGF-β stimulation. Remarkably, cells previously 
stimulated with 10 ng/ml of TGF-β for 6 days showed resistance to doxorubicin even 
without expressing CD133, making them comparable to the CD133+ fraction. These 
results confirm that TGF-β might enable cells to acquire stem cell-like characteristics 
such as resistance to chemotherapeutic agents without necessarily expressing stem 
cell markers like CD133. 
 
 
Figure 4.11. TGF-β-stimulated and unstimulated REM CD133+ cells were resistant to 
doxorubicin. REM cells expressing the stem cell marker CD133, treated with 10 ng/ml of TGF-β 
demonstrated no change in sensitivity to doxorubicin compared to vehicle-treated control 
CD133+ cells. REM CD133+ = CD133+ REM cells; REM T CD133+ = CD133+, TGF-β-
stimulated REM cells. A Mann-Whitney test was carried out where the overall p-value was 
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Figure 4.12. TGF-β-stimulated REM cells showed resistance to doxorubicin with and without 
expression of stem cell surface marker CD133. REM cells stimulated with 10 ng/ml of TGF-β 
showed resistance to the cytotoxic effects of doxorubicin, regardless of their expression of the 
stem cell marker CD133. REM T CD133- = CD133-, TGF-β-stimulated REM cells; REM T 
CD133+ = CD133+, TGF-β-stimulated REM cells. A Mann-Whitney test was carried out where 
the overall p-value was 0.08727 for the whole experiment. An ANOVA test was carried out for 
the comparison between the CD133+ and CD133- fractions at individual concentrations where 
p-values were 0.2432 for 0.001 µM of TGF-β, 0.00027 for 1µM, 0.0007618 for 5µM, 1 for 10µM, 
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4.4 Discussion  
Cancer cells with stem cell-like characteristics are more resistant to apoptosis 
and different therapeutic approaches including chemotherapeutic agents (Wright et 
al., 2008, Aomatsu et al., 2012). The mechanisms through which these cancer cells 
acquire tumorigenic and resistant traits have not been fully elucidated, nevertheless, 
cancer research is moving rapidly towards the understanding of these events. 
Different research groups have confirmed the presence of tumorigenic 
properties in oncogenic cell lines of breast cancer in humans assessed by their sphere 
forming abilities under limiting survival conditions and the expression of stem cell 
surface markers including CD44+CD24- (Morel et al., 2008) and CD133 (Xiao et al., 
2008). More importantly, they found that non-tumorigenic cell lines such as MCF10 
after undergoing EMT expressed surface markers characteristic of stem cells 
suggesting that there could be a link between EMT and the acquisition of stem cell 
characteristics in human breast cancer cells (Morel et al., 2008). Similarly, Chen et al 
demonstrated that head and neck cancer cells expressing CD133 have stem cell-like 
characteristics, and show EMT-associated changes (Chen et al., 2011).  To date 
similar features of breast cancer in companion animals have not been investigated. It 
is crucial to carry out studies to assess whether such companion animal species are 
able to generate breast cancer cells with stem cell-like characteristics and therefore if 
they can serve as useful animal models for the development of novel strategies to 
understand and combat the disease in humans.  
Here we confirmed the presence of canine and feline breast CSCs, and that 
these cells have a more resistant phenotype than differentiated breast cancer cells in 
these species. These subpopulations of resistant cells have self-renewal properties 
demonstrated through their sphere forming ability while grown in limiting 
conditions. Spheres are considered putative CSCs as they self-renew and they are 
resistant to limiting conditions. Interestingly, we confirmed that cells previously 
treated with 10 ng/ml of TGF-β displayed morphological changes consistent with 
EMT in adherent culture, as shown in Chapter 3.3.1, and an enhanced sphere forming 
ability with changes in protein expression profile in both culture conditions 
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consistent with EMT.  These findings are similar to those reported by other research 
groups with human cell lines (Morel et al., 2008, Lim et al., 2013). Interestingly, the 
canine and feline mammary carcinoma cell lines, REM and CMC, respectively 
showed downregulation of epithelial markers and upregulation of mesenchymal 
markers after forming spheres. With these findings we can confirm some 
pathophysiological similarities with which human and companion animal breast 
cancer cells acquire stem cell-like characteristics in association with an induced 
EMT. Similarly, Mani et al., 2008 showed that exposure of human mammary 
epithelial and breast cancer cells to EMT inducers, including TGF-β, twist and snail, 
resulted in at least 40 fold more mammospheres than unstimulated control cells, with 
attendant increases in vimentin and fibronectin mRNA, and decreased E-cadherin 
expression. They concluded that the acquisition of sphere forming ability and the 
expression of these EMT-associated transcriptional changes can be attributed to cells 
acquiring stem cell characteristics after an induced EMT, similar to our findings in 
Chapter 4.3.1 (Mani et al., 2008). 
Previous work in our lab showed that spheres harvested from canine 
mammary carcinoma cells without TGF-β stimulation resembled CSCs, acquired 
resistance to doxorubicin, became more invasive and expressed embryonic stem cell 
markers Oct4 and Nanog compared to adherent cells (Pang et al., 2011). Both the 
latter markers confer self-renewal characteristics and maintain the undifferentiated 
state of cells as reviewed by Pan and Thomson, 2007. Furthermore, in order to 
expand this previous study in our lab, Dr. Lisa Pang examined whether spheres have 
a mesenchymal phenotype compared to parental adherent cells at the protein 
expression level by western blot analysis. She showed that non-TGF-β-stimulated 
spheres displayed an evident decrease in the expression of epithelial markers (E-
cadherin and β-catenin) whilst the expression of mesenchymal markers (fibronectin 
and vimentin) was increased, compared to parental adherent cells (Pang et al., 2011). 
Moreover, in keeping with EMT being associated with migration and invasion. The 
spheres exhibited a greater invasive potential than adherent cells (Pang et al., 2011). 
These observations confirmed that EMT and the CSC theory are closely related. We 
can conclude from this that CSCs can have invasive features, and EMT might be an 
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important promoter of the acquisition of CSC features, as spheres, which are 
considered putative CSCs, showed EMT-associated changes. These findings are in 
line with our results where we show that tumourspheres derived from canine and 
feline mammary carcinoma cells express several EMT-associated changes. 
Xu et al., 2014 showed that the acquisition of stem cell-like characteristics 
associated with an induced EMT is also seen in non-small cell lung cancer (NSCLC) 
cells fused with bone marrow-derived mesenchymal stem cells. These hybrid cells 
were highly malignant and showed EMT-associated changes including a more 
mesenchymal morphology, upregulation of mesenchymal markers, downregulation 
of E-cadherin and acquired stem cell characteristics. These hybrid cells were capable 
of forming tumourspheres and showed overexpression of CD133, OCT4 and Nanog 
among other embryonic stem cell markers, similar to the data presented herein 
generated in our laboratory by Dr. Lisa Pang (Pang et al., 2011).   It would be 
interesting to compare TGF-β exposure with fusion with bone marrow-derived 
mesenchymal stem cells in terms of CSC and EMT induction in veterinary breast 
cancer cell lines. 
Furthermore, in order to confirm that these EMT-induced cells express stem 
cell surface markers, we submitted them to a MACS analysis and found that the 
EMT-induced cells had a larger CD133+ subpopulation than the untreated cells. 
These TGF-β-stimulated cells were also confirmed to have undergone an EMT by 
morphological changes and changes in protein expression prior to the cell sorting. In 
line with the observations described above by Morel et al and Xiao et al, these EMT-
induced cells are capable of forming spheres and express stem cell markers, 
supporting a link between EMT and the acquisition of stem cell-like characteristics 
in canine and feline breast cancer cell lines. 
Moreover, typically, cells with stem cell characteristics within a tumour 
comprise a very low percentage of the whole population (reviewed by Reya et al., 
2001 and All Hajj et al., 2003), thus, the CD133+ cell subpopulations in our results 
were expected to be far smaller than the CD133- fractions. In line with this, we 
showed that the CD133 stem cell marker was expressed in only 3% and 1.3% of 
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mammary carcinoma cells of dogs and cats, respectively, after exposure to TGF-β. 
TGF-β exposure tripled and doubled the percentage of CD133+ cells within 
mammary carcinoma cells without TGF-β stimulation of dogs and cats, respectively, 
as expected. A study carried out by Giordano et al. in 2012 with HER2+ human 
mammary carcinoma-bearing patients showed a positive association between the 
expression of EMT-associated transcription factors (snail and ZEB1) and the 
percentage of CD133+ cells (Giordano et al., 2012). It would be interesting to submit 
our CD133+ and CD133- cells for EMT-associated marker protein and mRNA 
expression analyses to evaluate the similarities between humans and veterinary 
species in this respect. On a distinct approach, Quintana et al demonstrated that in 
human melanoma, by modifying xenotransplantation assays in immunodeficient 
mice, 1 in 9 melanoma cells were capable of forming tumours (Quintana et al., 
2008). Interestingly, after individualisation of melanoma cells by flow cytometry, 
they observed that 27% of single cell injections developed tumours in 
immunodeficient mice. They used NOD/SCID mice lacking the interleukin-2 gamma 
receptor to confirm these findings. Their observations suggest that there might be a 
much higher frequency of human melanoma cells with tumorigenic traits than the 
reported frequency for other kinds of cancer (Quintana et al., 2008). 
After observing that canine and feline mammary carcinoma cells became 
more resistant to limiting survival conditions and acquired enhanced sphere forming 
ability after a TGF-β-induced EMT, we assessed whether putative stem cells derived 
from TGF-β-stimulated cells also acquired resistance to chemotherapeutic agents. As 
previously stated in Chapter 4.2, Nadal et al observed that CD133+ breast cancer 
human patients had higher probabilities of tumour recurrence due to resistance to 
apoptosis and chemotherapy (Nadal et al., 2013). To confirm this, we subjected 
canine and feline mammary carcinoma cell lines with and without TGF-β stimulation 
to chemosensitivity assays with doxorubicin and mitoxantrone. It is known that cells 
with a faster growth rate are more susceptible to chemotherapy (reviewed by Argyle, 
2008), but it has been thought that cells with resistant properties enter quiescent 
periods during chemotherapeutic protocols through an autophagy process, as 
reviewed by Kimmelman, 2011. This latency enables them to survive and eventually 
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cause relapse. In this study, EMT-induced cells and the CD133+ fractions of each 
cell line were expected to show greater resistance to chemotherapeutic drugs than the 
untreated cells and their CD133- subpopulations. Interestingly, the feline mammary 
carcinoma cell line, despite showing enhanced sphere-forming ability after TGF-β 
stimulation, did not show a change in resistance to doxorubicin or mitoxantrone after 
TGF-β stimulation. Interestingly, these EMT-induced cells contained a greater 
subpopulation of CD133+ cells compared to the untreated controls indicating that 
TGF-β stimulation does increase the percentage of putative CSCs in CMC, which 
does not translate into increased resistance to doxorubicin. A single feline cell line 
was used here and further experimentation on a panel of feline cancer cell lines is 
required to determine if this result is cell line or species-specific.   
In contrast to our findings in CMC cells, TGF-β-stimulated REM cells 
showed a better survival rate than untreated cells when exposed to doxorubicin but 
not mitoxantrone. Both drugs are considered antineoplastic antibiotics and inhibit 
DNA and RNA synthesis, mitoxantrone being a synthetic form of doxorubicin. The 
main mechanism of action of both drugs is not fully understood and thus, it is 
difficult to find an explanation of why canine breast cancer cells are more resistant to 
doxorubicin than to mitoxantrone after an EMT induction. 
Our results show that the TGF-β-stimulated REM cells survived better at all 
concentrations of doxorubicin compared to vehicle-treated, control cells. 
Furthermore, we decided to carry out more chemosensitivity assays with the REM 
cells to assess if there was a difference between TGF-β-stimulated and unstimulated 
cells and their respective CD133+ and CD133- fractions. Interestingly, CD133+ cells 
sorted from the untreated population survived doxorubicin exposure better than 
CD133- cells. This result shows that CD133+ cells, which might represent the CSC 
population in a tumour, are resistant to doxorubicin compared to the CD133-fraction 
from the same cell line. The similarity between these assays suggests a link between 
EMT and the acquisition of stem cell-like characteristics in canine mammary 
carcinoma cells. A study carried out by Zhu et al. in 2014 showed that in humans, 
CD133+ gastric carcinoma cells were more resistant to  5-fluorouracil, which they 
consider an important chemotherapeutic agent for advanced gastric cancer. Similar to 
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our findings, they confirmed that CD133+ cells were more resistant to the afore 
mentioned agent than CD133- cells. Furthermore, they silenced CD133 in gastric 
cancer cells with small interfering RNA against CD133 and observed that this 
enhanced the cytotoxicity effects conferred by the same agent (Zhu et al., 2014). The 
similarities between these findings and our chemosensitivity assays give an 
important idea for future plans in our search for more answers regarding 
chemoresistance in stem cell-like mammary carcinoma cells in dogs, cats and 
humans, and their association with EMT-induced stemness. 
Moreover, in order to assess if CD133+ cell fractions from TGF-β-stimulated 
and unstimulated canine mammary carcinoma cells shared resistant characteristics, 
we subjected both to chemosensitivity assays and both proved equally resistant to 
doxorubicin. These results are consistent with CD133+ cells being representative of 
CSCs. To determine if the expression of CD133 is essential for doxorubicin 
resistance in EMT-induced cells, we compared TGF-β-stimulated CD133+ cells to 
TGF-β-stimulated CD133- cells as shown in Figure 4.12. Interestingly, both cell 
populations showed greater survival than non-TGF-β-stimulated, CD133- cells as 
shown in Figures 4.12 and 4.10, respectively. The CD133+ fraction showed a steady 
percentage of cell survival throughout the entire assay. The CD133- fraction showed 
resistance to doxorubicin at all but the highest concentrations used. It is of 
importance to mention that the data acquired from the TGF-β-stimulated REM cells 
and the TGF-β-stimulated CD133- REM cells look very similar in our assays, as 
shown in Figures 4.9 and 4.12, respectively. A possible explanation for this outcome 
would be that the percentage of the CD133+ cells was very low compared to the 
CD133- cells as reported in Chapter 4.3.2. The percentage of the CD133- cells within 
the TGF-β-stimulated REM cells was 97%, thus, the results for their 
chemosensitivity assays would be expected to be quite similar to sorted CD133- 
TGF-β-exposed REM cells.  
This chemosensitivity assay proved that the expression of CD133, in this cell 
line, is not a necessary characteristic in EMT-induced cells to acquire resistance to 
doxorubicin, thus, probably there is a subpopulation of TGF-β-stimulated cells 
resistant to doxorubicin without expressing CD133 perhaps with other stem cell-like 
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properties. Diehn et al., 2006 analysed research studies carried out by Phillips et al., 
2006 regarding CSC markers and stem cell-like characteristics in breast cancer cells 
where they confirmed that CD24-/CD44+ cells were radioresistant (Phillips et al., 
2006), and after an exhaustive inspection of this study, Diehn et al., 2006 concluded 
that the expression or absence of stem cell markers does not always confirm the stem 
cell functional phenotype, as cancer cells with tumorigenic traits might not 
necessarily share specific cell surface markers even within the same cell line in vitro 
or in vivo. It has also been reported that in order to confirm that cells acquire stem 
cell-like properties, it is essential that these cells exhibit said characteristics, 
including self-renewal and resistant traits rather than just the expression of cell 
surface markers (reviewed by Diehn and Clarke, 2006). 
  Our data, showing the functional impact of TGF-β-induced EMT and CD133 
expression suggest further investigation of EMT as a potential therapeutic target in 
companion animal oncology. The TGF-β pathway including its transcription factors 
could be targeted to combat breast cancer progression and metastasis. The 
understanding of how TGF-β might be involved in the induction and/or plasticity of 
CSCs is of great importance to achieve meaningful insights for future TGF-β-
directed cancer therapeutics in human and veterinary oncology. Further investigation 
is needed to confirm these findings in vivo as is the assessment of the impact of TGF-
β-directed therapies on vital functions such as wound healing and tissue remodelling 
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Chapter 5: Global changes in microRNA levels 
during Epithelial to Mesenchymal Transition in 
dogs 
5.1 Abstract  
MicroRNAs (miRNAs) are small RNA molecules involved in a variety of 
vital processes. They are also involved in many diseases, including cancer. They can 
promote or regulate cancer-related genes, but they can also be targeted by different 
means such as different mRNAs or other miRNAs. The role of miRNAs in EMT has 
yet to be fully elucidated. Previous studies have shown a role for several miRNAs, 
including the miRNA 200 family in metastasis of breast cancer, lung carcinoma and 
cervical cancer in humans (Iorio et al., 2005, Cheng et al., 2005). Moreover, since 
2008, different research groups have been correlating the association of specific 
miRNA expression in different types of cancer in humans and companion animals, 
including mammary carcinoma and lymphoma (Boggs et al., 2008, Uhl et al., 2011, 
von Deetzen et al., 2014 and Mohammad et al., 2015). In this study we aimed to 
determine changes in miRNA expression through a thorough screening of canine 
mammary carcinoma cells during TGF-β-induced EMT. We found significant 
changes regarding the expression of different miRNAs in TGF-β-stimulated canine 
mammary carcinoma cells compared to untreated cells. Future research on the role of 
miRNAs in cancer could lead to a better understanding of how they are involved in 
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5.2 Introduction  
MicroRNAs (miRNAs) are small RNA molecules with 19-25 nucleotides 
(reviewed by Ambros, 2004, Hwang and Mendell, 2006) which can be associated 
with several organic functions including fundamental physiological cell processes 
such as tissue differentiation, but they can also be involved in the development and 
progression of different diseases like cancer (Foubert et al., 2010). They work in a 
post-transcriptional fashion, guiding the RNA-induced silencing complex and 
targeting their complementary mRNAs which are then translationally silenced or 
cleaved (reviewed by Bartel, 2004 and Hwang and Mendell, 2006). One miRNA can 
target several mRNAs and can also be targeted by several mRNAs (reviewed by 
Bartel, 2004) as detailed in Chapter 1.15. The understanding of different processes 
through which miRNAs act is essential to elucidate how these small RNA molecules 
repress or promote tumour suppressor genes in order to develop novel therapeutics 
against specific types of cancer as reviewed by Esquela-Kerscher and Slack, 2006.  
Research studies have shown a correlation between different families of 
miRNAs and oncogenesis in human cancers. Deregulation of miR-143, miR145 and 
miR-125 among other miRNAs has been correlated to cancer arising in different 
human tissues including colorectal, breast, prostate, cervical, lymphoid and 
pancreatic tissues (Michael et al., 2003, Kent et al., 2010, Feliciano et al., 2013, Yin 
et al., 2014 and Zhang et al., 2014). Michael et al., 2003 showed that in cancer cells 
from human breast, prostate, cervical, colorectal and lymphoid cancers the 
expression of miR-143 and miR-145 is downregulated (Michael et al., 2003). On a 
similar basis, Kent et al., 2010 also found significant reduced expression of miR-143 
and miR-145 in mice xenograft models of human pancreatic adenocarcinoma cells 
harbouring KRAS mutations when compared with normal pancreatic tissue (Kent et 
al., 2010). Furthermore, Yin et al., 2014 showed that the expression of miR-145 is 
strongly downregulated in plasma and colorectal tissues of human patients with 
colorectal cancer (Yin et al., 2014). Regarding the expression of miR-125 in human 
cancer, Feliciano et al., 2013 demonstrated that amongst 939 analysed miRNAs, 
miR-125b showed the most profound decrease in expression in breast cancer. They 
analysed breast cancer tissues and adjacent normal breast tissues from 50 breast 
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cancer patients and concluded that miR-125b acts as a tumour suppressor gene in 
breast cancer in humans (Feliciano et al., 2013).  
Consistently reduced levels of miRNA expression in cancer compared to 
normal tissues indicate their possible direct involvement in carcinogenesis and 
tumour progression as shown by the afore mentioned research groups (Michael et al., 
2003, Kent et al., 2010, Feliciano et al., 2013 and Yin et al., 2014). Interestingly, 
opposed to the observations of Feliciano et al., 2013 in breast cancer patients, Zhang 
et al., 2014 showed that miR-125b is strongly expressed in squamous cell carcinoma 
of humans and mice at early stages of malignant progression and also promotes 
tumour initiation in mice (Zhang et al., 2014). These opposing observations made by 
Feliciano et al., 2013 and Zhang et al., 2014 regarding the expression of miR-125b 
in different types of cancer might give insights on how the expression of specific 
miRNAs may be cancer type-dependent.  
Iorio et al, 2005 identified a set of 15 miRNAs the pattern of expression of 
which could accurately define whether human breast tissues were normal or 
cancerous, due to a clear difference in miRNA expression between breast cancer and 
normal tissues. They found consistent deregulations in miR-145, miR-10b, miR-
125b, miR-155 and miR-21 confirmed by northern blot analysis and microarray. 
(Iorio et al., 2005). Among these miRNAs, miR-21 and miR-155 were upregulated 
whilst miR-10b, miR-125b and miR-145 were downregulated in breast cancer tissue, 
compared with normal breast tissue, suggesting their potential activity as oncogenes 
and tumour suppressor genes, respectively. They also identified possible targets of 
these deregulated miRNAs. Tumour suppressor genes are possible targets of the 
upregulated miRNAs and oncogenes possible targets of the downregulated miRNAs. 
They used three different algorithms including miRansa, TargetScan and PicTar as 
methods to detect human miRNA target genes and they found that TGF-β is a 
predicted target of miR-21. Mir-21 was progressively upregulated in breast cancer 
with higher tumour stages. In contrast, miR-145 was found to be downregulated in 
breast cancer tissues and negatively correlated with high proliferation index. These 
data imply that changes in miRNA expression might be associated, perhaps causally, 
with molecular events at specific stages of cancer progression (Iorio et al., 2005). 
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Screening for miRNA expression profiles is a useful tool to investigate their 
involvement in cancer and its progression. Cheng et al., 2005 identified miRNAs that 
influenced in vitro cell growth regulation and apoptosis in different experiments in 
both a cervical cancer-derived cell line (HeLa) and a lung carcinoma cell line 
(A549). They found that individual inhibition of 19 different miRNAs caused a 
decreased cell growth rate, but that inhibition of miR-21 and miR-24 caused an 
increase in cell growth in HeLa cells. MiR-21 is suggested to be a cell growth 
regulator in HeLa cells in vitro. These findings are opposed to the observations of  
Iorio et al., 2005 observed where miR-21 expression was upregulated in breast 
cancer tissue. When compared to A549 cells, Cheng et al., 2005 found 3 miRNAs 
inhibition of which caused decreased cell growth, but inhibition of the miRNAs 
under study was not associated with increased growth in vitro. Moreover, they found 
that inhibiting some miRNAs produced opposing effects on growth rate in the cell 
lines under study. For example, an increased cell growth in HeLa cells but a decrease 
in that of A549 cells after miR-24 inhibition was observed. Similarly, inhibition of 
miR-191 caused an increase in the cell growth rate of A549 cells but a decrease in 
that of HeLa cells. These three examples including miR-21, miR-24 and miR-191 
and their differences in these cell lines, suggest that miRNAs might have cell type 
specific effects: different targets for each cell line; or perhaps miRNAs are 
differentially expressed in different cell lines. The same research group also screened 
miRNAs to assess their involvement in apoptosis in HeLa cells. They observed that 
the inhibition of 8 different miRNAs including 4 from the miR-200 family increased 
the level of apoptosis measured through caspase activity assays (Cheng et al., 2005).  
The variation in the effects of miR-21, miR-24 and miR-191 strongly suggests that 
miRNAs have cell and context specific effects. 
MicroRNA expression has also been studied in companion animals by several 
research groups. Researchers have been correlating the association of specific 
miRNA expression with different types of cancer in humans and companion animals, 
including lymphoma and mammary carcinoma (Boggs et al., 2008, Uhl et al., 2011, 
von Deetzen et al., 2014 and Mohammad et al., 2015). Boggs et al., 2008 
investigated the role of specific miRNAs in canine mammary carcinoma and 
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observed similar results to those from human research (Boggs et al., 2008). They 
analysed the expression patterns of 10 specific miRNAs (miR-15a, miR-16, miR-17-
5p, miR-21, miR-29b, miR-125b, miR-145, miR-155, miR-181b and let-7f) in canine 
mammary tumours and normal canine mammary tissues, as these specific miRNAs 
are known to be associated with human mammary malignancies (reviewed by Calin 
et al., 2004 and Boggs et al., 2008).  Interestingly, they observed that from all 
analysed canine miRNAs, only miR-145 did not follow a similar pattern of 
expression as in human samples (Boggs et al., 2008). Von Deetzen et al., 2014 
extended these findings by comparing the expression of 16 specific miRNAs not 
only between canine mammary cancer and normal gland samples, but also between 
samples of tumours with different malignancies, including adenomas, metastasising 
and non-metastasising carcinomas and lymph node metastases. They found that the 
expression of 5 miRNAs (miR-29b, miR-101, miR-125a, miR-143 and miR-145) 
was different between primary tumours and their metastases. When they compared 
primary tumours of different aggressiveness, they only identified one significant 
difference in miRNA expression, with miR-125a expression being significantly 
different between metastasising carcinoma and adenoma (Von Deetzen et al., 2014). 
Based on these observations, further investigation is needed to assess the differences 
in miRNA expression between canine mammary tumours at different stages in order 
to elucidate potential therapeutic targets. 
In 2011 a different research group observed that the expression of specific 
miRNAs associated with apoptosis, differentiation and cancer in human lymphoma 
was similar to that of naturally occurring canine B- and T-cell lymphomas (Uhl et al., 
2011). They used a human cancer miRNA qPCR array to assess miRNA expression 
in canine lymphoid cell lines and naturally occurring lymphomas compared with 
normal canine peripheral blood mononuclear cells and healthy lymph nodes. 
Upregulation in the expression of miR-19-apb and miR-17-5p, and a decreased 
expression of miR-203, miR-218 and miR-181a was observed (Uhl et al., 2011), 
consistent with miRNA expression in human lymphoid malignancies as reviewed by 
Khana et al., 2006. Based on these observations, Uhl et al., 2011 emphasise that 
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spontaneous canine lymphoma may act as a useful animal model of human 
lymphoma. 
MicroRNA activity has also been inhibited efficiently in vivo by Krutzfeldt et 
al., 2005 utilising antimiRNA oligonucleotides (AMOs) against human miR-16, 
miR-122, miR-192 and mir-194 injected intravenously in mice. They utilised a 
cholesterol conjugation in order to improve delivery of these miRNA inhibitors. 
AMOs are small interfering double-stranded RNAs (siRNAs) engineered as 
cholesterol-conjugated single-stranded RNA analogues which are complementary to 
the targeted miRNAs. The inhibition of these miRNAs resulted in a remarkable 
reduction in miRNA levels in lungs, kidney, heart, intestine, fat, skin, bone marrow, 
muscle, ovaries and adrenal glands. These chemically engineered oligonucleotides 
were called antagomirs (Krutzfeld et al., 2005). These findings suggest that 
antagomirs may become a potential therapeutic approach for silencing specific 
miRNAs in several diseases including different types of cancer. 
In the case of miRNAs acting as tumour suppressor genes or miRNAs 
inhibiting oncogenes, delivery techniques including viral and liposomal transfection 
have been studied in order to more accurately elucidate miRNA roles in cancer and 
potentially develop therapeutic protocols, as reviewed by Izquierdo, 2005 and Zhang 
et al., 2013. These delivery techniques could be utilised for the treatment of specific 
types of tumours, as observed by different research groups (Zhu et al., 2008, 
Takeshita et al., 2010 and Wu et al., 2013). Zhu et al., 2008 were able to suppress 
miR-21 in human metastatic breast cancer cells after successful delivery of antisense 
miR-21 oligonucleotide (anti-mir-21). They observed a significant reduction in cell 
invasion after cell transfection in vitro, whilst the number of lung metastases was 
lower in young female nude mice transfected with anti-miR-21 in vivo, compared 
with mice bearing negative control-transfected cells. They also assessed the 
inhibition of invasiveness in metastatic prostate cancer cells after treatment with anti-
miR-21 and found similar results (Zhu et al., 2008). On a similar approach, Takeshita 
et al., 2010 transfected human prostatic carcinoma cells with synthetic miR-16 and 
observed a significant reduction in cell proliferation in vitro. Moreover, they 
successfully delivered synthetic miR-16 to metastatic prostatic tumours in bone 
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tissues in mice after injection into their tail veins and observed significant growth 
inhibition in these tumours in vivo (Takeshita et al., 2010),thus, indicating that 
systemic delivery of miRNAs could be used to treat cancer patients. Furthermore, 
Wu et al., 2013 developed a cationic lipoplexes-based carrier to efficiently deliver 
miR-29b to non-small-cell lung carcinoma cells and showed that cell growth was 
strongly reduced in vitro after delivery of miR-29b. Also, after miR-29b systemic 
transfection into a xenograft murine model in vivo, tumour miR-29b expression was 
increased by approximately fivefold and tumour growth was inhibited by 
approximately 60% compared with negative control-transfected mice. They 
concluded that their delivery system could be considered an important potential tool 
for the development of miRNA-based therapeutics for lung cancer (Wu et al., 2013). 
Optimisation of delivery of miRNAs to reach pharmacologic targets is the 
key to robustly assess the effectiveness of these approaches in vivo, as reviewed by 
Zhang et al., 2013. This research group emphasises the importance of further 
studying miRNA delivery techniques as to diminish the concerns about cells evading 
treatment, especially in diseases like cancer, for which conventional medicine has 
proven ineffective (reviewed by Zhang et al., 2013). It has been observed that the 
efficacy of cancer gene therapies can be limited by the immune system response of 
the organism (Gitlin et al., 2002 and Sledz et al., 2003, reviewed by Zhang et al., 
2013).  
Future research in this field will provide important information regarding the 
role of miRNAs in different stages of cancer progression and oncogenesis, and might 
give rise to novel therapeutic targets for specific tumours and their metastases (Zhu 
et al., 2008, Takeshita et al., 2010, Wu et al., 2013 and reviewed by Esquela-
Kerscher and Slack, 2006 and Zhang et al., 2013). The future development of novel 
techniques to inhibit or to transfect miRNAs will not only be useful to inactivate or 
to overexpress known miRNAs in specific tumours as therapeutic options, but could 
also elucidate their involvement in different stages of cancer progression and in 
manipulable model systems.  
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In this study, we mapped global changes in miRNA expression during TGF-
β-induced EMT in canine mammary carcinoma cells at different time points. We 
observed significant changes in miRNA expression over time. We observed that 5 
different miRNAs were upregulated in TGF-β-stimulated canine mammary 
carcinoma cells over time compared to cells treated only with vehicle. Interestingly 
from these 5 upregulated miRNAs, cfa-miR-411, 381, 410 and 380 showed peak 
expression by day 10 of stimulation and started decreasing their expression 
thereafter. The remaining miRNA (cfa-miR-363) showed an overexpression until day 
23 of TGF-β treatment. Previous studies in human cancer have determined that these 
5 miRNAs have roles in carcinogenesis:  miR-380 and miR-363 are overexpressed in 
neuroblastoma and breast cancer, respectively (Swarbrick et al., 2010, Beltran et al., 
2011); miR-411 and 381 are downregulated in breast cancer; and miR-410 is 
downregulated in endometrial carcinoma (van Schooneveld et al., 2012, Liu et al., 
2013, Torres et al., 2013). Our findings provide insight into the regulation of EMT in 
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5.3 Results  
5.3.1 Target identification 
Prior to screening canine mammary carcinoma cells for miRNA expression 
we needed to identify EMT-associated changes in TGF-β-stimulated cells to assess 
the correlation between EMT and miRNA expression in breast cancer in dogs.  We 
identified EMT-associated changes in REM cells at 6, 12, 18 and 24 days after 
treatment with 10 ng/ml of TGF-β. Morphological changes were observed over 24 
days. Untreated cells from day 6 and vehicle control-treated cells from day 6 were 
utilised throughout the experiment, as TGF-β-stimulated cells started showing 
mesenchymal traits at day 6 and kept these characteristics until day 24. We 
stimulated cells with 10 ng/ml of TGF-β for 24 days and extracted RNA as described 
in Chapter 2.6.1.2 at days 6, 12, 18 and 24. Previously we have observed that 
withdrawal of TGF-β caused a reversion of morphological changes, for which we 
sought to investigate whether there was an associated change in miRNA expression 
profile. TGF-β was withdrawn from stimulated cells after 19 days of treatment and 
interestingly, we found that cells started showing morphological changes consistent 
with an epithelial phenotype such as polygonal shape and increased cell to cell 
contact (data not shown). We also extracted RNA from these cells at day 24 (5 days 
after TGF-β withdrawal) in order to compare their miRNA expression profile with 
control and stimulated cells. These cells will be called TGF-β withdrawal cells.  
We initially determined mRNA expression levels of EMT markers including 
E-cadherin, vimentin and fibronectin; and house-keeping gene RPL32, as described 
in Chapter 2.7.3. We found EMT-associated changes in mRNA expression from day 
6 until day 24 with perhaps the most significant changes occurring at day 18. 
Downregulation of the epithelial marker E-cadherin and upregulation of 
mesenchymal markers vimentin and fibronectin are considered hallmarks of EMT 
(Bolos et al., 2003). We found that E-cadherin mRNA expression was slightly 
downregulated at day 6 and 12 of TGF-β stimulation, and further downregulated by 
day 18 and 24. In the TGF-β withdrawal sample, E-cadherin expression was slightly 
higher than in TGF-β-stimulated cells at day 18 and day 24 of TGF-β stimulation. 
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This finding would suggest that cells return to a more epithelial phenotype after EMT 
due to a withdrawal of TGF-β by day 19 of stimulation (Figure 5.1).  
  
 
Figure 5.1 . Canine mammary carcinoma (REM) cells show a significant downregulation of the 
mRNA expression of the epithelial marker E-cadherin after 18 and 24 days of stimulation with 
10 ng/ml of TGF-β. E-cadherin expression is slightly upregulated after TGF-β withdrawal 
compared to days 18 and 24 of treatment. Control = untreated cells from day 6, Mock = vehicle-
treated cells for 6 days. Day 6 10 ng/ml = cells harvested at day 6 of TGF-β treatment, Day 12 10 
ng/ml = cells harvested at day 12 of TGF-β treatment, Day 18 10 ng/ml = cells harvested at day 
18 of TGF-β treatment, Day 24 10 ng/ml = cells harvested at day 24 of TGF-β treatment, Day 19 
WD = cells harvested at day 24 after TGF-β withdrawal at day 19. P values comparing 
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In contrast to E-cadherin, mRNA expression of the mesenchymal marker 
vimentin was significantly upregulated by days 6 and 12 and also upregulated at day 
24 compared to the control and mock-treated cells as shown in Figure 5.2. It is 
important to mention that these EMT associated markers do not necessarily show 
changes at the same time as they are different genes with different functions during 
EMT as described in Chapter 1.9. Interestingly, the level of mRNA expression of 
vimentin in the TGF-β withdrawal samples was intermediate between that of day 18 
of TGF-β stimulation and earlier time points, consistent with a partial reversal of the 
EMT-induced mRNA expression changes. 
 
Figure 5.2. REM cells significantly upregulate the expression of mRNA of the mesenchymal 
marker vimentin after 6 and 12 days of TGF-β-induced EMT. Control = untreated cells from 
day 6, Mock = vehicle treated cells for 6 days. Day 6 10 ng/ml = cells harvested at day 6 of TGF-
β treatment, Day 12 10 ng/ml = cells harvested at day 12 of TGF-β treatment, Day 18 10 ng/ml = 
cells harvested at day 18 of TGF-β treatment, Day 24 10 ng/ml = cells harvested at day 24 of 
TGF-β treatment, Day 19 WD = cells harvested at day 24 after TGF-β withdrawal at day 19. P 
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Expression of mRNA of the mesenchymal marker fibronectin was markedly 
increased with TGF-β stimulation at all time points compared to untreated and mock-
treated cells. REM cells stimulated with TGF-β for 6, 12 and 18 days showed a 
progressive upregulation of fibronectin mRNA. By day 24, fibronectin mRNA was 
also significantly upregulated compared to control and mock-treated cells, but less 
profoundly than at day 18 of TGF-β stimulation as shown in Figure 5.3. Similarly to 
our findings regarding mRNA expression of vimentin described in Figure 5.2, the 
level of mRNA expression of fibronectin in the TGF-β withdrawal samples was 
lower than that of day 18 of TGF-β stimulation, but higher compared to earlier time 
points, also suggesting a partial reversal of the EMT-induced mRNA expression 
changes. 
 
Figure 5.3. REM cells show significant upregulation of mRNA of the mesenchymal marker 
fibronectin after TGF-β stimulation throughout the entire assay. Control = untreated cells from 
day 6, Mock = vehicle-treated cells for 6 days. Day 6 10 ng/ml = cells harvested at day 6 of TGF-
β treatment, Day 12 10 ng/ml = cells harvested at day 12 of TGF-β treatment, Day 18 10 ng/ml = 
cells harvested at day 18 of TGF-β treatment, Day 24 10 ng/ml = cells harvested at day 24 of 
TGF-β treatment, Day 19 WD = cells harvested at day 24 after TGF-β withdrawal at day 19. P 
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5.3.2 MicroRNA expression analysis 
After confirming EMT-associated mRNA expression changes by qRT-PCR 
during the TGF-β time course described above, REM cells were harvested and RNA 
extracted after stimulation with 10 ng/ml of TGF-β at day 1, 10, 17 and 23. We 
utilised samples harvested on these days as cells demonstrated a more mesenchymal 
phenotype from day 6 to day 24 confirmed by changes in morphology, translation, 
transcription, migration and invasiveness, as demonstrated in Chapters 3.3.1, 3.3.2, 
3.3.3, 3.3.4 and 3.3.5, respectively. Moreover, cells treated with TGF-β for 19 days 
were harvested at day 23 (4 days after TGF-β withdrawal) in order to investigate if 
cells return to a more epithelial phenotype and exhibit associated changes in their 
miRNA expression after TGF-β withdrawal. Cells harvested on day 1 after TGF-β 
stimulation were chosen to be analyzed in order to map changes at the beginning of a 
TGF-β-induced EMT and to investigate whether epithelial breast cancer cells exhibit 
miRNA changes in advance of phenotypic changes during early TGF-β stimulation. 
Likewise, RNA was extracted with the same protocol from REM cells treated only 
with vehicle solution (mock-treated cells) which were harvested at the same time 
points as the treated cells. 
All RNA extracts were sent to Edinburgh Genomics-Roslin Institute for 
miRNA sequencing as described in Chapter 2.12. In order to screen REM RNA 
samples for miRNA expression, all reads were mapped to known canine miRNAs. 
The reads left unmapped were then mapped to known human miRNAs. All counts 
were normalised to reads per million (RPM) mapped sequences and were organised 
where miRNAs were displayed in rows and the comparative experiments in columns 
in order to carry out a comparative study between the miRNA profiles of our samples 
as displayed in Appendix 2. 
5.3.2.1 Experiment design 
The differential expression analysis between samples was designed to 
compare miRNA expression in mock-treated cells and TGF-β-stimulated cells at 
each time point, and also to compare miRNA expression between both groups and 
the TGF-β withdrawal sample at day 23 as shown in Table 5.1. 
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Mock day 1 v TGF-β day 1 
Mock day 10 v TGF-β day 10 
Mock day 17 v TGF-β day 17 
Mock day 23 v TGF-β day 23 
Mock day 23 v TGF-β withdrawal 
TGF-β day 23 v TGF-β withdrawal 
Table 5.1 MicroRNA differential analysis in canine mammary carcinoma cells with and without 
TGF-β stimulation. MiRNA expression in mock-treated cells was compared to expression in 
contemporaneous TGF-β-stimulated cells. MicroRNA expression of TGF-β withdrawal samples 
was compared to both mock-treated and TGF-β-stimulated groups at day 23. 
This type of analysis is concerned with differential expression rather than 
with the quantification of expression levels. It is concerned with relative changes in 
expression levels between conditions, but not directly with estimating absolute 
expression levels. Based on these concerns, all counts from mock-treated, TGF-β-
stimulated and TGF-β withdrawal samples were normalised to reads per million 
(RPM) mapped sequences and were analysed for fold change (LogFC) and average 
counts per million (LogCPM). In order to evaluate the significance of the differences 
between miRNA expression groups, p-values incorporated false discovery rate 
(FDR) using the Benjamini and Hochberg correction as explained in Chapter 2.12. 
Due to the experimental design, there were not many miRNAs that passed the FDR≤ 
0.05 filter, as would be expected when there are no biological replicates. 
Positive and negative fold change (LogFC) values represent upregulated and 
downregulated expression, respectively. Average count per million (LogCPM) is a 
subjective continuous variable utilised to evaluate the relative level of expression, 
and as we do not have technical or biological replicates, these variables should be 
considered descriptive rather than absolute. High values showed that miRNAs are 
highly expressed and low values show that miRNAs are lowly expressed, regardless 
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if their fold changes were upregulated or downregulated. Whether any particular 
value for logCPM is high or low is subjective and should always be analysed through 
a comparative differential expression analysis rather than as an absolute count for 
one condition alone.  
5.3.3 Multidimensional scaling analysis 
All samples were analysed in a multidimensional scaling (MDS) analysis 
after miRNA mapping to compare similarities between samples, as described in 
Chapter 2.12. This model was constructed to primarily produce a simple and easily 
assimilated geometrical picture of our data, where distances between each point 
represent the empirical dissimilarities between our samples. These points are placed 
in such a way that the numerical value of their correlation coefficients is reproduced 
by the distances between them. A large matrix of numbers would be considerably 
more difficult to visually assimilate than a picture of the data (Coxon et al., 1982a). 
By these means, it is practically impossible to interpret the whole data configuration, 
but we could aim to discover a structure within parts of our data. 
We are comparing a set of 9 samples for which we needed to establish how 
dissimilar they are to each other. MicroRNA profiles of cell samples showed 
outstanding separations along the first dimension (x-axis), in which mock-treated 
cells and TGF-β-stimulated cells separate remarkably as two large groups, where the 
highest level of dissimilarity was represented between TGF-β-stimulated cells at day 
10 and mock-treated cells at day 10. The TGF-β withdrawal sample miRNA profile 
is closer to that of the mock-treated cells than to that of the TGF-β-stimulated 
samples (Figure 5.4).  
Interestingly, mock-treated and TGF-β-stimulated samples from day 1 are 
relatively close in both dimensions, meaning that after only 1 day of treatment, TGF-
β-stimulated cells miRNA expression is not very different to that of mock-treated 
cells. Apparently, miRNA profiles of mock-treated samples from day 10 to day 23 
are very similar to each other, compared to the miRNA profiles of TGF-β-stimulated 
cells at the same time points which appear more widely dispersed along dimension 1. 
Moreover, TGF-β-stimulated cells miRNA profiles from days 10, 17 and 23 are 
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remarkably separated from that of TGF-β-stimulated cells at day 1 along dimension 2 
in contrast with mock-treated cells, in which miRNA profiles show a lower degree of 
dissimilarity to each other. This could perhaps be explained knowing that our 
previous results show that cells change their phenotype after TGF-β stimulation in a 
time- and dose-dependent manner, as described in Chapters 3 and 4. 
Interestingly, the degree of dissimilarity of miRNA expression profiles along 
dimension 1 between TGF-β withdrawal cells and mock-treated cells is lower than 
that between TGF-β withdrawal and TGF-β-stimulated cells. However, along 
dimension 2, TGF-β withdrawal cells miRNA expression profile appears more 
similar to that of TGF-β stimulated cells. This result could suggest that after TGF-β 
withdrawal, cells might regain some epithelial features but their miRNA expression 
is different with respect to mock-treated cells and cells continuously treated with 
TGF-β, conceivably displaying an intermediate state or cellular plasticity.  
As mentioned above, it would be difficult to analyse all the information 
contained in all the correlation coefficients (Coxon et al., 1982b), although some 
features are obvious. Mock-treated cells at day 17 and 23 are clearly very much 
alike, as are TGF-β-stimulated cells at the same days, as indicated by their low 
degree of dissimilarity (short distance between each point). In contrast, the 
dissimilarity between mock-treated cells and TGF-β-stimulated cells in general is 
remarkable along dimension 1. One of the main objectives of this MDS analysis is to 
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Figure 5.4. Multidimensional scaling analysis. Mock-treated cells (blue) separate from the TGF-
β-stimulated cells (red) along the first dimension. Mock-treated and TGF-β-stimulated cells are 
least distinct in miRNA expression on day 1 of treatment (yellow). TGF-β withdrawal sample 
(green) appears closer to mock-treated cells than to TGF-β-stimulated cells along the first 
dimension, but appears remarkably separated from mock-treated cells. The TGF-β withdrawal 
sample is more similar to TGF-β-stimulated cells at days 10, 17 and 23 along the second 
dimension than to mock-treated cells. Mock 1, 10, 17, 23 = mock-treated cells harvested on days 
1, 10, 17 and 23, respectively. TGF-B 1, 10, 17, 23 = TGF-β-stimulated cells harvested on days 1, 
10, 17 and 23, respectively. TGF-Bwd19 = Cells from which TGF-β stimulation was withdrawn 
at day 19, harvested at day 23. 
 
5.3.4 Mapping changes in miRNA expression during TGF-β-
induced EMT in canine mammary carcinoma cells 
In Figures 5.5, 5.6, 5.7 and 5.8, we show that 33 miRNAs from all miRNAs 
screened showed changes in expression as they were upregulated (positive logFC) or 
downregulated (negative logFC) in TGF-β-stimulated cells normalised to mock-
treated cells for all different time points. A majority of miRNAs are upregulated, 
including at day 1 of TGF-β stimulation as shown in Figure 5.5. Moreover, at day 10 
of TGF-β stimulation, only one miRNA was downregulated as shown in Figure 5.6. 
The results from days 17 and 23 of TGF-β stimulation show all miRNAs are 
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upregulated, as shown in Figure 5.7 and Figure 5.8, respectively. Also, when 
assessing miRNA expression in TGF-β withdrawal samples normalised to TGF-β-
stimulated cells at day 23, only one miRNA was upregulated whilst the rest of them 
were downregulated as shown in Figure 5.9. Interestingly, miRNA expression 
analysis of TGF-β withdrawal samples normalised to mock-treated cells, showed that 
4 of these 33 miRNAs were not expressed at all (cfa-miR-376b, cfa-miR-369, hsa-
miR-1197 and cfa-miR-543). Also, the results of this particular study are ambiguous 
as 8 miRNAs were upregulated whilst 21 miRNAs were downregulated as shown in 
Figure 5.10. All these observations appear similar to what was observed in the MDS 
analysis results where the TGF-β withdrawal cells were different from both the 
mock-treated and the TGF-β-stimulated cells.  
As previously explained, the MDS analysis in Chapter 5.3.3 should not be 
considered significant prior to a complete comparative study as we need to elucidate 
which properties are shared between our samples regarding miRNA expression. Even 
if we discovered the tendency of variation between our samples after the MDS 
analysis, and our comparative miRNA expression results are similar to the MDS 
data, it would be subjective to affirm that our comparative results are fully consistent 
with what we observed in the MDS analysis. Nevertheless, we can observe that the 
MDS analysis can suggest a general differentiation without specifying individual 
miRNA expression changes. For example, we could possibly correlate our 
comparative results at day 10 in Figure 5.6 with the MDS plot in Figure 5.4, where 
TGF-β-stimulated cells normalised to mock-treated cells show the greatest fold 
changes in upregulated miRNAs (Figure 5.6) consistent with the greatest separation 
between TGF-β-stimulated and mock-treated cells in dimension 1 (Figure 5.4). Also, 
comparing the logFC data generated from TGF-β withdrawal cells normalised to 
both mock-treated cells and TGF-β-stimulated cells at day 23 with the MDS analysis, 
in both miRNA expression is opposite in direction in TGF-β withdrawal cells when 
compared to TGF-β-stimulated cells and mock-treated cells, in dimension 1 of the 
MDS analysis plot. Moreover, changes in dimension 2 of the MDS analysis plot 
could also be correlated with our logFC data showing that the miRNA expression is 
in the same direction but more profound in TGF-β withdrawal cells compared to 
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mock-treated and TGF-β-stimulated cells at day 23 on MDS analysis (Figure 5.4), 
consistent with logFC miRNA expression changes between TGF-β withdrawal cells 
normalised to TGF-β-stimulated cells and mock-treated cells at all time points of our 
























Chapter 5: Global changes in microRNA levels during Epithelial to       



































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       






































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       






































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       





































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       





































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       

















































































































































































































































































































Chapter 5: Global changes in microRNA levels during Epithelial to       
Mesenchymal Transition in dogs  144 
5.3.5 TGF-β-stimulated cells show significant changes in 
miRNA expression 
For each different time point during this study, we chose only the significant 
expression changes in specific miRNAs according to the adjusted p-values (FDR) for 
each mock and TGF-β comparison. Each time point showed different results 
compared to the other time points.  As expected after observing the results from the 
MDS analysis in Figure 5.4, there were no significant changes according to the FDR 
(adjusted p-value) of ≤0.05 between mock-treated and TGF-β-stimulated cells after 
only 1 day of treatment, while those from days 10, 17 and 23 showed significant 
changes in miRNA expression, some of which were consistent at all time points. 
Only significant results from calculations for logFC for each time point will be 
shown. These results are based on TGF-β-stimulated and TGF-β withdrawal cell data 
normalised to mock-treated cell data, and also TGF-β withdrawal cell data 
normalised to TGF-β-stimulated cell data. 
 
5.3.5.1 MiRNA expression after 10 days of stimulation with TGF-β  
From all the upregulated miRNAs shown above, 29 miRNAs were 
significantly upregulated in TGF-β-stimulated REM cells compared to mock-treated 
REM cells harvested at day 10. From these, 16 were known canine miRNAs and 13 
were mapped to known human miRNAs as shown in Figure 5.11. There were no 
downregulated miRNAs found in TGF-β-stimulated cells harvested at day 10 as only 
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Furthermore, in order to assess how highly expressed the upregulated 
miRNAs were compared to each other in the TGF-β-stimulated samples normalised 
to mock-treated cells after 10 days of stimulation, the logCPM was calculated where, 
as stated in Chapter 5.3.2, high or low values would show if the miRNAs are highly 
or lowly expressed, respectively. Here, we show that there are differences in relative 
levels of expression between the upregulated miRNAs in these samples. Among the 
5 miRNAs that showed the highest expression, we observed 2 human (has-miR-
181a-2-3p and 409-3p) and 3 canine (cfa-miR-411, 381 and 410) miRNAs as shown 
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5.3.5.2 MiRNA expression after 17 days of stimulation with TGF-β  
After 17 days of stimulation with TGF-β, the expression of 11 miRNAs was 
significantly upregulated when compared to mock-treated cells, including 6 canine 
and 5 human miRNAs. Similar to the comparative study after 10 days of TGF-β 
stimulation, no mapped miRNA expression was found to be significantly 
downregulated in TGF-β-stimulated samples compared to the mock-treated samples 
as shown in Figure 5.13. Interestingly, 9 out of the 11 significantly upregulated 
miRNAs at day 17 of TGF-β stimulation were also significantly upregulated after 10 
days of treatment (cfa-miR-411, 410, 381, 487a and 380, and hsa-miR-409-3p, 654-
3p, 1468 and 889). 
 
 
Figure 5.13. Significant fold changes in mapped miRNA expression in REM cells stimulated 
with TGF-β for 17 days, normalised to mock-treated cells at day 17. Log(2) fold change data are 
presented with normalisation of TGF-β-stimulated cell data to mock-treated cell data, only 
significant fold changes are presented (i.e. False Discovery Rate ≤0.05). Expression of all 
mapped miRNAs is significantly upregulated after TGF-β-stimulation compared to mock-
treated cells at day 17. 
When expressed in logCPM values the changes in miRNA expression after 
17 days of TGF-β stimulation compared to mock-treated cells were similar to those 
after 10 days of stimulation. Of the 5 most highly expressed miRNAs in cells after 17 
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days of TGF-β stimulation compared to mock-treated cells, 3 were canine miRNAs 
(cfa-miR-411, 381 and 410) and 2 were human miRNAs (hsa-miR-409-3p and 889) 
as shown in Figure 5.14. Comparing these data with those following 10 days of TGF-
β stimulation we demonstrated that the 3 canine miRNAs and 1 human miRNA (hsa-
miR-409-3p) were amongst the 5 most highly expressed miRNAs in both analyses, 
even though they are ranked in different order based on their magnitudes of 
expression on days 10 and 17. 
 
 
Figure 5.14. Differences in miRNA expression in REM cells stimulated with TGF-β for 17 day, 
compared to mock-treated cells at day 17. Average log (2) counts per million data are presented 
(with normalisation of TGF-β-stimulated cell data to mock-treated cell data). According to the 
fold change data showed in Figure 5.13, only significant data are presented (False Discovery 
Rate ≤0.05).  
 
5.3.5.3 MiRNA expression after 23 days of stimulation with TGF-β  
After 23 days of stimulation with TGF-β, the expression of 12 miRNAs was 
significantly upregulated compared with mock-treated REM cells. Eight of these 
upregulated miRNAs were canine and only 4 were human as shown in Figure 5.15. 
Of these 12 upregulated miRNAs, 9 were also upregulated in cells after 17 days of 
TGF-β stimulation. The miRNAs significantly upregulated at both days 17 and 23 
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included 5 canine (cfa-miR-363, 411, 410, 381 and 380) and 4 human (hsa-miR-409-
3p, 1468, 889 and 125b-2-3p) miRNAs. Likewise, 10 of the 12 significantly 
upregulated miRNAs after 23 days of TGF-β stimulation were also significantly 
upregulated after 10 days of TGF-β stimulation. Overall, there were 7 miRNAs 
significantly upregulated following TGF-β stimulation at the 3 different time points, 
including 4 canine (cfa-miR-411, 410, 381 and 380) and 3 human (hsa-miR-409.3p, 
1468 and 889) miRNAs.  
 
 
Figure 5.15. Significant fold changes in mapped miRNA expression in REM cells stimulated 
with TGF-β for 23 days, normalised to mock-treated cells at day 23. Log(2) fold change data are 
presented with normalisation of TGF-β-stimulated cell data to mock-treated cell data, only 
significant fold changes are presented (i.e. False Discovery Rate ≤0.05). Expression of all 
mapped miRNAs is significantly upregulated after TGF-β-stimulation compared to mock-
treated cells at day 23. 
As stated above, there were 7 miRNAs consistently significantly upregulated 
in TGF-β-stimulated cells after the three different time points. When expressed as 
logCPM values for day 23 after TGF-β stimulation, we observed that 4 of the 5 most 
highly expressed miRNAs compared with mock-treated cells, were also amongst the 
5 most highly expressed miRNAs after 10 and 17 days of TGF-β stimulation (Figure 
5.16). The 5 most highly expressed miRNAs at day 23 were human has-miR-409-3p 
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and canine cfa-miR-411, 381, 410 and 363, the latter being the only miRNA not to 
be also highly expressed after days 10 and 17 of TGF-β stimulation. 
 
 
Figure 5.16. Differences in miRNA expression in REM cells stimulated with TGF-β for 23 day, 
compared to mock-treated cells at day 23. Average log (2) counts per million data are presented 
(with normalisation of TGF-β-stimulated cell data to mock-treated cell data). According to the 
fold change data showed in Figure 5.15, only significant data are presented (False Discovery 
Rate ≤0.05).  
 
5.3.5.4 MiRNA expression comparison between mock-treated cells and 
cells stimulated with TGF-β for 19 days prior to withdrawal until 
day 23 
There were not many significant differences in miRNA expression between 
mock-treated cells and cells stimulated with TGF-β for 19 days and harvested on day 
23 (4 days after TGF-β withdrawal), the only upregulated miRNA in the TGF-β 
withdrawal sample was hsa-miR-1468 (Figure 5.17). Interestingly, this human 
miRNA was also upregulated in all time points described above. TGF-β withdrawal 
cells would be expected to return to a regular epithelial phenotype, exhibited by the 
mock-treated cells after TGF-β withdrawal, although there are no studies 
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demonstrating how long canine mammary carcinoma cells would take to go back to 
an epithelial phenotype after TGF-β withdrawal. 
 
Figure 5.17. Significant fold change in mapped miRNA expression in REM cells from which 
TGF-β was withdrawn after 19 days and harvested for analysis 4 days later, normalised to 
mock-treated cells at day 23. Log(2) fold change data are presented with normalisation of TGF-
β withdrawal cell data to mock-treated cell data, only significant fold changes are presented (i.e. 
False Discovery Rate >0.05). Expression of only one mapped miRNA is significantly upregulated 
after TGF-β withdrawal compared to mock-treated cells at day 23.  
 As this human miRNA was the only upregulated miRNA in this study, we do 
not have a way to assess how highly expressed it was compared to other miRNAs 
within the same comparative study, however, if we compare it to upregulated 
miRNAs from different time points, we can observe that its logCPM value, as shown 
in Figure 5.18, is not as highly expressed as any of the 5 most highly expressed 
miRNAs at the other time points described above. 
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Figure 5.18. Difference in mapped miRNA expression in REM cells from which TGF-β was 
withdrawn after 19 days and harvested for analysis 4 days later, normalised to mock-treated 
cells at day 23. Average log (2) counts per million data are presented (with normalisation of 
TGF-β-stimulated cell data to mock-treated cell data). According to the fold change data 
showed in Figure 5.17, only significant data are presented (False Discovery Rate ≤0.05). 
Expression of only one miRNA is significantly increased after TGF-β withdrawal compared to 
mock-treated cells. 
 
5.3.5.5 MiRNA expression comparison between TGF-β-stimulated and 
TGF-β withdrawal samples 
When the miRNA expression profile of cells stimulated with TGF-β for 23 
days was compared with that of cells from which TGF-β was withdrawn from day 19 
to 23, several of the miRNAs observed to be significantly upregulated during TGF-β 
stimulation (Figures 5.13, 5.15, 5.17) were downregulated on TGF-β withdrawal 
cells (Figure 5.19).  
In this case, TGF-β-stimulated cell data were used to normalise the TGF-β 
withdrawal cell data. The significantly upregulated miRNAs found when TGF-β-
stimulated cell data were normalised with mock-treated cell data at 10, 17, and 23 
days of TGF-β stimulation, and the near total lack of significant miRNA expression 
changes when withdrawal cells were compared to mock-treated cells. 
All the significant changes in miRNA expression were downregulations, and 
none were found to be significantly upregulated as shown in Figure 5.19. Significant 
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fold changes in mapped miRNA expression in REM cells from which TGF-β was 
withdrawn after 19 days and harvested for analysis 4 days later, normalised to cells 
stimulated with TGF-β for 23 days. Log(2) fold change data are presented with 
normalisation of TGF-β withdrawal cell data to TGF-β-stimulated cell data, only 
significant fold changes are presented (i.e. False Discovery Rate >0.05). Expression 
of all mapped miRNAs is significantly downregulated after TGF-β withdrawal 
compared to TGF-β-stimulated cells at day 23.. Half of the 16 significantly 
downregulated miRNAs were canine and half were human miRNAs. Six of these 
significantly downregulated miRNAs in TGF-β withdrawal cells were upregulated in 
TGF-β-stimulated samples in all the time points previously shown. These miRNAs 
were the canine cfa-miR-411, 410, 381 and 380 and the human hsa-miR-409-3p and 
889. 
 
Figure 5.19. Significant fold changes in mapped miRNA expression in REM cells from which 
TGF-β was withdrawn after 19 days and harvested for analysis 4 days later, normalised to cells 
stimulated with TGF-β for 23 days. Log(2) fold change data are presented with normalisation of 
TGF-β withdrawal cell data to TGF-β-stimulated cell data, only significant fold changes are 
presented (i.e. False Discovery Rate >0.05). Expression of all mapped miRNAs is significantly 
downregulated after TGF-β withdrawal compared to TGF-β-stimulated cells at day 23. 
When expressed using logCPM values among the 5 most profoundly 
differently expressed miRNAs in withdrawal cells, canine cfa-miR-411 and 381 were 
also highly expressed following TGF-β stimulation for 10, 17 and 23 days (Figures 
5.12, 5.13 and 5.16). Human miRNA hsa-miR-181a-2-3p showed the highest 
 
 
Chapter 5: Global changes in microRNA levels during Epithelial to       
Mesenchymal Transition in dogs  155 
expression in withdrawal cells and was also highly expressed in cells stimulated with 
TGF-β for 10 days. 
 
Figure 5.20. Differences in mapped miRNA expression in REM cells from which TGF-β was 
withdrawn after 19 days and harvested for analysis 4 days later, normalised to cells stimulated 
with TGF-β for 23 day. Average log (2) counts per million data are presented (with 
normalisation of TGF-β-stimulated cell data to mock-treated cell data). According to the fold 
change data showed in Figure 5.19, only significant data are presented (False Discovery Rate 
≤0.05). Expression of all mapped miRNAs is significantly increased after TGF-β withdrawal 
compared to TGF-β-stimulated cells.  
 
5.3.6 Canine miRNAs with the most significant changes 
From all the significantly upregulated or downregulated miRNAs throughout 
the various time points analysed, 6 of them (canine cfa-miR-411, 410, 381 and 380; 
and human hsa-miR-409-3p and 889) showed similar changes at all time points. 
These data are presented in Figure 5.21where all miRNAs are significantly 
upregulated after TGF-β stimulation at days 10, 17 and 23; and significantly 
downregulated after TGF-β withdrawal when compared to contemporaneous mock-
treated cells. These data are also presented as a table (Table 5.2) showing the fold 
change difference of each miRNA expression at these different time-points after 
TGF-β stimulation and after TGF-β withdrawal. Only results with adjusted p-values 
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or false discovery rate (FDR) of ≤ 0.05 showing significant changes among the 
different samples were taken into account.  
 
Figure 5.21. Consistent significant changes in miRNA expression in REM cells exposed to TGF-
β at various time points. There is a remarkable upregulation in fold change of cfa-miR-381, 411, 
410, 380, has-miR-889 and has-miR-409-3p at days 10, 17 and 23; whereas in the TGF-β 
withdrawal samples they were all downregulated. All data are normalised to mock-treated cells.  
 
 
Table 5.2. Fold change differences in the expression of several miRNAs at different time points 
of TGF-β stimulation of REM cells. At days 10, 17 and 23 of TGF-β stimulation, cells show a 
significant increase in the expression of cfa-miR-381, 411, 410, 380, hsa-miR-889 and hsa-miR-
409-3p. REM cells from which TGF-β was withdrawn after 19 days and harvested for analysis 4 
days later expressed significant decreases in these mRNAs when compared to cells continuously 
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stimulated with TGF-b for 23 days. ** = False discovery rate ≤ 0.005, *** = False discovery rate 
≤ 0.05 
 
5.3.7 MicroRNA validation assays 
Considering that validation is needed for the confirmation of these global 
miRNA analysis findings, we carried out specific miRNA expression assays 
targeting the mature sequences of the 4 canine miRNAs that the expression of which 
were consistently similarly altered on TGF-β stimulation throughout this study (cfa-
miR-411, 410, 381 and 380). As described in Chapter 2.13, we performed qRT-PCR 
targeting the specific mature sequences of these miRNAs, which all showed a peak 
in expression by day 10 of treatment with TGF-β and they were also downregulated 
in the TGF-β withdrawal sample. All fold changes of miRNA expression were 
normalised to reference gene RPL32 as specified in Chapter 2.7.7. The results of the 
specific miRNA analyses were therefore consistent with the global miRNA 
expression analysis patterns, confirming our findings are relevant and further 
investigation in this field is warranted. The specific qRT-PCR expression data for 
cfa-miR-380, cfa-miR-381, cfa-miR-410 and cfa-miR-411 are presented in Figure 






Chapter 5: Global changes in microRNA levels during Epithelial to       
Mesenchymal Transition in dogs  158 
 
Figure 5.22. Canine miRNA-380 expression is increased after TGF-β stimulation of REM cells, 
and decreases after its withdrawal, assessed by specific qRT-PCR. As observed in global miRNA 
analyses, peak expression was observed at day 10 of TGF-β stimulation and decreased 
thereafter. Control = untreated cells harvested at day 23, Day 1 10 ng/ml = cells harvested at 
day 1 of TGF-β treatment, Day 10 10 ng/ml = cells harvested at day 10 of TGF-β treatment, Day 
17 10 ng/ml = cells harvested at day 17 of TGF-β treatment, Day 23 10 ng/ml = cells harvested at 
day 23 of TGF-β treatment, Day 19 WD = cells harvested at day 23 after TGF-β withdrawal at 
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Figure 5.23. Canine miRNA-381 expression is increased after prolonged TGF-β stimulation of 
REM cells, and decreases after its withdrawal, assessed by specific qRT-PCR. As observed in 
global miRNA analyses, peak expression was observed at day 10 of TGF-β stimulation and 
decreased thereafter. Control = untreated cells harvested at day 23, Day 1 10 ng/ml = cells 
harvested at day 1 of TGF-β treatment, Day 10 10 ng/ml = cells harvested at day 10 of TGF-β 
treatment, Day 17 10 ng/ml = cells harvested at day 17 of TGF-β treatment, Day 23 10 ng/ml = 
cells harvested at day 23 of TGF-β treatment, Day 19 WD = cells harvested at day 23 after TGF-
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Figure 5.24. Canine miRNA-410 expression is increased after short term TGF-β stimulation of 
REM cells, and decreases after its withdrawal, assessed by specific qRT-PCR. As observed in 
global miRNA analyses, peak expression was observed at day 10 of TGF-β stimulation and 
decreased thereafter. Control = untreated cells harvested at day 23, Day 1 10 ng/ml = cells 
harvested at day 1 of TGF-β treatment, Day 10 10 ng/ml = cells harvested at day 10 of TGF-β 
treatment, Day 17 10 ng/ml = cells harvested at day 17 of TGF-β treatment, Day 23 10 ng/ml = 
cells harvested at day 23 of TGF-β treatment, Day 19 WD = cells harvested at day 23 after TGF-
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Figure 5.25. Canine miRNA-411 expression is increased after TGF-β stimulation of REM cells, 
and decreases after its withdrawal, assessed by specific qRT-PCR. As observed in global miRNA 
analyses, peak expression was observed at day 10 of TGF-β stimulation and decreased 
thereafter. Control = untreated cells harvested at day 23, Day 1 10 ng/ml = cells harvested at 
day 1 of TGF-β treatment, Day 10 10 ng/ml = cells harvested at day 10 of TGF-β treatment, Day 
17 10 ng/ml = cells harvested at day 17 of TGF-β treatment, Day 23 10 ng/ml = cells harvested at 
day 23 of TGF-β treatment, Day 19 WD = cells harvested at day 23 after TGF-β withdrawal at 
day 19. P values comparing stimulated samples with control cells harvested at day 23: ** = p 
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5.4 Discussion  
MiRNAs are key regulators of fundamental physiological cell processes, such 
as tissue differentiation, and in the progression of several diseases like cancer 
(Foubert, et al., 2010). In cancer they have been shown to have important roles in 
promotion and suppression of oncogenes (Croce, 2009) as described in Chapter 1.15. 
After analysing all our samples in an MDS plot (Figure 5.4), we still needed to 
answer many questions in regards to what properties some of the depicted points 
were sharing, and in what ways these points differ from each other. This type of 
analysis is quite useful to discover the tendency of variation between our data, 
nevertheless, it should not be considered significant prior to a complete comparative 
study (Coxon et al., 1982b). In order to elucidate which properties our samples 
shared between each other, we assessed the miRNA expression profiles in a 
comparative study between mock-treated, TGF-β-stimulated and TGF-β withdrawal 
cells at different time points.  We have shown four key miRNAs are associated with 
TGF-β-induced EMT of canine mammary carcinoma cells. Both in global miRNA 
analyses and in specific miRNA-targeted qRT-PCR of TGF-β-stimulated cells at 
days 10, 17 and 23, mock-treated cells and TGF-β withdrawal cells, we identified 4 
canine miRNAs (cfa-miR-411, 381, 410 and 380) which were consistently similarly 
changed in their expression.  
According to the adjusted p-values or false discovery rate (FDR), these 
miRNAs showed significant changes among the different samples at days 10, 17, and 
23 of TGF-β stimulation. In contrast to the TGF-β-stimulated cells, after withdrawal 
of TGF-β, cells displayed a decrease in the expression of these miRNAs, suggesting 
that the miRNA expression changes that are associated with a mesenchymal 
phenotype after TGF-β stimulation are reversed on TGF-β withdrawal. Further 
investigation is needed to assess the time required for cells to return to their epithelial 
phenotype after TGF-β withdrawal. Tian et al., 2013 showed that after exogenous 
TGF-β withdrawal, Madin-Darby canine kidney epithelial cells might be able to 
maintain a stable mesenchymal phenotype if autocrine TGF-β signalling is sustained, 
which can be achieved by stimulation with large doses of exogenous TGF-β (3 
ng/ml) (Gal et al., 2013). However, they mention that the irreversibility of EMT is 
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cell-type-dependent. This is in line with what Gal et al., 2008 previously 
demonstrated after TGF-β withdrawal in normal murine mammary epithelia after 
being exposed to 5 ng/ml of TGF-β for up to 3 weeks, and after confirming that cells 
acquired a mesenchymal phenotype assessed by morphological and molecular 
changes. These cells gradually reverted to epithelial monolayers in 2D cultures 
within 2-12 days after TGF-β withdrawal, and also re-expressed epithelial markers 
and strongly reduced mesenchymal marker expression levels (Gal et al., 2008). It is 
not well understood how different cell types respond to TGF-β stimulation and 
withdrawal regarding EMT- and MET-associated changes and this warrants further 
investigation with specific cell types, including canine and feline mammary 
carcinoma cell lines. 
Studies in human cancer have shown contrasting results to the data presented 
here (Swarbrick et al., 2010, Beltran et al., 2011, Snowdon et al., 2011, van 
Schooneveld et al., 2012, Liu et al., 2013, Torres et al., 2013). Van Schooneveld et al, 
2012 determined that human miR-411 is downregulated in breast cancer samples, 
using tissue and blood samples obtained from breast cancer patients and healthy 
volunteers to compare miRNA expression. The breast cancer patients were divided 
into 3 different groups with localised breast cancer, metastatic breast cancer under 
treatment, and metastatic breast cancer without treatment. They compared miRNA 
expression in tumour samples between the breast cancer patients groups and the 
healthy breast samples, and found that miR-411 was one of the downregulated 
miRNAs with greater expression in the tumour samples. Interestingly, they observed 
a similar pattern when analysing serum samples, whereby miR-411 was among other 
miRNAs which were significantly downregulated in breast cancer patients compared 
to healthy volunteers. Moreover, they compared the expression of the most 
significantly downregulated miRNAs in serum samples of patients with metastatic 
breast cancer under treatment, patients with metastatic breast cancer without 
treatment, and healthy volunteers. They observed that the expression of miR-411 
along with 3 other miRNAs was lower in untreated metastatic breast cancer, 
compared to samples from patients under treatment, which exhibited a similar 
miRNA expression to the healthy volunteers samples (van Schooneveld et al., 2012). 
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Similarly, Liu et al, 2013 compared miRNA expression in treatment-naive tissue and 
blood samples from breast cancer patients and healthy donors. They identified one 
miRNA that was significantly upregulated in expression (miR-155) and 9 other 
miRNAs significantly downregulated, including miR-381 (Liu et al., 2013). In this 
case, they did not compare breast cancer samples at different metastatic stages.  
Although in the studies by van Schooneveld et al, 2012 and Liu et al, 2013 
described above human miR-411 and miR-381 expression was downregulated in 
breast cancer and metastatic breast cancer samples compared to healthy tissues; in 
our study, canine miR-411 and miR-381 were upregulated in the TGF-β-stimulated 
canine mammary epithelial cancer cells compared to mock-treated cells in vitro. In 
previous chapters herein, we showed that REM cells morphologically demonstrate an 
EMT process after TGF-β stimulation and acquire greater migratory capabilities, and 
at similar time points in this chapter we found upregulation of canine miR-411 and -
381, among others, perhaps related to miRNA expression changes after TGF-β-
induced EMT. 
Moreover, human miR-410 was found to be decreased in expression in 
human endometrioid endometrial carcinoma tissues when compared to control 
samples from patients with a precursor lesion (complex atypical hyperplasia) in a 
previous study (Snowdon et al., 2011), and similarly, a different group compared 
tissue and blood samples of patients with endometrial cancer and healthy volunteers 
finding that miR-410 and a pool of other miRNAs were significantly downregulated 
in cancer patients (Torres et al., 2013). 
These conflicting results for cfa-miR-411 and cfa-miR-381 expression in our 
study and the human miRNAs in the reports presented above might be explained by 
our study being an in vitro study focussed on miRNA expression after TGF-β-
induced EMT in canine mammary carcinoma in which metastasis was not assessed. 
The human studies assessed miRNA expression in human cancers but without 
assessing EMT-associated changes after TGF-β stimulation. In order to acquire a 
better understanding of how these specific miRNAs act in canine mammary 
carcinoma metastasis, we could assess their expression in mammary tissues from 
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healthy donors and compare them with primary breast cancer tissues and metastatic 
tissues, with and without treatment. This could allow us assess how well correlated 
our findings are with those from human cancer research (van Schooneveld et al, 2012 
and Liu et al, 2013). As previously mentioned, TGF-β has been shown to have 
paradoxical activities in cancer progression where it can act as a context-specific 
tumour suppressor gene or as a tumour promoter (Levy and Hill, 2005). MicroRNAs 
have also been found to act differently in context-specific environments, as reviewed 
by Boggs et al., 2008. They show that several miRNAs, including miR-17-5p, miR-
181b, miR-155 and let-7f, may act as tumour suppressor genes and/or oncogenes 
depending on their microenvironmental context within different types of tumours, 
such as mammary tumours, glioblastoma, chronic lymphocytic leukemia and 
haemopoietic cancers among others (reviewed by Boggs et al., 2008). These could 
also be some of the reasons why our data show conflicting results with some of the 
studies mentioned above. 
Furthermore, Swarbrick et al, 2010 observed that human miR-380-5p 
regulates the expression of p53 in neuroblastoma, and thus, the inhibition of this 
miRNA increases p53 activity, inducing apoptosis. They found that high expression 
of miR-380 in neuroblastoma was correlated with poor prognosis in neuroblastoma, 
and after knockdown of miR-380-5p in vitro, they observed upregulation of p53 and 
consequently a higher apoptotic rate. Moreover, they transfected mouse mammary 
epithelial cells with miR-380-5p before transplantation into mammary fat pads of 
mice, and observed that miR-380-5p-transfected cells gave rise to a greater 
frequency in tumour formation than the control groups (Swarbrick et al., 2010). 
These results are in line with our data, where miR-380 was upregulated in TGF-β-
stimulated canine mammary carcinoma cells in vitro (which, as described in Chapter 
4.3, acquire resistant features associated with a more malignant phenotype). 
Although Swarbrick et al., 2010 assessed miRNA expression changes in human 
neuroblastoma, which is a different type of cancer from a different species; this gives 
an idea for future research in this respect. We could perhaps assess if canine miR-380 
also regulates the expression of p53 in canine mammary carcinoma cells and whether 
the inhibition of said miRNA enhances p53 activity, inducing apoptosis. An 
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interesting way to assess the correlation between TGF-β exposure and miRNA 
expression changes in canine mammary cancer cells would be to assess p53 activity 
in TGF-β-stimulated and unstimulated cells. This way we could confirm the 
regulatory activity of different miRNAs on p53 and correlate these changes with 
TGF-β-induced EMT and resistance to apoptosis. 
There are no previous studies reporting a full screening of miRNA expression 
in canine mammary carcinoma cells associated with EMT-associated changes. Our 
data were validated by specific qRT-PCR assays targeting the mature miRNA 
sequences suggesting further research into the roles of miRNAs in other cancers and 
their inhibition is warranted. Different research groups investigated the role of 
specific miRNAs without global miRNA analysis in canine mammary carcinoma 
(Boggs et al., 2008, von Deetzen et al., 2014). Boggs et al, 2008 studied10 specific 
canine miRNAs based on previous human breast cancer miRNA expression profiles. 
Most miRNAs displayed similar expression profiles to those observed in human 
samples (Boggs et al., 2008). On a similar approach, von Deetzen et al., 2014 
assessed the expression of 16 specific miRNAs in canine mammary tumours and 
normal mammary gland samples. From these studied miRNAs, they observed the 
most significant changes between primary tumours and metastatic cells in 5 
miRNAs; including miR-29b, miR-101, miR-125a, miR-143 and miR-145. 
Interestingly, none of the upregulated miRNAs in our study were included in their 
research. The data obtained by these research groups is very useful for the study of 
specific miRNAs associated with cancer progression (Boggs et al., 2008 and von 
Deetzen et al., 2014), nevertheless, our data is more comprehensive and might 
discover miRNAs that have greater significance in the canine rather than merely ones 
which are specifically measured based on human data. Therefore, our study could be 
considered a more comprehensive assessment as to whether the canine is a good 
model for human cancer miRNA research. 
Using a different approach, Rybicka et al., 2015 investigated miRNA 
expression profiles in canine mammary cancer stem-like cells expressing stem cell 
antigen 1, CD44 and EpCAM (stem cell markers) derived from 3 different cell lines. 
They observed 24 downregulated miRNAs in cancer stem-like cells compared to 
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differentiated tumour cells. From these miRNA profiles, cfa-miR-10b expression was 
downregulated in cancer stem-like cells; consistent with the findings of Iorio et al., 
2005 in breast cancer tissue samples compared to normal tissue in humans. 
Interestingly, Rybicka et al., 2015 also found that cfa-miR-15a expression was 
upregulated and cfa-let-7f expression was downregulated in cancer stem-like cells, 
opposed to the findings of Boggs et al., 2008 who observed downregulation of cfa-
miR-15a in canine ductal carcinomas and upregulation of cfa-let-7f in tubular 
papillary carcinomas, respectively, compared to normal mammary tissues. These 
data also support the context-specific role for miRNAs, as reviewed by Boggs et al., 
2008. 
Moreover, Rybicka et al., 2015 correlated miRNA expression profiles to 
specific target genes, according to KEGG and BioCarta databases, where they found 
that target genes of significantly downregulated miRNAs were involved in the TGF-
β signalling pathway, among other pathways, and interestingly, one of the most 
important genes found to be overlapping with different pathways was TGFβR1. In 
future research we could investigate these specific miRNA expression profiles not 
only in cells that had undergone a TGF-β-induced EMT, but also in cells that had 
acquired stem cell-like characteristics after TGF-β stimulation to fully elucidate the 
role of these miRNAs in TGF-β-induced EMT and TGF-β-induced stemness. 
It is evident that there is still much to be understood regarding the roles of 
miRNAs in cancer. We have shown that specific miRNAs are involved in TGF-β-
induced EMT of a canine mammary carcinoma cell line in vitro. The discovery of 
new miRNAs and the understanding of action of known miRNAs could be very 
useful for cancer research in companion animals; and dogs and cats might have an 
important role as animal models for cancer research in humans. Inhibition of 
miRNAs might become a therapeutic option in the future, although outstanding 
questions regarding their function in healthy and diseased organisms need to be 
answered. Further investigation could lead to novel diagnostic and therapeutic tools 
for breast cancer and its progression in both companion animals and humans. On a 
similar approach, Jin et al., 2014 found specific miRNA molecules involved in 
colorectal cancer in humans, and they emphasise their studies in the development of 
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therapies against specific clinical targets of EMT-associated miRNAs as they are 
regarded as important oncogenes and tumour suppressor genes (Jin et al., 2014). As 
stated by Liu et al (Liu et al., 2013), different diagnostic and prognostic protocols 
could be developed by simple blood tests to analyse circulating miRNA expression 
in the serum of patients. 
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Chapter 6: Final Discussion 
Here, we have shown that there is an association between EMT and the 
acquisition of stem cell characteristics in mammary carcinoma cells of companion 
animals. These finding are in accordance with the literature which supports that 
induction of EMT in human breast cancer cells leads to an accumulation of cancer 
cells with stem cell characteristics (Morel et al., 2008, Mani et al., 2008, Chen et al., 
2011) such as increased self-renewal potential; resistance to therapeutic agents; and 
enhanced migratory properties. Our results further highlight the benefits of 
developing new EMT/stem cell-based diagnostic and therapeutic protocols to be of 
benefit in the treatment of companion animal cancer patients and for advancement of 
veterinary medicine. Moreover, this work reinforces that dogs and cats are good 
animal models for the human disease regarding progression and metastasis of cancer 
(Vail and Macewen, 2000, and reviewed by Porrello et al., 2006, Boggs et al., 2008, 
Gama et al., 2008, Cassali et al., 2011 and Rybicka et al., 2015). 
Both canine and feline mammary carcinoma cells go through an EMT process 
similar to human cells, which were used as a comparative control in this study. All 
cells exhibited a more mesenchymal phenotype after EMT was induced by TGF-β 
treatment, as shown in Chapter 3.3.1. These phenotypic changes were concurrent 
with changes in EMT-associated protein and gene expression levels as demonstrated 
in Chapters 3.3.2 and 3.3.3, respectively. Furthermore, after treatment with TGF-β, 
both feline and canine mammary carcinoma cells acquired increased motility in vitro 
(Chapter 3.3.4). Metastatic cells also require invasive features to pass through 
surrounding tissues and membranes in order to be able to reach lymphatic and blood 
vessels, and subsequently migrate to their new microenvironment. It is important to 
separate the terms migration and invasion in experimental biology. Migration is 
defined as the directed movement of cells on a 2D substrate without any kind of 
obstacle. On the other hand, invasion is defined as cell movement through a 3D 
extracellular matrix (ECM), which represents a true barrier for moving cells, as 
reviewed by Kramer et al., 2013. Invading cells would have to modify their shape 
and secrete proteolytic enzymes in order to dissolve the ECM and pass through it. 
Migrating cells may be capable of moving in 3D matrices but without destructive or 
 
  170 
proteolytic features (reviewed by Kramer et al., 2013). In order to confirm whether 
our studied cells become more invasive after EMT, further investigation is needed, 
including invasion assays with different cell lines stimulated with different TGF-β 
concentrations and selected time points in vitro. As reviewed by Kramer et al., 2013, 
a comprehensive in vitro metastasis assay is practically impossible to achieve in the 
near future (Kramer et al., 2013). Nevertheless, there are different means to assess 
cell invasiveness. It is always recommended to calculate the invasive index, which 
represents the ratio of invasive cells to migratory cells in order to determine the cell 
line’s relative invasiveness (Kramer et al., 2013). Also, in vivo invasion assays would 
be required to confirm the invasive characteristics of these cells in a living organism. 
Currently, in the author’s lab, we are investigating the role of EMT in vivo in a 
chicken chorioallantoic membrane-based model for breast cancer. A different 
approach to study these characteristics in vivo would be to inoculate 
immunocompromised mice with labelled canine and feline mammary carcinoma 
cells into different organs and track their migratory and invasive capabilities 
thereafter. To reduce the use of experimental animals, an in vitro model that could 
accurately resemble cancer cell invasiveness in vivo is necessary. As an example, 
with or without TGF-β stimulation, canine mammary carcinoma cells could be in 3D 
ECM gels and their invasive traits could be measured after a period of incubation. 
This type of model has been previously utilised by Dolznig et al., 2011, where they 
assessed the invasiveness of different tumour-spheroid cells in vitro. They showed 
that an ovarian carcinoma cell line produced two populations, with non-invasive cells 
in compact spheres and invasive cells with cellular astral outgrowth into the collagen 
gel (Dolznig et al., 2011). If we could carry out a similar invasion assay, we could 
assess the acquired invasive features of canine mammary carcinoma cells after the 
acquisition of stem cell-like characteristics after TGF-β stimulation, and investigate 
the potential correlation between TGF-β-induced EMT, invasiveness and stemness. 
As there is limited data published on EMT in canine cancer, especially in 
canine mammary cancer, and given the context-specific effects of some of the major 
factors involved, direct comparison with some previous human and murine work is 
difficult (reviewed by Yang and Weinberg, 2008, Thompson et al., 2005, and Tarin 
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et al., 2005). The disparity between phenotypic and transcriptional data in our study, 
shown in Chapter 3.3.3 could also be due to the complexity of the different TGF-β 
roles during EMT and cancer progression (Shipitsin et al., 2007, and reviewed by 
Blobe et al., 2000, Derynck et al., 2001 and Singh and Settleman, 2010). 
Interestingly, we also found that EMT-associated translational and transcriptional 
changes are not always expressed clearly in TGF-β-stimulated feline and canine 
mammary carcinoma cells, as described in Chapters 3.3.2 and 3.3.3, respectively. 
This finding could be in part due to loss of Smad4 during tumourigenesis by 
modulating the function of TGF-β, regulating its tumour suppressor activity and 
enhancing its oncogenic properties (Levy and Hill, 2005, Deckers et al., 2006, Piek 
et al., 1999, Valcourt et al., 2005). The Smad family is thought to be important for 
the acquisition of tumour suppression and tumour promotion features (reviewed by 
Derynck et al., 2001) and is a well-characterised effector signalling pathway initiated 
by TGF-β receptors (reviewed by Miyazono et al., 2000, Massagué and Wotton, 
2000). Smad4 plays an important role in the acquisition of migratory and invasive 
characteristics in epithelial cells after TGF-β stimulation (Deckers et al., 2006, Piek 
et al., 1999, Valcourt et al., 2005). Nevertheless, Levy and Hill, 2005 propose that 
Smad4 inhibition can be of importance during tumorigenesis by modulating TGF-β-
induced response so that oncogenic and tumour promotion functions are retained but 
tumour suppressor activities are lost (Levy and Hill, 2005). Further investigation is 
necessary to clarify the role of Smad4 in our studied cell lines after TGF-β 
stimulation in order to understand its role during TGF-β-induced EMT in vitro. 
Therefore, elucidating the potential roles of Smad4 among other transcription factors 
and the cross-talk between different molecular pathways should lead to a more in-
depth understanding of EMT-associated changes in canine mammary cancer. Even 
though there are some studies that correlate the loss of Smad4 to cancer progression 
in human pancreatic (Lüttges et al., 2001), colon (Mesker et al., 2009) and colorectal 
cancer (Ahn et al., 2011); and mice gastric cancer (Xu et al., 2000), none of these 
studies correlate their findings to EMT-associated changes in canine mammary 
cancer. It would be ideal to assess the expression of Smad4 at the posttranscriptional 
level in epithelial cells with and without TGF-β stimulation, especially 
contemporaneous with TGF-β-induced morphological changes.  
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Our data suggest that treatment could be directed towards EMT at early 
stages of tumourigenesis, targeting TGF-β and its downstream effectors to prevent 
cell migration, self-renewal and the acquisition of several other stem cell-like 
characteristics, including dysregulated cell growth and metastasis. Inhibition of TGF-
β as a therapeutic approach against cancer has been studied by Derynck et al, 2001 
who concluded that due to its context-specific roles, inhibiting this growth factor 
might induce tumour regression in advanced cancers, but might stimulate growth in 
quiescent tumours. Their suggestion was to inhibit TGF-β signalling in advanced 
metastatic cancer, but to augment it as a factor inhibiting progression in cancer at 
early stages. Moreover, they suggest that Smad6 and Smad7 may inhibit the 
functions of Smad4 after TGF-β induction, which could also serve as a potential 
therapeutic intervention to prevent migration and invasion in cancer cells (reviewed 
by Derynck et al., 2001).  
Furthermore, EMT leads to the acquisition of stem cell characteristics, and 
tumours have previously been shown to be comprised of a heterogeneous mix of 
cells, of which a typically small percentage are CSC (reviewed by Reya et al., 2001) 
and are capable of driving tumour relapse and cancer progression due to their self-
renewal properties and resistance to chemotherapy and radiotherapy (reviewed by 
Dean et al., 2005, Diehn and Clarke, 2006, Phillips et al., 2006, Pang et al., 2013). 
We carried out experiments with promising results confirming the association 
between the acquisition of migratory properties in mesenchymal-like cells and the 
acquisition of stem cell characteristics including self-renewal and resistance to 
apoptosis and chemotherapy after a TGF-β-induced EMT. These findings could lead 
to further research and a potential development of novel diagnostic and therapeutic 
techniques for breast cancer in companion animals and humans. 
We showed that feline and canine mammary carcinoma cells acquire self-
renewal and resistant characteristics after treatment with TGF-β, as they were 
capable of forming bigger and more spheres compared with the untreated cells in 
harsh culture conditions, as described in Chapter 4.3.1. These spheres are thought to 
be representative of CSCs (Morel et al., 2008, Mani et al., 2008 and Pang et al., 
2011). Interestingly; these spheres were expressing a more mesenchymal phenotype 
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at the translational level, as they showed decreased protein expression of epithelial 
markers compared with adherent cells. Canine and feline TGF-β-stimulated 
mammary carcinoma cells also showed an approximate 3-fold increase in the number 
of cells expressing the putative CSC marker CD133. This is consistent with a study 
that showed that CD133+ cells from head and neck cancer had stem cell 
characteristics and acquired EMT-associated changes (Chen et al., 2011). Both 
sphere forming abilities and the expression of CD133 in TGF-β-stimulated cells, 
along with the protein expression of mesenchymal markers in spheres; indicate a 
correlation between EMT and the acquisition of CSC characteristics in canine and 
feline mammary carcinoma cells. Moreover, different research groups have found 
that there is a close link between the expression of this CSC marker and EMT in 
vitro and in vivo in different types of cancer, including metastatic pancreatic cancer  
(Ding et al., 2014 and Nomura et al., 2015) and lung carcinoma in humans (Koren et 
al., 2015). Ding et al., 2014 showed that CD133+ human pancreatic cancer cells 
were able to produce metastatic tumours in immunodeficient mice, however, after 
CD133 knockdown with shRNA, cancer invasion and metastasis was suppressed in 
vivo while the EMT-related genes Slug and N-cadherin, along with the mesenchymal 
marker fibronectin were downregulated in vitro. These data confirm that CD133 
plays a crucial role in invasion and metastasis of human pancreatic cancer in vivo and 
in vitro by upregulating the expression of EMT-related genes and the mesenchymal 
marker fibronectin (Ding et al., 2014). This correlation between CD133 and EMT 
induction in pancreatic cancer cells was confirmed by Nomura et al., 2015 in vitro. 
They demonstrated that a different human pancreatic cancer cell line became more 
invasive after CD133 overexpression in vitro. Moreover, these invasive CD133+ 
cells showed an increased expression of EMT transcription factors Snail and Zeb1, 
and mesenchymal markers vimentin and N-cadherin, confirming the cells go through 
an EMT process following CD133 overexpression (Nomura et al., 2015). 
Furthermore, Koren et al., 2015 assessed the correlations between mRNA expression 
levels of EMT transcription factors (BMI1 and Twist) and CSC markers (CD133 and 
ALDH1A1) in primary tumours and whole blood samples from human patients with 
non-small-cell lung carcinoma and metastatic disease, respectively. They observed 
that there is a correlation between the mRNA expression of BMI1 and CD133 in 
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primary tumours and whole blood samples. This correlation was confirmed by 
immunohistochemical analysis where coexpression of BMI1 and CD133 was present 
in tumour samples (Koren et al., 2015). In order to confirm these findings in canine 
and feline mammary carcinoma, we could expand our investigation by assessing the 
expression of EMT markers in CD133+ cells, but more importantly after CD133 
knockdown. Also, we could include invasion assays before and after CD133 
overexpression and after subsequent CD133 knockdown in CD133+ cells. 
Previously, CSCs have been shown to be inherently resistant to conventional 
chemotherapy and radiation therapy (Phillips et al., 2006 and Pang et al., 2013). Here 
we implemented a chemosensitivity assay, utilising two chemotherapeutic drugs 
commonly used for breast cancer in companion animals, doxorubicin and 
mitoxantrone. Feline mammary carcinoma cells did not show resistance to either of 
the drugs, with or without previous stimulation with TGF-β, compared to mock-
treated cells. In contrast, TGF-β-stimulated canine mammary carcinoma cells showed 
a remarkable resistance to doxorubicin at increasing concentrations compared to the 
untreated cells. In canine mammary carcinoma cells, we expanded this experiment   
to establish a correlation between resistance to chemotherapy and the expression of 
the stem cell marker CD133 with and without TGF-β stimulation. We utilised 
CD133- untreated cells, CD133+ untreated cells, CD133- TGF-β-stimulated cells 
and CD133+ TGF-β-stimulated cells. When comparing the CD133+ untreated cells 
with the CD133- untreated cells, the former showed greater resistance to 
doxorubicin. Interestingly, the TGF-β-stimulated cells were all resistant to the drugs 
used regardless of their CD133 expression, indicating that there are resistance 
mechanisms within TGF-β-stimulated cells that are not associated with surface 
CD133. Moreover, we observed that the CD133+ cells demonstrated greater 
resistance to the drugs used compared to CD133- cells with or without previous 
TGF-β stimulation, which supports that CD133+ could be a marker for cancer cells 
with stem cell-like features, as shown by Pang et al., 2013, Ding et al., 2014, Koren 
et al., 2015 and Nomura et al., 2015. The overall conclusion of this experiment is 
that TGF-β-stimulated canine carcinoma cells are comparable in chemotherapy 
resistance to the CD133+ cells, consistent with canine mammary carcinoma cells 
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acquiring stem cell characteristics through a TGF-β-induced EMT. It has been shown 
that TGF-β regulation of CD133 expression might be partially dependent on the 
Smad pathway (You et al., 2010). In order to elucidate if this pathway is associated 
with chemoresistance mechanisms, we could investigate if TGF-β stimulation 
decreases or increases CD133 expression and resistance to chemotherapeutic drugs 
in canine and feline mammary carcinoma cell lines after Smad knockdown. We 
could further assess if CD133 knockdown leads to a downregulation or upregulation 
in the expression of Smad in these cancer cell lines. 
Further investigation is needed to assess if these findings are relevant in vivo. 
The confirmation of these results, regarding EMT-associated changes and the 
acquisition of stem cell characteristics in vitro could be followed by further 
experiments including antagonists of downstream effectors of TGF-β such as small 
interfering RNAs (siRNAs) to elucidate the druggable pathway involved, with a view 
to developing rational EMT-targeted treatments. 
On a different note, miRNAs have important roles in physiological processes 
(Foubert, et al., 2010). Aberrant expression of miRNAs has been linked with 
different types of cancer in humans, including breast, lung, endometrial, 
gastrointestinal and prostate cancer (Calin et al., 2002, Volinia et al., 2006, Esquela-
Kercher et al., 2008, Chin et al., 2008 and reviewed by Croce, 2009). Knowing that 
some genes related to cancer can be promoted or suppressed by different miRNAs as 
mentioned in Chapter 5.4, we screened miRNA expression in canine mammary 
carcinoma cells with and without TGF-β stimulation to investigate for changes in 
miRNA expression in cells before and after undergoing EMT. We compared the 
miRNA expression in cells with and without TGF-β stimulation at days 1, 10, 17 and 
23, including samples in which TGF-β was withdrawn at day 19 and kept growing 
until day 23. Several miRNAs were upregulated in TGF-β-stimulated cells compared 
with the control groups. We observed 4 canine miRNAs that showed similar 
significant changes throughout the different time-points analysed herein. These 
miRNAs were upregulated in samples treated with TGF-β compared with untreated 
cells, but were downregulated in samples in which TGF-β was withdrawn, compared 
with the TGF-β-stimulated cells. This result shows that the TGF-β withdrawal 
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samples have a similar miRNA profile to untreated cells; meaning that they might 
undergo a mesenchymal to epithelial transition (MET) returning to a more epithelial 
phenotype profile after TGF-β is withdrawn. 
The miRNAs expressing these similar significant changes were cfa-miR-411, 
381, 410 and 380. These miRNAs were upregulated from day 1, showing a peak at 
day 10. It is unknown why they show a peak at day 10; a possible explanation would 
be that after 10 days of treatment with TGF-β, cells have acquired a mesenchymal 
phenotype and no longer require stimulation for an EMT induction after 10 days, 
when these miRNA expressions started to decrease. Another possible reason would 
be that the constant stimulation with TGF-β have resulted in downregulation of 
receptors and pathways leading to less profound miRNA expression changes after 10 
days. However, we observed that TGF-β-stimulated cells acquired a mesenchymal 
morphology after 6 days of stimulation and preserved it until TGF-β was withdrawn. 
A feasible way to corroborate these ideas would be to perform miRNA expression 
analyses in TGF-β stimulated cells and TGF-β withdrawal cells at many different 
time points and at different concentrations of TGF-β, while observing morphological 
changes and evaluating the protein and mRNA expression levels of EMT markers 
and transcription factors at all time points. This approach would help us elucidate the 
role of TGF-β in miRNA expression after a TGF-β-induced EMT in canine 
mammary cancer cells. 
Our view is that these findings could give significant insight into the 
regulation of EMT in canine cancer cells and identified several potential targets, 
however, several research groups have shown significant results regarding these 4 
miRNAs and their association with various types of cancer in humans, which were 
not fully consistent with our findings. For instance, in contrast to what we observed 
in canine mammary carcinoma, miR-411 and miR-381 were downregulated in breast 
cancer in humans in 2 different studies carried out by van Schooneveld et al., 2012 
and Liu et al., 2013, respectively. Van Schooneveld et al., 2012 showed that miR-411 
was downregulated in localised and untreated metastatic breast cancer, compared to 
healthy tissue samples, while Liu et al., 2013 showed that miR-381 was 
downregulated in non-metastatic infiltrating mammary carcinoma, compared to 
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healthy tissues. These opposing results suggest that these miRNAs may be 
bystanders and/or perhaps act in a tumour and/or context specific manner. An 
important approach to investigate these features would be to inhibit these miRNAs in 
canine and human mammary carcinoma cells during and after EMT induction and 
assess if their inhibition alters measurable aspects of EMT such as morphological 
changes, chemotherapy resistance, sphere forming ability, etc.  This would provide a 
better idea of which miRNAs are essential for EMT and thus worthwhile targeting in 
future canine mammary cancer research and therapeutic trials, perhaps as a model for 
the human. 
We are the first group to globally assess miRNA expression in canine breast 
cancer cells in association with EMT-associated changes. Different research groups 
have investigated the role of specific miRNAs in mammary carcinoma and 
lymphoma, among other types of cancer in humans and companion animals (Boggs 
et al., 2008, Uhl et al., 2011, von Deetzen et al., 2014, Rybicka et al., 2015 and 
Mohammad et al., 2015), giving a relevant insight into the functions of these 
miRNAs during cancer progression and prognosis in companion animals as 
described in Chapter 5.4, however, EMT was not a focus of their studies. We 
observed that the expression profiles of individual miRNAs in canine mammary 
carcinoma cells were in line with previous research on different types of cancer in 
humans (Swarbrick, et al., 2010), however, some of our findings were contrary to 
human cancer research (Snowdon et al., 2011, Van Schooneveld et al., 2012, Torres 
et al., 2013, and Liu et al., 2013). These discordant outcomes are not unexpected as 
some miRNAs can bind to several target mRNAs and thus, can effect both tumour 
suppressive and oncogenic functions (Boggs, et al., 2008). Examples of this can be 
seen with the human miR-17-5p, which has been classified as a tumour suppressor 
(Hossain, et al., 2006) but can also act as an oncogene (Iorio, et al., 2005) in 
mammary cancer. It is evident that there is still much to be understood in this field, 
nonetheless, the discovery of different miRNAs in cancer and its progression may be 
useful for the development of new therapeutic strategies to inhibit their functions. 
Our results bring light into the elucidation of further questioning regarding the role of 
specific miRNAs during EMT in mammary carcinoma of companion animals. 
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Elucidating different functions of miRNAs associated with cancer and its progression 
will undoubtedly advance cancer diagnostics and gene therapies in animals and 
humans in the future, providing important tools to create targeted therapies. These 
observations make clear that collaborations between veterinarians and researchers are 
particularly necessary to obtain the desired objectives to cure cancer and its 
progression. 
Targeted therapies are becoming more popular than conventional 
chemotherapy among cancer treatment options, thus, miRNAs and antimiRNAs will 
perhaps contribute extensively to these kinds of selective therapies, as reviewed by 
Croce, 2009. Moreover, dogs bearing tumours such as mast cell tumours and 
gastrointestinal stromal tumours might benefit from the inclusion of tyrosine kinase 
(TK) inhibitors, as demonstrated by different research groups (Zemke et al., 2002, 
Frost et al., 2003, London et al., 2003 and Klopfleisch et al., 2012). The significance 
of TK in veterinary oncology has not been extensively studied with the exception 
perhaps of mast cell tumours; however, many studies have been conducted in human 
breast cancer (reviewed by Ranieri et al., 2014). A growth factor receptor on mast 
cells, CD117/c-Kit, is vital for their survival and proliferation (Tsai, et al., 1991) and 
plays an important role in angiogenesis in canine mast cell tumours (Klopfleisch et 
al., 2012), and in canine and human mammary carcinoma as reviewed by Ranieri et 
al., 2013. These observations could lead to important advances in veterinary 
oncology research regarding the development of targeted therapies against specific 
receptors of known importance in cancer progression and metastasis. The role of 
TKIs and miRNA inhibitors could be further researched in veterinary and 
comparative oncology. 
In conclusion, the role of EMT applying the CSC theory to breast cancer of 
dogs and cats has not been previously studied. Further directions for our research 
include confirmation of our findings in vivo to more robustly investigate whether 
TGF-β induces EMT and confers migratory, invasive and other stem cell-like 
characteristics to mammary carcinoma cells and thus its relevance in patients rather 
than model systems. This would allow us to confirm whether breast cancer cells 
undergoing EMT gain resistance to apoptosis and chemotherapy, and have enhanced 
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migratory or invasive capabilities, thus contributing to progression and metastasis. 
As the role for currently available chemotherapy in small animal breast cancer has 
not been robustly proven, a more personalised approach based on druggable 
molecular targets might be needed for the discovery of novel therapeutic protocols 
for specific cancers. According to our findings, further investigation is necessary to 
assess if components of the TGF-β pathway and specific miRNAs can regulate EMT 
and prevent cancer progression and metastasis in mammary carcinoma of companion 
animals, confirming what has been observed by different research groups in several 

























To all those cancer patients out there… 
 
“Now, this is not the end, it is not even the beginning of the 
end, but perhaps it is, the end of the beginning.” 
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Appendix 1: Published papers and 
collaborations 
1) Canine Mammary Cancer Stem Cells are 
Radio- and Chemo-Resistant and Exhibit an 
Epithelial-Mesenchymal Transition Phenotype 
2) Epithelial-mesenchymal transition as a 


















































































































































































































































































































































































































































































































































































































































































































































































































  251 
Appendix 2: Canine mammary carcinoma cells 
microRNA full screening. Data included in CD. 
Folder 1: Normalised counts of the full miRNA screening 
Folder 2: Counts for miRNA expressed after day1 of TGF-β stimulation 
Folder 3: Counts for miRNA expressed after day 10 of TGF-β stimulation 
Folder 4: Counts for miRNA expression after day 17 of TGF-β stimulation 
Folder 5: Counts for miRNA expression after day 23 of TGF-β stimulation 
Folder 6: Counts for miRNA expression after TGF-β withdrawal at day 23 
Folder 7: counts for miRNA expression after TGF-β withdrawal, compared 
 with TGF-β-stimulated samples. 
 
 
 
 
